

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 29/00, A01N 43/04, C07H 21/04, C07K 14/00, C12N 5/10, 15/00, C12P 19/34, G01N 33/53	A1	(11) International Publication Number: WO 00/19988 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/US99/23156 (22) International Filing Date: 6 October 1999 (06.10.99) (30) Priority Data: 09/168,229 7 October 1998 (07.10.98) US 09/258,670 26 February 1999 (26.02.99) US 09/413,136 6 October 1999 (06.10.99) US (71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US). (72) Inventors: LEHAR, Sophie; 2301 Fairview Avenue E#408, Seattle, WA 98102 (US). MANNING, Stephen; 151 Mystic Street, Apartment M5, Arlington, MA 02474 (US). COYLE, Anthony, J.; 30 Clarendon Street, Boston, MA 02116 (US). GUTIERREZ-RAMOS, Jose-Carlos; 31 Little's Point Road, Swampscott, MA 01907 (US). (74) Agents: SPRUILL, W., Murray et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF (57) Abstract Novel Th2-specific polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Th2-specific proteins, the invention further provides isolated Th2-specific fusion proteins, antigenic peptides, and anti-Th2-specific antibodies. The invention also provides Th2-specific nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Th2-specific gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF

FIELD OF THE INVENTION

The invention relates to novel Th2-specific nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.

5

BACKGROUND OF THE INVENTION

Two distinct types of T lymphocytes are recognized: CD8⁺ cytotoxic T lymphocytes (CTLs) and CD4⁺ helper T lymphocytes (Th cells). CTLs recognize and kill cells that display foreign antigens on their surfaces in conjunction with class I major histocompatibility complex (MHC) molecules. This recognition
10 process triggers the activation, maturation, and proliferation of the precursor CTLs, resulting in CTL clones capable of destroying the cells recognized as foreign.

T cell activation involves a two-step process. An antigen-specific signal is generated by the TCR/CD3 complex, defining the specificity of recognition,
15 followed by a second signal (CD28) delivered by an accessory cell thought to regulate lymphokine expression and proliferation (Meuller *et al.* (1989) *Ann. Rev. Immunol.* 7:445; Kohno *et al.* (1990) *Cell. Immunol.* 131:1). CD28 is a disulfide-linked homodimer of 44 kDa expressed on the surface of CD4⁺ and CD8⁺ thymocytes (Martin *et al.* (1986) *J. Immunol.* 136:3282) and the majority of T cells
20 (Hara *et al.* (1985) *J. Exp. Med.* 161:1513). Structurally, CD28 is comprised of a single immunoglobulin-like domain and a 51 amino acid cytoplasmic tail (Aruffo *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:8573). CD28 signaling initially stabilizes mRNA for various lymphokines, followed by an increase in transcription (Lindsten *et al.* (1989) *Science* 244:339).

25

Th cells are involved in both humoral and cell-mediated forms of effector immune responses. The cell-mediated, or cellular, immune response functions to neutralize microbes that inhabit intracellular locations. Foreign antigens, such as, for example, viral antigens, are synthesized within infected cells and presented on

the surfaces of such cells in association with class I MHC molecules leading to the stimulation of the CD8⁺ class I MHC-restricted CTLs. With respect to the humoral, or antibody, immune response, antibodies are produced by B lymphocytes through interactions with Th cells. Specifically, extracellular
5 antigens are endocytosed by antigen-presenting cells (APCs), processed, and presented preferentially in association with class II MHC molecules to CD4⁺ class II MHC-restricted Th cells. These Th cells in turn activate B lymphocytes, resulting in antibody production.

During the course of an immune response, T cells differentiate into Th
10 phenotypes defined by their pattern of cytokine secretion and immunomodulatory properties (Abbas *et al.* (1996) *Nature* 383:787). Th cells are composed of at least two distinct subpopulations, termed Th1 and Th2 cell subpopulations (Mosmann *et al.* (1989) *Ann. Rev. Immunol.* 7:145; Del Prete *et al.* (1991) *J. Clin. Invest.* 88:346; Wiernenga *et al.* (1990) *J. Immunol.* 144:4651; Yamamura *et al.* (1991) *Science* 254:277; Robinson *et al.* (1993) *J. Allergy Clin. Immunol.* 92:313). Th1
15 and Th2 cells appear to function as part of the different effector functions of the immune system (Mosmann *et al.* (1989) *Ann. Rev. Immunol.* 7:145). Specifically, Th1 cells direct the development of cell-mediated immunity, triggering phagocyte-mediated host defenses, and are associated with delayed hypersensitivity.
20 Accordingly, infections with intracellular microbes tend to induce Th1-type responses. Th2 cells drive humoral immune responses, which are associated with, for example, defenses against certain helminthic parasites, and are involved in antibody and allergic responses.

Th1 cells secrete interleukin-2 (IL-2), interferon- γ (IFN- γ), and tumor
25 necrosis factor - α (TNF- α). These cytokines enhance inflammatory cell-mediated responses and have a pathogenic role in the development of autoimmune disease. Th2 cells secrete interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-10 (IL-10), and interleukin-13 (IL-13). These cytokines suppress inflammatory responses while potentiating humoral immunity and control and reverse disease
30 evolution (Scott *et al.* (1994) *Immunity* 1:73; Smith *et al.* (1998) *J. Immunol.* 160:4841; Abbas *et al.* (1996) *Nature* 383:787). The different type of cytokines released upon stimulation has been demonstrated to be central to disease evolution

(Chu and Londei (1996) *J. Immunol.* 157:2685; Hsieh *et al.* (1993) *Science* 260:547).

In vivo treatment with soluble CD28 antagonists in animal models can suppress transplant rejection and autoimmunity. This inhibitory effect was first demonstrated to be the result of inhibition of IL-2 production and clonal expansion required to generate inflammatory responses (Padrid *et al.* (1998) *Am. J. Respir. Cell. Mol. Biol.* 18:453; and Lenschow *et al.* (1992) *Science* 257:789). Recently, studies have indicated that differential signaling through the CD28 receptor has distinct effects on the production of Th2 cytokines, including IL-4 and IL-5. Generally, CD28 signaling can enhance the development of Th2 cells by regulating IL-4 production but is not essential for the development of Th1 cells (Reilifson *et al.* (1997) *J. Immunol.* 158:658).

Once Th1 and Th2 subpopulations are expanded, the cell types tend to negatively regulate one another through the actions of cytokines unique to each. For example, Th1-produced IFN- γ negatively regulates Th2 cells, while Th2-produced IL-10 negatively regulates Th1 cells. Moreover, cytokines produced by Th1 and Th2 antagonize the effector functions of one another (Mosmann *et al.* (1991) *Immunol. Today* 12:49). Furthermore, the induction and maintenance of tolerance in both transplant and autoimmune diseases is a direct consequence of enhanced Th2 activity at the expense of Th1 cells (Strom *et al.* (1996) *Curr. Opin. Immunol.* 8:688).

Failure to control or resolve an infectious process often results from an inappropriate, rather than an insufficient immune response, and can underlie a variety of distinct immunological disorders. Such disorders can include, for example, atopic conditions (i.e., IgE-mediated allergic conditions) such as asthma, allergy, including allergic rhinitis, dermatitis, including psoriasis, pathogen susceptibilities, chronic inflammatory disease, organ-specific autoimmunity, graft rejection, and graft versus host disease. For example, nonhealing forms of human and murine leishmaniasis result from strong but counterproductive Th2-like-dominated immune responses. Lepromatous leprosy also appears to feature a prevalent, but inappropriate, Th2-like response. A drop in the ratio of Th1-like

cells to other Th cell subpopulations may play a critical role in the progression toward disease symptoms in HIV infection.

Further, while Th1-mediated inflammatory responses to many pathogenic microorganisms are beneficial, such responses to self antigens are usually deleterious. It has been suggested that the preferential activation of Th1-like responses is central to the pathogenesis of such human inflammatory autoimmune diseases as multiple sclerosis and insulin-dependent diabetes. For example, Th1-type cytokines predominate in the cerebrospinal fluid of patients with multiple sclerosis, pancreases of insulin-dependent diabetes patients, thyroid glands of Hashimoto's thyroiditis, and gut of Crohn's disease patients, suggesting that such patients mount a Th1-like, not a Th2-like, response to the antigen(s) involved in the etiopathogenesis of such disorders.

The profile of the natural immune response, specifically cytokine production by natural killer cells or cells of basophil lineage, may determine the phenotype of the subsequent immune response. Therefore, methods are needed to regulate an immune response, particularly to modulate a Th1 or Th2 response. Genes and proteins differentially expressed between the two subsets of T cells may play a role in determining the phenotype of the subsequent immune response.

SUMMARY OF THE INVENTION

Isolated nucleic acid molecules corresponding to Th2-specific nucleic acid sequences are provided. Additionally amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, and 16 or the nucleotide sequences encoding the DNA sequence deposited in a bacterial host as ATCC Accession Number 203302, ATCC Accession Number 203569, and ATCC Accession Number 203797. Further provided are Th2-specific polypeptides having an amino acid sequence encoded by a nucleic acid molecule described herein.

The present invention also provides vectors and host cells for recombinant expression of the nucleic acid molecules described herein, as well as methods of

making such vectors and host cells and for using them for production of the polypeptides or peptides of the invention by recombinant techniques.

The Th2-specific molecules of the present invention are useful for modulating the phenotype of immune and respiratory responses, particularly for regulating a Th1 or Th2 response. The molecules are useful for the diagnosis and treatment of immune and respiratory disorders, particularly for the treatment and diagnosis of T-lymphocyte-related disorders, including, but not limited to, atopic conditions, such as asthma and allergy, including allergic rhinitis, psoriasis, the effects of pathogen infection, chronic inflammatory diseases, organ-specific autoimmunity, graft rejection, and graft versus host disease. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding Th2-specific proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of Th2-specific-encoding nucleic acids.

Another aspect of this invention features isolated or recombinant Th2-specific proteins and polypeptides. Preferred Th2-specific proteins and polypeptides possess at least one biological activity possessed by naturally occurring Th2-specific proteins.

Variant nucleic acid molecules and polypeptides substantially homologous to the nucleotide and amino acid sequences set forth in the sequence listings are encompassed by the present invention. Additionally, fragments and substantially homologous fragments of the nucleotide and amino acid sequences are provided.

Antibodies and antibody fragments that selectively bind the Th2-specific polypeptides and fragments are provided. Such antibodies are useful in detecting the Th2-specific polypeptides as well as in regulating the T-cell immune response.

In another aspect, the present invention provides a method for detecting the presence of Th2-specific activity or expression in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of Th2-specific activity such that the presence of Th2-specific activity is detected in the biological sample.

In yet another aspect, the invention provides a method for modulating Th2-specific activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) Th2-specific activity or expression such that Th2-specific activity or expression in the cell is modulated. In one embodiment, the agent is an antibody
5 that specifically binds to Th2-specific protein. In another embodiment, the agent modulates expression of Th2-specific protein by modulating transcription of a Th2-specific gene, splicing of a Th2-specific mRNA, or translation of a Th2-specific mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of the Th2-specific mRNA or the Th2-specific gene.
10

In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant Th2-specific protein activity or nucleic acid expression by administering an agent that is a Th2-specific modulator to the subject. In one embodiment, the Th2-specific modulator is a Th2-specific
15 protein. In another embodiment, the Th2-specific modulator is a Th2-specific nucleic acid molecule. In other embodiments, the Th2-specific modulator is a peptide, peptidomimetic, or other small molecule.

The present invention also provides a diagnostic assay for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of
20 the following: (1) aberrant modification or mutation of a gene encoding a Th2-specific protein; (2) misregulation of a gene encoding a Th2-specific protein; and (3) aberrant post-translational modification of a Th2-specific protein, wherein a wild-type form of the gene encodes a protein with a Th2-specific activity.

In another aspect, the invention provides a method for identifying a
25 compound that binds to or modulates the activity of a Th2-specific protein. In general, such methods entail measuring a biological activity of a Th2-specific protein in the presence and absence of a test compound and identifying those compounds that alter the activity of the Th2-specific protein.

The invention also features methods for identifying a compound that
30 modulates the expression of Th2-specific genes by measuring the expression of the Th2-specific sequences in the presence and absence of the compound.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows the amino acid sequence alignment for the protein (m1022; SEQ ID NO:6) encoded by murine 1022 (SEQ ID NO:5) and the protein (h1022; SEQ ID NO:14) encoded by human 1022 (SEQ ID NO:13) with the *Trypanosoma brucei* alpha core subunit of DNA polymerase (GenBank Accession Number CAA43286, SEQ ID NO:17).

10 Figure 2 shows the amino acid sequence alignment for the protein (m1228, referred to as mICOS; SEQ ID NO:10) encoded by murine 1228 (SEQ ID NO:9) and the protein (h1228, referred to as hICOS; SEQ ID NO:12) encoded by human 1228 (SEQ ID NO:11) with the murine glycoprotein CD28 precursor (mCD28; GenBank Accession Number AAA37395; SEQ ID NO:18), the human T-cell-specific surface glycoprotein CD28 precursor (hCD28; SP Accession Number P10747; SEQ ID NO:19), the murine cytotoxic t-lymphocyte protein 4 precursor (mCTLA-4; SP Accession Number P09793; SEQ ID NO:20), and the human cytotoxic t-lymphocyte protein 4 precursor (hCTLA-4; GI Accession Number 4885167; SEQ ID NO:21). The putative transmembrane domain of these sequences
15
20 is indicated by the box.

 Figure 3 shows the amino acid sequence alignment for the protein (m1419; SEQ ID NO:2) encoded by murine 1419 (SEQ ID NO:1) and the protein (h1419; SEQ ID NO:16) encoded by human 1419 (SEQ ID NO:15) with the *Caenorhabditis elegans* C54H2.1 gene product (sequence U58728 no. 1326268; GenBank Accession Number AAB00590; SEQ ID NO:22).
25

 Figure 4 shows real time PCR analysis (TaqmanTM) of mICOS expression on resting and activated leukocytes.

 Figure 5 demonstrates that mICOS-Ig (100 µg/ml) (heavy solid line) fails to bind to either mB7-1 or mB7-2 EL-4 transfectants, whereas CTLA-4-Ig (1 µg/ml) (light line) and CD28-Ig (10 µg/ml) (dashed lines) bind at 10- to 100-fold lower concentrations. Cells treated with human Ig (dotted lines) are shown for comparison.
30

Figure 6 demonstrates that mICOS-Ig (10 μ g/ml) binds to CD40-activated, but not resting B cells (A), and to resting and CD40-stimulated bone marrow-derived dendritic cells (B).

Figure 7 demonstrates that mICOS signaling is critical for activation of Th2, but not Th1 effector cells. CD4+ T cells from DO11.10 $\alpha\beta$ -TCR transgenic mice were differentiated to Th1 or Th2 effector populations. Cells were then reactivated in the presence of mICOS-Ig (1-100 μ g/ml) (open squares) or hIg (closed bars). Data are shown as the mean \pm s.e.m. of triplicate wells and is representative of 4 different experiments.

Figure 8 demonstrates inhibition of humoral responses by ICOS-Ig. Mice were immunized in the footpad with OVA/alum on day 0 boosted s.c. on day 8. Ten days later, blood was taken from the tail vein and sera titers of antigen-specific IgE (A) and IgG1 (B) measured by specific ELISA. Mice were treated i.p. with ICOS-Ig (100 μ g/mouse) (closed squares) or hIg as the appropriate control (open squares) on day 7, 8, and 9. Data are shown as the mean \pm s.e.m. absorbance (O.D.) at serial sera dilution and represent data from n=5-6 individual animals.

Figure 9 demonstrates inhibition of eosinophilic inflammation of the airways in an active immunization model by ICOS-Ig and CTLA-4Ig. One hour prior to allergen challenge, immunized mice were treated intranasally with 100 μ g of either ICOS-Ig (open columns), CTLA-4-Ig (shaded columns) or hIg (closed columns) as the appropriate isotype control. Data are shown as the mean \pm s.e.m. eosinophils/ml $\times 10^3$ for n=5 animals. Statistical significance ($p < 0.05$) was determined by a Student's T-test and indicated by *.

Figure 10 demonstrates attenuation of Th2, but not Th1 mediated mucosal inflammation by mICOS-Ig. Aeroallergen challenge of Th1 (A) or Th2 (B) recipient mice after adoptive transfer results in a neutrophilic or eosinophilic lung inflammatory response, respectively, associated with IFN- γ or IL-5 secretion. Pretreatment with mICOS-Ig or CTLA-4-Ig (open bars) inhibited Th2-mediated inflammation. In contrast, CTLA-4-Ig, but not ICOS-Ig, inhibited Th1 mediated inflammation as compared to mice treated with hIg (closed bars). Data are shown as the mean \pm s.e.m. of n=4-6 mice and is representative of 3 different experiments.

Significance (*) was determined by a Student's T-test and a value of $p < 0.05$ considered significant.

Figure 11 demonstrates selective suppression of Th2-mediated altered airway hyperresponsiveness by ICOS-Ig. Exposure to OVA in both (A) Th1 and (B) Th2 recipient mice results in increased airway hyperresponsiveness to methacholine (20 mg/ml) as compared to PBS-exposed mice. The baseline response is indicated in the open bars and the maximal response to inhaled methacholine in closed bars. Significance (#) was determined by a Student's T-test and a value of $p < 0.05$ considered significant. Control mice received hIg as the appropriate isotype control. Data are shown as the mean \pm s.e.m. of $n = 3-6$ mice and is representative of 2 different experiments. Significance from Ig treated mice (*) was determined by a Student's T-test and a value of $p < 0.05$ considered significant.

15

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isolated nucleic acid molecules comprising a nucleotide sequence encoding the Th2-specific polypeptides whose amino acid sequence is given in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, and 16, respectively, or a variant or fragment of the polypeptide. Nucleotide sequences encoding the Th2-specific proteins of the invention are set forth in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, and 15.

The present invention relates to methods and compositions for the modulation, diagnosis, and treatment of immune and respiratory disorders, especially T helper (Th) cell and Th cell-like related disorders. Such immune disorders include, but are not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, allergen-provoked airway inflammation, and conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as

helminthic (e.g., leishmaniasis), certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.

Respiratory disorders include, but are not limited to, apnea, asthma, particularly bronchial asthma and associated airway hyperresponsiveness, reberillium disease, bronchiectasis, bronchitis, bronchopneumonia, cystic fibrosis, diphtheria, dyspnea, emphysema, chronic obstructive pulmonary disease, allergic bronchopulmonary aspergillosis, pneumonia, acute pulmonary edema, pertussis, pharyngitis, atelectasis, Wegener's granulomatosis, Legionnaires disease, pleurisy, rheumatic fever, and sinusitis.

Three novel human genes (h1419, h1022, and h1228), and their murine orthologues (m1419, m1022, and m1228), are provided. The genes are differentially expressed in the Th2 subset of T-helper cells. Such sequences are referred to as "Th2-specific" indicating that the genes are expressed in the Th2 subset of T-helper cells but not expressed, or only expressed at very low levels, in the Th1 subset. The genes are overexpressed in CD3/TCR-activated Th2 cells.

The molecules of the invention (e.g., nucleic acid molecules, polypeptides, antisense molecules, antibodies) can be used to modulate an immune response. By "modulating" is intended the upregulating or downregulating of an immune response. In one embodiment, the immune response is a T cell, e.g., T helper cell, e.g., Th1 and/or Th2 cell, response. T cell, e.g., T helper cell, responses are manifested by, for example, lymphokine production, cellular proliferation, signaling events, and other effector functions. For example, a Th1 cell response can include the production of IL-2, tumor necrosis factor beta, and interferon gamma. Generally, Th1 cells have a pathogenic role in the development of autoimmune disease. In another example, a Th2 cell response can include the production of IL-3, GM-CSF, IL-4, IL-5, IL-10, and/or IL-13 and/or the generation of antibodies, e.g., IgE antibodies (e.g., by modulating the development and/or function of B cells), and/or the production, migration, function and/or differentiation, e.g., terminal differentiation, of eosinophils. Additional Th1 and Th2 cell responses can be found in Anderson and Coyle (1994) *Trends in Pharmacological Sciences* 15:324-332, the contents of which are hereby incorporated by reference. Typically, Th2 cells control and reverse disease

evolution. Thus, modulation of an immune response can involve the modulation of one or more of the Th1 and/or Th2 cell responses described herein.

The first of these Th2-specific genes, h1419, encodes a 384 amino acid protein (SEQ ID NO: 16). The nucleotide sequence for h1419 is provided in SEQ ID NO: 15. Prosite program analysis was used to predict various sites within the h1419 protein. N-glycosylation sites were predicted at amino acids (aa) 214-217, 229-232, and aa 260-263. cAMP- and cGMP-dependent protein kinase phosphorylation sites were predicted at aa 61-64, 258-261, and 308-311. Protein kinase C phosphorylation sites were predicted at aa 47-49, 86-88, 116-118, 158-160, 174-176, 256-258, 281-283, 301-303, and 304-306. Casein kinase II phosphorylation sites were predicted at aa 17-20, 47-50, 130-133, 216-219, 251-254, 281-284, 317-320, 322-325, and 343-346. N-myristoylation sites were predicted at aa 29-34, 112-117, 166-171, 177-182, 183-188, 270-275, and 364-369.

The murine orthologue m1419 encodes a 3.6 Kb transcript having the corresponding cDNA set forth in SEQ ID NO:1. This transcript encodes a 392 amino acid protein (SEQ ID NO:2) having a molecular weight of approximately 42.8 kDa (excluding post-translational modifications). N-glycosylation sites were predicted at amino acids (aa) 230-233 and aa 261-264. cAMP- and cGMP-dependent protein kinase phosphorylation sites were predicted at aa 61-64, 259-262, and 316-319. Protein kinase C phosphorylation sites were predicted at aa 47-49, 86-88, 116-118, 158-160, 174-176, 257-259, 289-291, 309-311, and 312-314. Casein kinase II phosphorylation sites were predicted at aa 17-20, 47-50, 130-133, 217-220, 252-255, 325-328, 330-333, and 351-354. N-myristoylation sites were predicted at aa 29-34, 112-117, 166-171, 177-182, 183-188, 271-276, and 372-377. This protein displays homology (at least 40% to about 44% identity over a 140 amino acid overlap) to the predicted protein sequence encoded by a putative *Caenorhabditis elegans* gene (GenBank Accession Number AAB00590) whose function is unknown.

A plasmid containing the h1419 cDNA insert, designated P1419, was deposited with American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia, on February 25, 1999 and assigned Accession Number

203797. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. § 112.

The second of these Th2-specific genes, h1022, encodes a 481 amino acid protein (SEQ ID NO:14). The nucleotide sequence for h1022 is set forth in SEQ ID NO:13. An analysis of h1022 predicts that the N-terminal 70 amino acids represent a signal peptide. A transmembrane segment from amino acids (aa) 7-23 was predicted by MEMSAT. Prosite program analysis was used to predict various sites within the h1022 protein. N-glycosylation sites were predicted at aa 293-296 and aa 397-400. N-glycosylation sites were predicted at aa 293-296 and 397-400. Glycosaminoglycan attachment sites were predicted at aa 20-23 and 236-239. Protein kinase C phosphorylation sites were predicted at aa 117-119, 148-150, 176-178, 226-228, 276-278, 430-432, and 466-468. Casein kinase II phosphorylation sites were predicted at aa 143-146, 156-159, 240-243, 248-251, 284-287, 306-309, 449-452, and 466-469. A tyrosine kinase phosphorylation site was predicted at aa 67-73. N-myristoylation sites were predicted at aa 10-15, 112-117, 237-242, 266-271, 406-411, and 420-425. An amidation site was predicted at aa 94-97. An EF-hand calcium-binding domain was predicted at aa 158-171.

The murine orthologue m1022 encodes two transcripts, a shorter 1.6 Kb form having the corresponding murine cDNA set forth in SEQ ID NO:3, and a longer 4.4 Kb form having the corresponding murine cDNA set forth in SEQ ID NO:5. Both transcripts encode a 464 amino acid protein (SEQ ID NOs:4 and 6) having a molecular weight of approximately 54.2 kDa (excluding post-translational modifications). The m1022 protein is homologous (about 20-25% identity overall) to the alpha core subunit of DNA polymerase from *Trypanosoma brucei* (GenBank Accession Number CAA43286). An analysis of m1022 predicted that the N-terminal 70 amino acids (aa) represent a signal peptide. A transmembrane segment from aa 7-23 was predicted by MEMSAT. Prosite program analysis was used to predict various sites within the m1022 protein. N-glycosylation sites were predicted at aa 276-279 and aa 380-383. A glycosaminoglycan attachment site was

predicted at aa 219-222. Protein kinase C phosphorylation sites were predicted at aa 117-119, 147-149, 219-221, 259-261, 413-415, and 449-451. Casein kinase II phosphorylation sites were predicted at aa 142-145, 155-158, 163-166, 267-270, 289-292, 432-435, and 449-452. Tyrosine kinase phosphorylation sites were
5 predicted at aa 67-73 and 223-230. N-myristoylation sites were predicted at aa 6-11, 112-117, 249-254, 389-394, and 403-408. An amidation site was predicted at aa 94-97.

A plasmid containing the h1022 cDNA insert, designated P1022, was deposited with American Type Culture Collection (ATCC), 10801 University
10 Blvd., Manassas, Virginia, on January 8, 1999 and assigned Accession Number 203569. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35
15 U.S.C. § 112.

The third of these Th2-specific genes, h1228, encodes a 198 amino acid protein (SEQ ID NO:12). The nucleotide sequence for h1228 is set forth in SEQ ID NO:11. This protein is an Ig superfamily member with 33% homology to hCD28 and 26% homology to hCLTA-4. Examination of the amino acid sequence
20 revealed 4 conserved cysteine residues (aa 41, 62, 82, and 135 of SEQ ID NO:12) and a conserved PPP motif (present as FDPPPF, aa 113-118 of SEQ ID NO:12) in the extracellular domain, which is common to CD28 and its related homologue CTLA-4. The h1228 sequence additionally contains a YMFM motif (amino acid residues 178-181 of SEQ ID NO:12) similar to the phosphotyrosine-based motif
25 pYMNM common in CD28 and CTLA-4, which appears to be required for CD28-mediated PI-3K activity. Signaling through 1228 is required for Th2 cytokine production. Further, inhibition of 1228 in a murine model of asthma attenuates Th2 mucosal inflammation and airway hyperresponsiveness. 1228 effectively replaces the CD28 signal and can provide a costimulatory signal specific for
30 cytokine production from Th2 effector cells.

The murine orthologue m1228 encodes two transcripts, a shorter 2.1 Kb form having the corresponding cDNA sequence set forth in SEQ ID NO:7, and a

longer 3.3 Kb form having the corresponding cDNA sequence set forth in SEQ ID NO:9. Both transcripts encode a 200 amino acid protein (SEQ ID NOs:8 and 10) having a molecular weight of approximately 22.7 kDa (excluding post-translational modifications). This protein shares 69% identity with h1228, 36.5% identity with mCD28, and 38.5% identity with mCTLA-4.

A plasmid containing the h1228 cDNA insert, designated P1228, was deposited with American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia, on October 2, 1998, and assigned Accession Number 203302. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. § 112.

The Th2-specific sequences of the invention are members of a family of molecules (the "Th2-specific family") having conserved functional features. The term "family" when referring to the proteins and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having sufficient amino acid or nucleotide sequence identity as defined herein. Such family members can be naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of murine origin and a homologue of that protein of human origin, as well as a second, distinct protein of human origin and a murine homologue of that protein. Members of a family may also have common functional characteristics.

Preferred Th2-specific polypeptides of the present invention have an amino acid sequence sufficiently identical to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, or 16. The term "sufficiently identical" is used herein to refer to a first amino acid or nucleotide sequence that contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences that contain a common structural domain having at least about 45%,

55%, or 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., percent identity = number of identical positions/total number of positions (e.g., overlapping positions) x 100). In one embodiment, the two sequences are the same length. The percent identity between two sequences can be determined using techniques similar to those described below, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, nonlimiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.* (1990) *J. Mol. Biol.* 215:403. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to Th2-specific nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to Th2-specific protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389. Alternatively, PSI-Blast can be used to perform an iterated search that detects distant relationships between molecules. See Altschul *et al.* (1997) *supra*. When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated

into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

5 Accordingly, another embodiment of the invention features isolated Th2-specific proteins and polypeptides having a Th2-specific protein activity. As used interchangeably herein, a "Th2-specific protein activity", "biological activity of a Th2-specific protein", or "functional activity of a Th2-specific protein" refers to an activity exerted by a Th2-specific protein, polypeptide, or nucleic acid molecule on
10 a Th2-specific responsive cell as determined *in vivo*, or *in vitro*, according to standard assay techniques. A Th2-specific activity can be a direct activity, such as an association with or an enzymatic activity on a second protein, or an indirect activity, such as a cellular signaling activity mediated by interaction of the Th2-specific protein with a second protein. In a preferred embodiment, a Th2-specific
15 activity includes at least one or more of the following activities: (1) modulating (stimulating and/or enhancing or inhibiting) cellular proliferation, differentiation, and/or function, particularly immune cells, for example leukocytes; (2) modulating a Th2-specific immune response; (3) inhibiting a Th1 immune response; (4) inducing and/or maintaining tolerance in both transplant and autoimmune diseases;
20 (5) binding a Th2-specific ligand; or (6) modulating Th2-specific cytokines such as IL-4, IL-5, IL-10, and IL-13.

 An "isolated" or "purified" Th2-specific nucleic acid molecule or protein, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free
25 of chemical precursors or other chemicals when chemically synthesized. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For purposes of the invention, "isolated" when
30 used to refer to nucleic acid molecules, excludes isolated chromosomes. For example, in various embodiments, the isolated Th2-specific nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of

nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A Th2-specific protein that is substantially free of cellular material includes preparations of Th2-specific protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of non-Th2-specific protein (also referred to herein as a "contaminating protein"). When the Th2-specific protein or biologically active portion thereof is recombinantly produced, preferably, culture medium represents less than about 30%, 20%, 10%, or 5% of the volume of the protein preparation. When Th2-specific protein is produced by chemical synthesis, preferably the protein preparations have less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-Th2-specific chemicals.

Various aspects of the invention are described in further detail in the following subsections.

1. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules comprising nucleotide sequences encoding Th2-specific proteins or biologically active portions thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify Th2-specific-encoding nucleic acids (e.g., Th2-specific mRNA) and fragments for use as PCR primers for the amplification or mutation of Th2-specific nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

Nucleotide sequences encoding the Th2-specific proteins of the present invention include sequences set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15, the nucleotide sequences of the cDNA inserts of the plasmids deposited with the ATCC as Accession Numbers 203302, 203569, and 203797 (referred to as the "cDNA of ATCC 203302," the "cDNA of ATCC 203569," or the "cDNA of ATCC 203797"), and complements thereof. By "complement" is intended a nucleotide sequence that is sufficiently complementary to a given nucleotide sequence such

that it can hybridize to the given nucleotide sequence to thereby form a stable duplex. The corresponding amino acid sequences for the Th2-specific proteins encoded by these nucleotide sequences are set forth in SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, and 16, respectively.

5 Nucleic acid molecules that are fragments of these Th2-specific nucleotide sequences are also encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence encoding a Th2-specific protein of the invention. A fragment of a Th2-specific nucleotide sequence may encode a biologically active portion of a Th2-specific protein, or it may be a fragment that
10 can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a Th2-specific protein can be prepared by isolating a portion of one of the Th2-specific nucleotide sequences of the invention, expressing the encoded portion of the Th2-specific protein (e.g., by recombinant expression *in vitro*), and assessing the activity of the encoded portion
15 of the Th2-specific protein. Generally, nucleic acid molecules that are fragments of a Th2-specific nucleotide sequence comprise at least 15, 20, 50, 75, 100, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,350, 1,400, 1,450, 1,500, or 1,550 nucleotides, or up to the number of nucleotides present in a full-length Th2-specific nucleotide sequence disclosed
20 herein (for example, 3631, 1587, 4382, 2080, 3266, 2703, 1795, or 3868 nucleotides for SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15, respectively) depending upon the intended use.

It is understood that isolated fragments include any contiguous sequence not disclosed prior to the invention as well as sequences that are substantially the
25 same and which are not disclosed. Accordingly, if a fragment is disclosed prior to the present invention, that fragment is not intended to be encompassed by the invention. When a sequence is not disclosed prior to the present invention, an isolated nucleic acid fragment is at least about 12, 15, 20, 25, or 30 contiguous nucleotides. Other regions of the nucleotide sequence may comprise fragments of
30 various sizes, depending upon potential homology with previously disclosed sequences.

For h1022, for example, nucleotide sequences 1 to about 210 and about 565 to about 602 are not disclosed prior to the present invention. The nucleotide sequence from about 1 to about 325 encompasses fragments greater than 20, 21, or 25 nucleotides; the nucleotide sequence from about 306 to about 602 encompasses fragments greater than about 148, 150, or 160 nucleotides; the nucleotide sequence from about 600 to about 850 encompasses fragments greater than about 212, 215, or 220 nucleotides; the nucleotide sequence from about 815 to about 1006 encompasses fragments greater than about 54, 58, 60, or 70 nucleotides; the nucleotide sequence from about 1006 to about 1281 encompasses fragments greater than about 32, 35, or 40 nucleotides; and the nucleotide sequence from about 1200 to about 1795 encompasses fragments greater than about 490 or 500 nucleotides

For h1419, for example, nucleotide sequences 1 to about 1274, about 1385 to about 2146, about 2190 to about 2202, about 2404 to about 2434, about 2563 to about 2678, and about 3425 to about 3790 are not disclosed prior to the present invention. The nucleotide sequence from about 1 to about 2146 encompasses fragments greater than about 17, 20, or 25 nucleotides; the nucleotide sequence from about 2140 to about 2806 encompasses fragments greater than about 21, 23, or 25 nucleotides; the nucleotide sequence from about 2806 to about 3406 encompasses fragments greater than about 263, 265, or 275 nucleotides; and the nucleotide sequence from about 3406 to about 3868 encompasses fragments greater than about 37, 38, 40, or 45 nucleotides.

A fragment of a Th2-specific nucleotide sequence that encodes a biologically active portion of a Th2-specific protein of the invention will encode at least 15, 25, 30, 50, 100, 150, 200, 250, 300, 350, 400, or 450 contiguous amino acids, or up to the total number of amino acids present in a full-length Th2-specific protein of the invention (for example, 392, 464, 200, 198, 481, or 384 amino acids for SEQ ID NO:2, 4 and 6, 8 and 10, 12, 14, or 16, respectively). Fragments of a Th2-specific nucleotide sequence that are useful as hybridization probes for PCR primers generally need not encode a biologically active portion of a Th2-specific protein.

Nucleic acid molecules that are variants of the Th2-specific nucleotide sequences disclosed herein are also encompassed by the present invention.

"Variants" of the Th2-specific nucleotide sequences include those sequences that encode the Th2-specific proteins disclosed herein but that differ conservatively because of the degeneracy of the genetic code. These naturally occurring allelic variants can be identified with the use of well-known molecular biology techniques, such as polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences that have been generated, for example, by using site-directed mutagenesis but which still encode the Th2-specific proteins disclosed in the present invention as discussed below. Generally, nucleotide sequence variants of the invention will have at least 45%, 55%, 65%, 75%, 85%, 95%, or 98% identity to the nucleotide sequences disclosed herein. A variant Th2-specific nucleotide sequence will encode a Th2-specific protein that has an amino acid sequence having at least 45%, 55%, 65%, 75%, 85%, 95%, or 98% identity to an amino acid sequence of a Th2-specific protein disclosed herein.

In addition to the Th2-specific nucleotide sequences shown in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15, the nucleotide sequence of the cDNA of ATCC 203302, the nucleotide sequence of the cDNA of ATCC 230569, and the nucleotide sequence of the cDNA of ATCC 203797, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of Th2-specific proteins may exist within a population (e.g., the human population). Such genetic polymorphism in a Th2-specific gene may exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes that occur alternatively at a given genetic locus. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a Th2-specific protein, preferably a mammalian Th2-specific protein. As used herein, the phrase "allelic variant" refers to a nucleotide sequence that occurs at a Th2-specific locus or to a polypeptide encoded by the nucleotide sequence. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the Th2-specific gene. Any and all such nucleotide variations and resulting amino acid

polymorphisms or variations in a Th2-specific sequence that are the result of natural allelic variation and that do not alter the functional activity of Th2-specific proteins are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding Th2-specific proteins from
5 other species (Th2-specific homologues), which have a nucleotide sequence differing from that of the Th2-specific sequences disclosed herein, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the Th2-specific cDNAs of the invention can be isolated based on their identity to the mouse Th2-specific nucleic acids
10 disclosed herein using the mouse cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions as disclosed below.

In addition to naturally-occurring allelic variants of the Th2-specific sequence that may exist in the population, the skilled artisan will further appreciate
15 that changes can be introduced by mutation into the nucleotide sequences of the invention thereby leading to changes in the amino acid sequence of the encoded Th2-specific protein, without altering the biological activity of the Th2-specific protein. Thus, an isolated nucleic acid molecule encoding a Th2-specific protein having a sequence that differs from that of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, or 16
20 can be created by introducing one or more nucleotide substitutions, additions, or deletions into the nucleotide sequences disclosed herein, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Such variant nucleotide sequences
25 are also encompassed by the present invention.

For example, preferably, conservative amino acid substitutions may be made at one or more predicted, preferably nonessential amino acid residues. A "nonessential" amino acid residue is a residue that can be altered from the wild-type sequence of a Th2-specific protein (e.g., the sequence of SEQ ID NO:2, 4, 6,
30 8, 10, 12, 14, or 16) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid

residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Such substitutions would not be made for conserved amino acid residues, such as the cysteine residues of clone 1228, or for amino acid residues residing within a conserved motif, such as the PPP motif (present as FDPPPF, aa 113-118 of SEQ ID NO:12) and YMFM motif (aa 178-181 of SEQ ID NO:12) of 1228, where such residues are essential for protein activity.

Alternatively, variant Th2-specific nucleotide sequences can be made by introducing mutations randomly along all or part of a Th2-specific coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for Th2-specific biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly, and the activity of the protein can be determined using standard assay techniques.

Thus the nucleotide sequences of the invention include those sequences disclosed herein as well as fragments and variants thereof. The Th2-specific nucleotide sequences of the invention, and fragments and variants thereof, can be used as probes and/or primers to identify and/or clone Th2-specific homologues in other cell types, e.g., from other tissues, as well as Th2-specific homologues from other mammals. Such probes can be used to detect transcripts or genomic sequences encoding the same or identical proteins. These probes can be used as part of a diagnostic test kit for identifying cells or tissues that misexpress a Th2-specific protein, such as by measuring levels of a Th2-specific-encoding nucleic acid in a sample of cells from a subject, e.g., detecting Th2-specific mRNA levels or determining whether a genomic Th2-specific gene has been mutated or deleted.

In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences having substantial identity to the sequences of the

invention. See, for example, Sambrook *et al.* (1989) *Molecular Cloning: Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY) and Innis, *et al.* (1990) *PCR Protocols: A Guide to Methods and Applications* (Academic Press, NY). Th2-specific nucleotide sequences isolated based on their
5 sequence identity to the Th2-specific nucleotide sequences set forth herein or to fragments and variants thereof are encompassed by the present invention.

In a hybridization method, all or part of a known Th2-specific nucleotide sequence can be used to screen cDNA or genomic libraries. Methods for construction of such cDNA and genomic libraries are generally known in the art
10 and are disclosed in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Coldspring Harbor Laboratory Press, Plainview, NY). The so-called hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as ³²P, or any other detectable marker, such as other radioisotopes, a
15 fluorescent compound, an enzyme, or an enzyme co-factor. Probes for hybridization can be made by labeling synthetic oligonucleotides based on the known Th2-specific nucleotide sequences disclosed herein. Degenerate primers designed on the basis of conserved nucleotides or amino acid residues in a known Th2-specific nucleotide sequence or encoded amino acid sequence can additionally
20 be used. The probe typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 consecutive nucleotides of a Th2-specific nucleotide sequence of the invention or a fragment or variant thereof. Preparation of probes for hybridization is generally
25 known in the art and is disclosed in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Coldspring Harbor Laboratory Press, Plainview, New York), herein incorporated by reference.

For example, in one embodiment, a previously unidentified Th2-specific nucleic acid molecule hybridizes under stringent conditions to a probe that is a
30 nucleic acid molecule comprising one of the Th2-specific nucleotide sequences of the invention or a fragment thereof. In another embodiment, the previously unknown Th2-specific nucleic acid molecule is at least 300, 325, 350, 375, 400,

425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 2,000, 3,000, 4,000 or 5,000 nucleotides in length and hybridizes under stringent conditions to a probe that is a nucleic acid molecule comprising one of the Th2-specific nucleotide sequences disclosed herein or a fragment thereof.

5 Accordingly, in another embodiment, an isolated previously unknown Th2-specific nucleic acid molecule of the invention is at least 300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1,100, 1,200, 1,300, or 1,400 nucleotides in length and hybridizes under stringent conditions to a probe that is a nucleic acid molecule comprising one of the nucleotide sequences of the invention,
10 preferably the coding sequence set forth in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15, the cDNA of ATCC 203302, the cDNA of ATCC 203569, the cDNA of ATCC 203797, or a complement, fragment, or variant thereof.

 As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide
15 sequences having at least 60%, 65%, 70%, preferably 75% identity to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology* (John Wiley & Sons, New York (1989)), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6X sodium
20 chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. In another preferred embodiment, stringent conditions comprise hybridization in 6 X SSC at 42°C, followed by washing with 1 X SSC at 55°C. Preferably, an isolated nucleic acid molecule that hybridizes under
25 stringent conditions to a Th2-specific sequence of the invention corresponds to a naturally occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

 Thus, in addition to the Th2-specific nucleotide sequences disclosed herein and fragments and variants thereof, the isolated nucleic acid molecules of the
30 invention also encompass homologous DNA sequences identified and isolated from other cells and/or organisms by hybridization with entire or partial sequences

obtained from the Th2-specific nucleotide sequences disclosed herein or variants and fragments thereof.

The present invention also encompasses antisense nucleic acid molecules, i.e., molecules that are complementary to a sense nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule, or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire Th2-specific coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to a noncoding region of the coding strand of a nucleotide sequence encoding a Th2-specific protein. The noncoding regions are the 5' and 3' sequences that flank the coding region and are not translated into amino acids.

Given the coding-strand sequences encoding a Th2-specific protein disclosed herein (e.g., SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, and 15), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of Th2-specific mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of Th2-specific mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of Th2-specific mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation procedures known in the art.

For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, including, but not limited to, for example e.g., phosphorothioate derivatives and acridine substituted nucleotides. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector

into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically
5 administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a Th2-specific protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic
10 acid molecules can be modified to target selected cells and then administered systemically. For example, antisense molecules can be linked to peptides or antibodies to form a complex that specifically binds to receptors or antigens expressed on a selected cell surface. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient
15 intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the invention can be an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific
20 double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-O-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

25 The invention also encompasses ribozymes, which are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave Th2-specific
30 mRNA transcripts to thereby inhibit translation of Th2-specific mRNA. A ribozyme having specificity for a Th2-specific-encoding nucleic acid can be designed based upon the nucleotide sequence of a Th2-specific cDNA disclosed

herein (e.g., SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15). See, e.g., Cech *et al.*, U.S. Patent No. 4,987,071; and Cech *et al.*, U.S. Patent No. 5,116,742. Alternatively, Th2-specific mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak
5 (1993) *Science* 261:1411-1418.

The invention also encompasses nucleic acid molecules that form triple helical structures. For example, Th2-specific gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the Th2-specific protein (e.g., the Th2-specific promoter and/or enhancers) to form triple
10 helical structures that prevent transcription of the Th2-specific gene in target cells. See generally Helene (1991) *Anticancer Drug Des.* 6(6):569; Helene (1992) *Ann. N.Y. Acad. Sci.* 660:27; and Maher (1992) *Bioassays* 14(12):807.

In preferred embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone to improve,
15 e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4:5). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is
20 replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid-phase peptide synthesis protocols as described in Hyrup *et al.* (1996), *supra*; Perry-O'Keefe *et al.*
25 (1996) *Proc. Natl. Acad. Sci. USA* 93:14670.

PNA of a Th2-specific molecule can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of the invention can also be used,
30 e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA-directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996), *supra*; or as probes or primers for

DNA sequence and hybridization (Hyrup (1996), *supra*; Perry-O'Keefe *et al.* (1996), *supra*).

In another embodiment, PNAs of a Th2-specific molecule can be modified, e.g., to enhance their stability, specificity, or cellular uptake, by attaching
5 lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*; Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63; Mag *et al.* (1989) *Nucleic Acids Res.* 17:5973; and Peterser *et al.* (1975) *Bioorganic Med*
10 *Chem. Lett.* 5:1119.

II. Isolated Th2-specific Proteins and Anti-Th2-specific Antibodies

Th2-specific proteins are also encompassed within the present invention. By "Th2-specific protein" is intended proteins having the amino acid sequence set
15 forth in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, or 16, as well as fragments, biologically active portions, and variants thereof.

"Fragments" or "biologically active portions" include polypeptide fragments suitable for use as immunogens to raise anti-Th2-specific antibodies. Fragments include peptides comprising amino acid sequences sufficiently identical
20 to or derived from the amino acid sequences of a Th2-specific protein of the invention and exhibiting at least one activity of a Th2-specific protein, but which include fewer amino acids than the full-length Th2-specific proteins disclosed herein. Typically, biologically active portions comprise a domain or motif with at least one activity of the Th2-specific protein. A biologically active portion of a
25 Th2-specific protein can be a polypeptide that is, for example, 10, 25, 50, 100 or more amino acids in length. Such biologically active portions can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native Th2-specific protein.

By "variants" is intended proteins or polypeptides having an amino acid
30 sequence that is at least about 45%, 55%, 65%, preferably about 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, or 16. Variants also include polypeptides encoded by the cDNA insert of the

plasmid deposited with ATCC as Accession Number 203302, ATCC Accession Number 203569, or ATCC Accession Number 203797, or polypeptides encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15, or a complement thereof, under stringent
5 conditions. Such variants generally retain the functional activity of the Th2-specific proteins of the invention. Variants include polypeptides that differ in amino acid sequence due to natural allelic variation or mutagenesis.

The invention also provides Th2-specific chimeric or fusion proteins. As used herein, a Th2-specific "chimeric protein" or "fusion protein" comprises a Th2-specific polypeptide operably linked to a non-Th2-specific polypeptide. A "Th2-specific polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a Th2-specific protein, whereas a "non-Th2-specific polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially identical to the Th2-specific protein, e.g., a protein that is
10 different from the Th2-specific protein and which is derived from the same or a different organism. Within a Th2-specific fusion protein, the Th2-specific polypeptide can correspond to all or a portion of a Th2-specific protein, preferably at least one biologically active portion of a Th2-specific protein. Within the fusion protein, the term "operably linked" is intended to indicate that the Th2-specific
15 polypeptide and the non-Th2-specific polypeptide are fused in-frame to each other. The non-Th2-specific polypeptide can be fused to the N-terminus or C-terminus of the Th2-specific polypeptide.

One useful fusion protein is a GST-Th2-specific fusion protein in which the Th2-specific sequences are fused to the C-terminus of the GST sequences. Such
20 fusion proteins can facilitate the purification of recombinant Th2-specific proteins.

In yet another embodiment, the fusion protein is a Th2-specific-immunoglobulin fusion protein in which all or part of a Th2-specific protein is fused to sequences derived from a member of the immunoglobulin protein family. The Th2-specific-immunoglobulin fusion proteins of the invention can be
25 incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a Th2-specific ligand and a Th2-specific protein on the surface of a cell, thereby suppressing Th2-specific-mediated signal

transduction *in vivo*. The Th2-specific-immunoglobulin fusion proteins can be used to affect the bioavailability of a Th2-specific cognate ligand. Inhibition of the Th2-specific ligand/Th2-specific interaction may be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (e.g., promoting or inhibiting) cell survival. Moreover, the Th2-specific-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-Th2-specific antibodies in a subject, to purify Th2-specific ligands, and in screening assays to identify molecules that inhibit the interaction of a Th2-specific protein with a Th2-specific ligand.

Preferably, a Th2-specific chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences may be ligated together in-frame, or the fusion gene can be synthesized, such as with automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments, which can subsequently be annealed and reamplified to generate a chimeric gene sequence (*see, e.g., Ausubel et al., eds. (1995) Current Protocols in Molecular Biology*) (Greene Publishing and Wiley-Interscience, NY). Moreover, a Th2-specific-encoding nucleic acid can be cloned into a commercially available expression vector such that it is linked in-frame to an existing fusion moiety.

Variants of the Th2-specific proteins can function as either Th2-specific agonists (mimetics) or as Th2-specific antagonists. Variants of the Th2-specific protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the Th2-specific protein. An agonist of the Th2-specific protein can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the Th2-specific protein. An antagonist of the Th2-specific protein can inhibit one or more of the activities of the naturally occurring form of the Th2-specific protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade that includes the Th2-specific protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the

biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the Th2-specific proteins.

5 Variants of the Th2-specific protein that function as either Th2-specific agonists or as Th2-specific antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the Th2-specific protein for Th2-specific protein agonist or antagonist activity. In one embodiment, a variegated library of Th2-specific variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.

10 A variegated library of Th2-specific variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential Th2-specific sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of Th2-specific sequences therein. There are a

15 variety of methods that can be used to produce libraries of potential Th2-specific variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the

20 sequences encoding the desired set of potential Th2-specific sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (*see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477*).

In addition, libraries of fragments of the Th2-specific protein coding

25 sequence can be used to generate a variegated population of Th2-specific fragments for screening and subsequent selection of variants of a Th2-specific protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double-stranded PCR fragment of a Th2-specific coding sequence with a nuclease under conditions wherein nicking occurs only about once

30 per molecule, denaturing the double-stranded DNA, renaturing the DNA to form double-stranded DNA which can include sense/antisense pairs from different nicked products, removing single-stranded portions from reformed duplexes by

treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, one can derive an expression library that encodes N-terminal and internal fragments of various sizes of the Th2-specific protein.

5 Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of Th2-specific proteins. The most widely used techniques, which are
10 amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.
15 Recursive ensemble mutagenesis (REM), a technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify Th2-specific variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

20 An isolated Th2-specific polypeptide of the invention can be used as an immunogen to generate corresponding antibodies that bind Th2-specific proteins using standard techniques for polyclonal and monoclonal antibody preparation. By "corresponding antibody" is intended that the antibody binds the particular Th2-specific protein used as the immunogen. The full-length Th2-specific protein can
25 be used or, alternatively, the invention provides antigenic peptide fragments of Th2-specific proteins for use as immunogens. The antigenic peptide of a Th2-specific protein comprises at least 8, preferably 10, 15, 20, or 30 amino acid residues of the amino acid sequence shown in SEQ ID NO:2, 4, 6, 8, 10, 12, 14, or 16 and encompasses an epitope of a Th2-specific protein such that an antibody
30 raised against the peptide forms a specific immune complex with the Th2-specific protein. Preferred epitopes encompassed by the antigenic peptide are regions of a

Th2-specific protein that are located on the surface of the protein, e.g., hydrophilic regions.

Accordingly, another aspect of the invention pertains to anti-Th2-specific polyclonal and monoclonal antibodies that bind a Th2-specific protein. Polyclonal anti-Th2-specific antibodies can be prepared by immunizing a suitable subject (e.g., rabbit, goat, mouse, or other mammal) with a Th2-specific immunogen. The anti-Th2-specific antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized Th2-specific protein. At an appropriate time after immunization, e.g., when the anti-Th2-specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (Kozbor *et al.* (1983) *Immunol. Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985) in *Monoclonal Antibodies and Cancer Therapy*, ed. Reisfeld and Sell (Alan R. Liss, Inc., New York, NY), pp. 77-96) or trioma techniques. The technology for producing hybridomas is well known (see generally Coligan *et al.*, eds. (1994) *Current Protocols in Immunology* (John Wiley & Sons, Inc., New York, NY); Galfre *et al.* (1977) *Nature* 266:550-52; Kenneth (1980) in *Monoclonal Antibodies: A New Dimension In Biological Analyses* (Plenum Publishing Corp., NY; and Lerner (1981) *Yale J. Biol. Med.*, 54:387-402).

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-Th2-specific antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with a Th2-specific protein to thereby isolate immunoglobulin library members that bind the Th2-specific protein. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409;

PCT Publication Nos. WO 92/18619; WO 91/17271; WO 92/20791; WO 92/15679; 93/01288; WO 92/01047; 92/09690; and 90/02809; Fuchs *et al.* (1991) *BioTechnology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J.* 12:725-734.

Additionally, recombinant anti-Th2-specific antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and nonhuman portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication Nos. WO 86101533 and WO 87/02671; European Patent Application Nos. 184,187, 171,496, 125,023, and 173,494; U.S. Patent Nos. 4,816,567 and 5,225,539; European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Such antibodies can be produced using transgenic mice that are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. See, for example, Lonberg and Huszar (1995) *Int. Rev. Immunol.* 13:65-93; and U.S. Patent Nos. 5,625,126; 5,633,425; 5,569,825; 5,661,016; and 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont, CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies that recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. This technology is described by Jespers *et al.* (1994) *Bio/Technology* 12:899-903).

An anti-Th2-specific antibody (e.g., monoclonal antibody) can be used to
5 isolate Th2-specific proteins by standard techniques, such as affinity
chromatography or immunoprecipitation. An anti-Th2-specific antibody can
facilitate the purification of natural Th2-specific protein from cells and of
recombinantly produced Th2-specific protein expressed in host cells. Moreover,
an anti-Th2-specific antibody can be used to detect Th2-specific protein (e.g., in a
10 cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of
expression of the Th2-specific protein. Anti-Th2-specific antibodies can be used
diagnostically to monitor protein levels in tissue as part of a clinical testing
procedure, e.g., to, for example, determine the efficacy of a given treatment
regimen. Detection can be facilitated by coupling the antibody to a detectable
15 substance. Examples of detectable substances include various enzymes, prosthetic
groups, fluorescent materials, luminescent materials, bioluminescent materials, and
radioactive materials. Examples of suitable enzymes include horseradish
peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase;
examples of suitable prosthetic group complexes include streptavidin/biotin and
20 avidin/biotin; examples of suitable fluorescent materials include umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine
fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent
material includes luminol; examples of bioluminescent materials include
luciferase, luciferin, and aequorin; and examples of suitable radioactive material
25 include ^{125}I , ^{131}I , ^{35}S , or ^3H .

Further, an antibody (or fragment thereof) may be conjugated to a
therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal
ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells.
Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine,
30 mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin,
daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin
D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine,

propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan, carmustine
5 (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine
10 and vinblastine). The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or
15 diphtheria toxin; a protein such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte
20 macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, *e.g.*, Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld *et al.* (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*,
25 "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of
30 Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of Antibody-Toxin

Conjugates", Immunol. Rev., 62:119-58 (1982). Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

The antibody-associated molecules of the invention, i.e., corresponding
5 antibodies that bind Th2-specific proteins and such corresponding antibodies that are conjugated to a therapeutic moiety, can be used alone or in any combination, with or without additional therapeutic moieties, to modify a given biological response, e.g., modulating a Th2 response, in accordance with methods of the invention. Thus, for example, modulation of a given biological response is
10 achieved by administering to a subject antibody-associated molecules of the invention, including, but not limited to, administering 1) at least one antibody of the invention, 2) at least one antibody of the invention and at least one free (i.e., not conjugated to an antibody) therapeutic moiety, 3) at least one antibody of the invention that is conjugated to a therapeutic moiety, 4) at least one antibody of the
15 invention and at least one antibody of the invention that is conjugated to a therapeutic moiety, 5) at least one antibody of the invention that is conjugated to a therapeutic moiety and at least one free therapeutic moiety, or 6) at least one antibody of the invention, at least one antibody of the invention that is conjugated to a therapeutic moiety, and at least one free therapeutic moiety. These antibody-associated molecules may be administered to the subject separately from one
20 another, either at the same time or at a different time. Alternatively, these antibody-associated molecules may be administered at the same time, as in a mixture, for example, a mixture comprising both an antibody of the invention and an antibody that is conjugated to a therapeutic moiety, or a mixture comprising any
25 combination of the antibody-associated molecules of the invention, as noted above.

III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression
vectors, containing a nucleic acid encoding a Th2-specific protein (or a portion
30 thereof). "Vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked, such as a "plasmid", a circular double-stranded DNA loop into which additional DNA segments can be ligated, or a viral

vector, where additional DNA segments can be ligated into the viral genome. The vectors are useful for autonomous replication in a host cell or may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome (e.g., nonepisomal mammalian vectors).

5 Expression vectors are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated
10 viruses), that serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for
15 expression, operably linked to the nucleic acid sequence to be expressed. "Operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory
20 sequence" is intended to include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). See, for example, Goeddel (1990) in *Gene Expression Technology: Methods in Enzymology* 185 (Academic Press, San Diego, CA). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct
25 expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby
30 produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., Th2-specific proteins, mutant forms of Th2-specific proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of Th2-specific protein in prokaryotic or eukaryotic host cells. Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or nonfusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA), and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible nonfusion *E. coli* expression vectors include pTrc (Amann *et al.* (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.* (1990) in *Gene Expression Technology: Methods in Enzymology* 185 (Academic Press, San Diego, CA), pp. 60-89). Strategies to maximize recombinant protein expression in *E. coli* can be found in Gottesman (1990) in *Gene Expression Technology: Methods in Enzymology* 185 (Academic Press, CA), pp. 119-128 and Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118. Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.

Suitable eukaryotic host cells include insect cells (examples of Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39)); yeast cells (examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari *et al.* (1987) *EMBO J.* 6:229-234), pMFa (Kurjan and Herskowitz (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.* (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (Invitrogen Corporation, San Diego, CA)); or mammalian cells (mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195)). Suitable mammalian cells include Chinese hamster ovary cells (CHO) or COS cells. In mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used

promoters are derived from polyoma, Adenovirus 2, cytomegalovirus, and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells, see chapters 16 and 17 of Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY). See, Goeddel (1990) in *Gene Expression Technology: Methods in Enzymology* 185 (Academic Press, San Diego, CA). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell but are still included within the scope of the term as used herein.

In one embodiment, the expression vector is a recombinant mammalian expression vector that comprises tissue-specific regulatory elements that direct expression of the nucleic acid preferentially in a particular cell type. Suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Patent Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379), the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546), and the like.

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to Th2-specific mRNA. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen to direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen to direct constitutive, tissue-specific, or cell-type-specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub *et al.* (1986) *Reviews - Trends in Genetics*, Vol. 1(1).

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY) and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin, and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that

encoding a Th2-specific protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

5 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) Th2-specific protein. Accordingly, the invention further provides methods for producing Th2-specific protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention, into which a recombinant expression vector
10 encoding a Th2-specific protein has been introduced, in a suitable medium such that Th2-specific protein is produced. In another embodiment, the method further comprises isolating Th2-specific protein from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention
15 is a fertilized oocyte or an embryonic stem cell into which Th2-specific-coding sequences have been introduced. Such host cells can then be used to create nonhuman transgenic animals in which exogenous Th2-specific sequences have been introduced into their genome or homologous recombinant animals in which endogenous Th2-specific sequences have been altered. Such animals are useful for
20 studying the function and/or activity of Th2-specific genes and proteins and for identifying and/or evaluating modulators of Th2-specific activity. As used herein, a "transgenic animal" is a nonhuman animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include
25 nonhuman primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a
30 "homologous recombinant animal" is a nonhuman animal, preferably a mammal, more preferably a mouse, in which an endogenous Th2-specific gene has been altered by homologous recombination between the endogenous gene and an

exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

5 A transgenic animal of the invention can be created by introducing Th2-specific-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The Th2-specific cDNA sequence can be introduced as a transgene into the genome of a nonhuman animal. Alternatively, a
10 homologue of the mouse Th2-specific gene can be isolated based on hybridization and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the Th2-specific transgene to direct expression of Th2-specific protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the
15 art and are described, for example, in U.S. Patent Nos. 4,736,866, 4,870,009, and 4,873,191 and in Hogan (1986) *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the Th2-specific transgene in its genome and/or expression of Th2-specific mRNA in tissues or cells of the animals. A
20 transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding Th2-specific gene can further be bred to other transgenic animals carrying other transgenes.

25 To create a homologous recombinant animal, one prepares a vector containing at least a portion of a Th2-specific gene or a homologue of the gene into which a deletion, addition, or substitution has been introduced to thereby alter, e.g., functionally disrupt, the Th2-specific gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous Th2-specific gene is functionally disrupted (i.e., no longer encodes a functional protein;
30 also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous Th2-specific gene is

mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous Th2-specific protein). In the homologous recombination vector, the altered portion of the Th2-specific gene is flanked at its 5' and 3' ends by additional nucleic acid of the Th2-specific gene to allow for homologous recombination to occur between the exogenous Th2-specific gene carried by the vector and an endogenous Th2-specific gene in an embryonic stem cell. The additional flanking Th2-specific nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (*see, e.g., Thomas and Capecchi (1987) Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation), and cells in which the introduced Th2-specific gene has homologously recombined with the endogenous Th2-specific gene are selected (*see, e.g., Li et al. (1992) Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (*see, e.g., Bradley (1987) in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, ed. Robertson (IRL, Oxford), pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

In another embodiment, transgenic nonhuman animals containing selected systems that allow for regulated expression of the transgene can be produced. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, *see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et

al. (1991) *Science* 251:1351-1355). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating
5 two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the nonhuman transgenic animals described herein can also be produced according to the methods described in Wilmot *et al.* (1997) *Nature* 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669.

10

IV. Pharmaceutical Compositions

The Th2-specific nucleic acid molecules, Th2-specific proteins, and anti-Th2-specific antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for
15 administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical
20 administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

25 The compositions of the invention are useful to treat any of the disorders discussed herein. The compositions are provided in therapeutically effective amounts. By "therapeutically effective amount" is intended an amount sufficient to modulate or bring about the desired response. For example, where a Th2 response is to be modulated, a therapeutically effective amount of a composition of
30 the invention would be an amount sufficient to modulate a Th2 response. As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*, an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably

about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.

5 The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments. In a
10 preferred example, a subject is treated with antibody, protein, or polypeptide in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody, protein, or
15 polypeptide used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such
20 small molecules include, but are not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (*i.e.*, including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less
25 than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

It is understood that appropriate doses of small molecule agents depends
30 upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample

being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention. Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or

dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile
5 aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF; Parsippany, NJ), or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be
10 fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained,
15 for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol,
20 ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride, in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
25 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a Th2-specific protein or anti-Th2-specific antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile
30 vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying

and freeze-drying, which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth, or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a

controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated with each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Depending on the type and severity of the disease, about 1 $\mu\text{g/kg}$ to about 15 mg/kg (e.g., 0.1 to 20 mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 $\mu\text{g/kg}$ to about 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. An exemplary dosing regimen is disclosed in WO 94/04188. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject

by, for example, intravenous injection, local administration (U.S. Patent 5,328,470), or by stereotactic injection (*see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057*). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can
5 comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g., retroviral vectors*, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or
10 dispenser together with instructions for administration.

V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: (a)
15 screening assays; (b) detection assays (*e.g., chromosomal mapping, tissue typing, forensic biology*); (c) predictive medicine (*e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics*); and (d) methods of treatment (*e.g., therapeutic and prophylactic*). The isolated nucleic acid molecules of the invention can be used to express Th2-specific protein (*e.g., via a*
20 recombinant expression vector in a host cell in gene therapy applications), to detect Th2-specific mRNA (*e.g., in a biological sample*) or a genetic lesion in a Th2-specific gene, and to modulate Th2-specific activity. In addition, the Th2-specific proteins can be used to screen drugs or compounds that modulate the immune response as well as to treat disorders characterized by insufficient or excessive
25 production of Th2-specific protein or production of Th2-specific protein forms that have decreased or aberrant activity compared to Th2-specific wild type protein. In addition, the anti-Th2-specific antibodies of the invention can be used to detect and isolate Th2-specific proteins and modulate Th2-specific activity.

30 A. Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e., candidate or test compounds or agents*

(e.g., peptides, peptidomimetics, small molecules, or other drugs) that bind to Th2-specific proteins or have a stimulatory or inhibitory effect on, for example, Th2-specific expression or Th2-specific activity.

The test compounds of the present invention can be obtained using any of
5 the numerous approaches in combinatorial library methods known in the art, including biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound" library method, and synthetic library methods using affinity
10 chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, nonpeptide oligomer, or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. USA*
15 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994) *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten
20 (1992) *Bio/Techniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (U.S. Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869), or phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.*
25 (1990) *Proc. Natl. Acad. Sci. USA* 87:6378-6382; and Felici (1991) *J. Mol. Biol.* 222:301-310).

Determining the ability of the test compound to bind to the Th2-specific protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the Th2-
30 specific protein or biologically active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the

radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate
5 substrate to product.

In a similar manner, one may determine the ability of the Th2-specific protein to bind to or interact with a Th2-specific target molecule. By "target molecule" is intended a molecule with which a Th2-specific protein binds or interacts in nature. In a preferred embodiment, the ability of the Th2-specific
10 protein to bind to or interact with a Th2-specific target molecule can be determined by monitoring the activity of the target molecule. For example, the activity of the target molecule can be monitored by detecting induction of a cellular second messenger of the target (e.g., intracellular Ca^{2+} , diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the
15 induction of a reporter gene (e.g., a Th2-specific-responsive regulatory element operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cellular differentiation or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free
20 assay comprising contacting a Th2-specific protein or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the Th2-specific protein or biologically active portion thereof. Binding of the test compound to the Th2-specific protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes
25 contacting the Th2-specific protein or biologically active portion thereof with a known compound that binds Th2-specific protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to preferentially bind to Th2-specific protein or biologically active portion thereof as compared to the known compound.

30 In another embodiment, an assay is a cell-free assay comprising contacting Th2-specific protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or

inhibit) the activity of the Th2-specific protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of a Th2-specific protein can be accomplished, for example, by determining the ability of the Th2-specific protein to bind to a Th2-specific target molecule as described
5 above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of a Th2-specific protein can be accomplished by determining the ability of the Th2-specific protein to further modulate a Th2-specific target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can
10 be determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting the Th2-specific protein or biologically active portion thereof with a known compound that binds a Th2-specific protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to
15 preferentially bind to or modulate the activity of a Th2-specific target molecule.

In the above-mentioned assays, it may be desirable to immobilize either a Th2-specific protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. In one embodiment, a fusion protein can be provided that
20 adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/Th2-specific fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione-derivatized microtitre plates, which are then combined with the test compound or the test compound and either
25 the nonadsorbed target protein or Th2-specific protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the
30 complexes can be dissociated from the matrix, and the level of Th2-specific binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either Th2-specific protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated Th2-specific molecules or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96-well plates (Pierce Chemicals). Alternatively, antibodies reactive with a Th2-specific protein or target molecules but which do not interfere with binding of the Th2-specific protein to its target molecule can be derivatized to the wells of the plate, and unbound target or Th2-specific protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the Th2-specific protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the Th2-specific protein or target molecule.

In another embodiment, modulators of Th2-specific expression are identified in a method in which a cell is contacted with a candidate compound and the expression of Th2-specific mRNA or protein in the cell is determined relative to expression of Th2-specific mRNA or protein in a cell in the absence of the candidate compound. When expression is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of Th2-specific mRNA or protein expression. Alternatively, when expression is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of Th2-specific mRNA or protein expression. The level of Th2-specific mRNA or protein expression in the cells can be determined by methods described herein for detecting Th2-specific mRNA or protein.

In yet another aspect of the invention, the Th2-specific proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol.*

Chem. 268:12046-12054; Bartel *et al.* (1993) *Bio-Techniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with Th2-specific protein ("Th2-specific-binding proteins" or "Th2-specific-bp") and modulate Th2-specific activity. Such Th2-specific-binding proteins are also likely to be involved in the propagation of signals by the Th2-specific proteins as, for example, upstream or downstream elements of the Th2-specific pathway.

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (1) map their respective genes on a chromosome; (2) identify an individual from a minute biological sample (tissue typing); and (3) aid in forensic identification of a biological sample. These applications are described in the subsections below.

1. Chromosome Mapping

The isolated complete or partial Th2-specific gene sequences of the invention can be used to map their respective Th2-specific genes on a chromosome, thereby facilitating the location of gene regions associated with genetic disease. Computer analysis of Th2-specific sequences can be used to rapidly select PCR primers (preferably 15-25 bp in length) that do not span more than one exon in the genomic DNA, thereby simplifying the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the Th2-specific sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but

retain the mouse chromosomes. By using media in which mouse cells cannot grow (because they lack a particular enzyme), but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established.

5 Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes (D'Eustachio *et al.* (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with

10 translocations and deletions.

Other mapping strategies that can similarly be used to map a Th2-specific sequence to its chromosome include *in situ* hybridization (described in Fan *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific

15 cDNA libraries. Furthermore, fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. For a review of this technique, see Verma *et al.* (1988) *Human Chromosomes: A Manual of Basic Techniques* (Pergamon Press, NY). The FISH technique can be used with a DNA sequence as short as 500 or

20 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results in a reasonable amount of time.

Reagents for chromosome mapping can be used individually to mark a

25 single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal

30 mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with

genetic map data. (Such data are found, for example, in V. McKusick, *Mendelian Inheritance in Man*, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-
5 inheritance of physically adjacent genes), described in, e.g., Egeland *et al.* (1987) *Nature* 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the Th2-specific gene can be determined. If a mutation is observed in some or all of the affected individuals but
10 not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete
15 sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

2. Tissue Typing

The Th2-specific sequences of the present invention can also be
20 used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes and probed on a Southern blot to yield unique bands for identification. The sequences
25 of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique for determining the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the Th2-specific sequences of
30 the invention can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The Th2-specific sequences of the invention uniquely represent portions of the human genome.

- 5 Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for
- 10 identification purposes. The noncoding sequences of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15 are used, a more appropriate number of primers for positive individual
- 15 identification would be 500 to 2,000.

3. Use of Partial Th2-specific Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. In this manner, PCR technology can be used to amplify DNA sequences

20 taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide

25 polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" that is unique to a particular individual. As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by

30 restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it

easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the Th2-specific sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15 having a length of at least 20 or 30 bases.

5 The Th2-specific sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes that can be used in, for example, an in situ hybridization technique, to identify a specific tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such Th2-specific probes, can be used to identify tissue
10 by species and/or by organ type.

In a similar fashion, these reagents, e.g., Th2-specific primers or probes can be used to screen tissue culture for contamination (i.e., screen for the presence of a mixture of different types of cells in a culture).

15 C. Predictive Medicine

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. These applications are described in the subsections
20 below.

1. Diagnostic Assays

One aspect of the present invention relates to diagnostic assays for detecting Th2-specific protein and/or nucleic acid expression as well as Th2-
25 specific activity, in the context of a biological sample. An exemplary method for detecting the presence or absence of Th2-specific proteins in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting Th2-specific protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes Th2-specific
30 protein such that the presence of Th2-specific protein is detected in the biological sample. Results obtained with a biological sample from the test subject may be compared to results obtained with a biological sample from a control subject.

A preferred agent for detecting Th2-specific mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to Th2-specific mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length Th2-specific nucleic acid, such as the nucleic acid of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 5 or 15, or a portion thereof, such as a nucleic acid molecule of at least 15, 30, 50, 100, 250, or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to Th2-specific mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting Th2-specific protein is an antibody capable 10 of binding to Th2-specific protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to 15 the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

20 The term "biological sample" is intended to include tissues, cells, and biological fluids isolated from a subject, as well as tissues, cells, and fluids present within a subject. That is, the detection method of the invention can be used to detect Th2-specific mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of Th2-specific mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* 25 techniques for detection of Th2-specific protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of Th2-specific genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for 30 detection of Th2-specific protein include introducing into a subject a labeled anti-Th2-specific antibody. For example, the antibody can be labeled with a

radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules
5 from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

The invention also encompasses kits for detecting the presence of Th2-specific proteins in a biological sample (a test sample). Such kits can be used to
10 determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of Th2-specific protein (e.g., an immunological disorder). For example, the kit can comprise a labeled compound or agent capable of detecting Th2-specific protein or mRNA in a biological sample and means for determining the amount of a Th2-specific protein in the sample
15 (e.g., an anti-Th2-specific antibody or an oligonucleotide probe that binds to DNA encoding a Th2-specific protein, e.g., SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15). Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of Th2-specific sequences if the amount of Th2-specific protein or mRNA is above or
20 below a normal level.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) that binds to Th2-specific protein; and, optionally, (2) a second, different antibody that binds to Th2-specific protein or the first antibody and is conjugated to a detectable agent. For oligonucleotide-based
25 kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, that hybridizes to a Th2-specific nucleic acid sequence or (2) a pair of primers useful for amplifying a Th2-specific nucleic acid molecule.

The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for
30 detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples that can be assayed and compared to the test sample contained. Each component of the kit is usually

enclosed within an individual container, and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of Th2-specific proteins.

5

2. Prognostic Assays

The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with Th2-specific protein, Th2-specific nucleic acid expression, or Th2-specific activity. Prognostic assays can be used for prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with Th2-specific protein, Th2-specific nucleic acid expression, or Th2-specific activity.

Thus, the present invention provides a method in which a test sample is obtained from a subject, and Th2-specific protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of Th2-specific protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant Th2-specific expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, using the prognostic assays described herein, the present invention provides methods for determining whether a subject can be administered a specific agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) or class of agents (e.g., agents of a type that decrease Th2-specific activity) to effectively treat a disease or disorder associated with aberrant Th2-specific expression or activity. In this manner, a test sample is obtained and Th2-specific protein or nucleic acid is detected. The presence of Th2-specific protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant Th2-specific expression or activity.

The methods of the invention can also be used to detect genetic lesions or mutations in a Th2-specific gene, thereby determining if a subject with the lesioned

gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding a Th2-specific-protein, or the misexpression of the Th2-specific gene. For example, such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: (1) a deletion of one or more nucleotides from a Th2-specific gene; (2) an addition of one or more nucleotides to a Th2-specific gene; (3) a substitution of one or more nucleotides of a Th2-specific gene; (4) a chromosomal rearrangement of a Th2-specific gene; (5) an alteration in the level of a messenger RNA transcript of a Th2-specific gene; (6) an aberrant modification of a Th2-specific gene, such as of the methylation pattern of the genomic DNA; (7) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a Th2-specific gene; (8) a non-wild-type level of a Th2-specific-protein; (9) an allelic loss of a Th2-specific gene; and (10) an inappropriate post-translational modification of a Th2-specific-protein. As described herein, there are a large number of assay techniques known in the art that can be used for detecting lesions in a Th2-specific gene. Any cell type or tissue, preferably peripheral blood leukocytes, in which Th2-specific proteins are expressed may be utilized in the prognostic assays described herein.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202*), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91:360-364*), the latter of which can be particularly useful for detecting point mutations in the Th2-specific-gene (*see, e.g., Abravaya et al. (1995) Nucleic Acids Res. 23:675-682*). It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include self sustained sequence replication (Guatelli *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878),

transcriptional amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.* (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art.

5 These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a Th2-specific gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns of isolated test sample and control DNA digested with one or more restriction
10 endonucleases. Moreover, the use of sequence specific ribozymes (*see, e.g., U.S. Patent No. 5,498,531*) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in a Th2-specific molecule can be identified by hybridizing a sample and control nucleic acids, *e.g., DNA or RNA*, to
15 high density arrays containing hundreds or thousands of oligonucleotide probes (Cronin *et al.* (1996) *Human Mutation* 7:244-255; Kozal *et al.* (1996) *Nature Medicine* 2:753-759). In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the Th2-specific gene and detect mutations by comparing the sequence of the sample Th2-specific gene
20 with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays
25 ((1995) *Bio/Techniques* 19:448), including sequencing by mass spectrometry (*see, e.g., PCT Publication No. WO 94/16101*; Cohen *et al.* (1996) *Adv. Chromatogr.* 36:127-162; and Griffin *et al.* (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the Th2-specific gene include methods in which protection from cleavage agents is used to detect mismatched
30 bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). *See also* Cotton *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:4397; Saleeba *et al.*

(1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more "DNA mismatch repair" enzymes that recognize mismatched base pairs in
5 double-stranded DNA in defined systems for detecting and mapping point mutations in Th2-specific cDNAs obtained from samples of cells. See, e.g., Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662. According to an exemplary embodiment, a probe based on a Th2-specific sequence, e.g., a wild-type Th2-specific sequence, is hybridized to a cDNA or other DNA product from a test
10 cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in Th2-specific genes. For example, single-strand
15 conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild-type nucleic acids (Orita *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:2766; see also Cotton (1993) *Mutat. Res.* 285:125-144; Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the
20 secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double-stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet.* 7:5).

In yet another embodiment, the movement of mutant or wild-type
25 fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further
30 embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys. Chem.* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6230). Such allele-specific oligonucleotides are hybridized to PCR-amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele-specific amplification technology, which depends on selective PCR amplification, may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule so that amplification depends on differential hybridization (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition, it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing prepackaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a Th2-specific gene.

3. Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on Th2-specific activity (e.g., Th2-specific gene expression) as identified by a screening assay described herein, can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant Th2-specific activity as well as to modulate the phenotype of an immune response. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of Th2-specific protein, expression of Th2-specific nucleic acid, or mutation content of Th2-specific genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as "altered drug action." Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as "altered drug metabolism". These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (antimalarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of Th2-specific protein, expression of Th2-specific nucleic acid, or mutation content of Th2-specific genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a Th2-specific modulator, such as a modulator identified by one of the exemplary screening assays described herein.

4. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of Th2-specific genes (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug
5 screening but also in clinical trials. For example, the effectiveness of an agent, as determined by a screening assay as described herein, to increase or decrease Th2-specific gene expression, protein levels, or protein activity, can be monitored in clinical trials of subjects exhibiting decreased or increased Th2-specific
10 expression or activity and preferably that of other genes that have been implicated in for example, a cellular proliferation disorder, can be used as a marker of the immune responsiveness of a particular cell.

For example, and not by way of limitation, genes that are modulated in cells by treatment with an agent (e.g., compound, drug, or small molecule) that
15 modulates Th2-specific activity (e.g., as identified in a screening assay described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of Th2-specific genes and other genes implicated in the disorder. The levels of gene expression (i.e., a gene
20 expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of Th2-specific genes or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent.
25 Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an
30 agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (1) obtaining a preadministration sample from a subject prior to administration of the agent; (2) detecting the level of expression of a Th2-

specific protein, mRNA, or genomic DNA in the preadministration sample; (3) obtaining one or more postadministration samples from the subject; (4) detecting the level of expression or activity of the Th2-specific protein, mRNA, or genomic DNA in the postadministration samples; (5) comparing the level of expression or activity of the Th2-specific protein, mRNA, or genomic DNA in the preadministration sample with the Th2-specific protein, mRNA, or genomic DNA in the postadministration sample or samples; and (vi) altering the administration of the agent to the subject accordingly to bring about the desired effect, i.e., for example, an increase or a decrease in the expression or activity of a Th2-specific protein.

C. Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant Th2-specific expression or activity. Additionally, the compositions of the invention find use in modulating the T-lymphocyte response. Thus, therapies for immune and respiratory disorders are encompassed herein.

1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject a disease or condition associated with an aberrant Th2-specific expression or activity by administering to the subject an agent that modulates Th2-specific expression or at least one Th2-specific gene activity. Subjects at risk for a disease that is caused, or contributed to, by aberrant Th2-specific expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the Th2-specific aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of Th2-specific aberrancy, for example, a Th2-specific agonist or Th2-specific antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating Th2-specific expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of Th2-specific protein activity associated with the cell. An agent that modulates Th2-specific protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a Th2-specific protein, a peptide, a Th2-specific peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of Th2-specific protein. Examples of such stimulatory agents include active Th2-specific protein and a nucleic acid molecule encoding a Th2-specific protein that has been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of Th2-specific protein. Examples of such inhibitory agents include antisense Th2-specific nucleic acid molecules and anti-Th2-specific antibodies.

These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a Th2-specific protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or a combination of agents, that modulates (e.g., upregulates or downregulates) Th2-specific expression or activity. In another embodiment, the method involves administering a Th2-specific protein or nucleic acid molecule as therapy to compensate for reduced or aberrant Th2-specific expression or activity.

Stimulation of Th2-specific activity is desirable in situations in which a Th2-specific protein is abnormally downregulated and/or in which increased Th2-specific activity is likely to have a beneficial effect. Conversely, inhibition of Th2-specific activity is desirable in situations in which Th2-specific activity is abnormally upregulated and/or in which decreased Th2-specific activity is likely to have a beneficial effect.

This invention is further illustrated by the following examples, which should not be construed as limiting.

EXAMPLES

5 *In vitro* and *in vivo* studies of T cell activation have lead to the widely accepted hypothesis that in addition to signals delivered to the T cell receptor (TCR) by MHC-II/peptide complexes, costimulatory signals by antigen presenting cells (APCs) are critical for complete immune activation, the absence of which results in an abortive immune response (Schwartz (1990) *Science* 4961:1349-56).
10 The most important costimulatory signal delivered to resting T cells occurs upon CD28 engagement by B7 molecules (Jenkins *et al.* (1991) *J. Immunol.* 8:2461-6; Harding *et al.* (1992) *Nature* 6370:607-9). In contrast to CD28, the second member of this family of molecules, CTLA-4 delivers a negative signal to the activated T cell, opposing CD28-mediated costimulation (Walunas *et al.* (1994)
15 *Immunity* 1(5):405-413).

Recent *in vitro* experiments have suggested that the dependency on CD28/B7 mediated costimulation is greatly influenced by the antigenic experience of the T cell. Thus, while naïve CD4+ T cells require CD28-mediated signaling for IL-2 production and clonal expansion (Seder *et al.* (1994) *J. Exp.*
20 *Med.* 1:299-304; McKnight *et al.* (1994) *J. Immunol.* 11:5220-5), optimal activation of recently activated T helper subsets occurs independent of CD28 ligation (Schweitzer and Sharpe (1998) *J. Immunol.* 6:2762-71). In addition, while CD28 stimulation has been reported to promote differentiation to the Th2 phenotype *in vitro* (Rulifson *et al.* (1997) *J. Immunol.* 15:658-65), studies
25 performed in CD28 gene targeted mice have demonstrated that at least under some circumstances, normal Th2 effector immune responses can be generated, suggesting other costimulatory signals are important in Th2 effector function (Brown *et al.* (1996) *J. Exp. Med.* 3:803-10; Gause *et al.* (1997) *J. Immunol.* 158:4082-7; Wu *et al.* (1998) *J. Exp. Med.* 187:1151-1156).

30 In an attempt to identify novel candidate genes that may function as costimulators of T helper effector cells, subtractive libraries from activated murine Th1 vs. Th2 clones were generated. Using a subtractive hybridization-PCR

approach on murine Th2 vs. Th1 mRNA, the murine orthologues for three novel human genes that are differentially expressed in the Th2 subset of T-helper cells were identified. The first of these orthologues, m1419, encodes a 3.6 Kb transcript (corresponding cDNA set forth in SEQ ID NO:1) that is overexpressed in

5 CD3/TCR-activated Th2 cells. The open reading frame (nt 126-1304) of this transcript encodes a predicted 392 amino acid, 42.8 kDa protein (SEQ ID NO:2). A search of the nucleotide and protein databases revealed that the m1419 cDNA is novel. The only significant homology detected was to a *Caenorhabditis elegans* sequence (GenBank Accession Number AAB00590; Fulton and Gattung (1994)

10 *Nature* 368:32-38; Waterston, R., Direct Submission, 19 May 1996, Genome Sequencing Center, Department of Genetics, Washington University, St. Louis, MO, 63110 USA). The amino acid sequence for m1419 showed approximately 40% identity over 140 amino acids with the putative translation of one of these *C. elegans* sequences. A cDNA (corresponding to a 3.9 Kb transcript) for the

15 corresponding human Th2-specific gene, h1419 (SEQ ID NO:15), has been isolated; the open reading frame (nt 325-1479) of this cDNA encodes a 384 amino acid protein (SEQ ID NO:16).

The second of these murine orthologues, m1022, encodes two transcripts, a shorter 1.6 Kb form (corresponding cDNA set forth in SEQ ID NO:3) and a longer

20 4.4 Kb form (corresponding cDNA set forth in SEQ ID NO:5), that are overexpressed in CD3/TCR-activated Th2 cells. These sequences differ only in their 3'-untranslated region, with the shorter form corresponding to nt 1-1587 of the longer form. The open reading frame (nt 36-1430) of both transcripts encodes a 464 amino acid, 54.2 kDa protein (SEQ ID NOs:4 and 6) that is homologous

25 (48.3% identity over a 60 amino acid overlap; see Figure 1) with GenBank Accession Number CAA43286, which codes for the alpha core subunit of DNA polymerase from *Trypanosoma brucei* (Leegwater, Direct Submission, 19 July 1991, International Laboratory for Research on Animal Disease, P.O. Box 30709, Nairobi, Kenya; Leegwater *et al.* (1991) *Nucleic Acids Res.* 19:6411-6447). A

30 cDNA (corresponding to a 1.8 Kb transcript) for the corresponding human Th2-specific gene, h1022 (SEQ ID NO:13), has been isolated; the open reading frame (nt 57-1502) of this cDNA encodes a 481 amino acid protein (SEQ ID NO:14).

The third of these murine orthologues, m1228, encodes two transcripts, a shorter 2.1 Kb form (corresponding cDNA set forth in SEQ ID NO:7) and a longer 3.3 Kb form (corresponding cDNA set forth in SEQ ID NO:9), that are overexpressed in CD3/TCR-activated Th2 cells. These sequences differ only in their 3'-untranslated region, with the shorter form corresponding to nt 1-2080 of the longer form. The open reading frame (nt 40-642) of both transcripts encodes a predicted 200 amino acid, 22.7 kDa protein (SEQ ID NOs:8 and 10). A cDNA (corresponding to a 2.7 Kb transcript) for the corresponding human Th2-specific gene, h1228 (SEQ ID NO:11), has been isolated; the open reading frame (nt 115-711) of this cDNA encodes a 198 amino acid protein (SEQ ID NO:12). The h1228 protein and the corresponding m1228 protein are Ig superfamily members, which share 69% identity over their full-length amino acid sequences.

The predicted h1228 and m1228 proteins share homology to both human and murine CD28 and CTLA-4 (see Figure 2). The h1228 sequence shares 33% identity with hCD28 and 26% identity with hCTLA-4. The murine orthologue m1228 shares 36.5% identity with mCD28 and 38.5% identity with mCTLA-4. The human homologue of m1228 has recently been designated ICOS, the third member of the CD28/CTLA-4 family (Hutloff *et al* (1999) *Nature* 6716:263). The m1228 gene and protein are thus also referred to as mICOS in Example 6 below.

Examination of the amino acid sequence of m1228 and of h1228 revealed 4 conserved cysteine residues (amino acid residues 42, 63, 83, and 137 of SEQ ID NOs:8 and 10; amino acid residues 41, 62, 82, and 135 of SEQ ID NO:12). There is a conserved PPP motif common in CD28 and its related homologue CTLA-4. This motif, which is in the extracellular domain, is found in human CD28 as MYPPPY (amino acid residues 117-122 of SEQ ID NO:19), in human CTLA-4 as MYPPPY (amino acid residues 134-139 of SEQ ID NO:21), in m1228 as FDPPPF (amino acid residues 114-119 of SEQ ID Nos:8 and 10), and in h1228 as FDPPPF (amino acid residues 113-118 of SEQ ID NO:12). In addition, the 1228 sequence contains a YXXM motif (where X can be any amino acid) common in CD28 and CTLA-4 that appears to be required for CD28-mediated phosphatidylinositol 3-kinase (PI-3K) activity. This motif, which is in the intracellular domain of CD28 and 1228, is involved in the signaling pathways. This sequence is found in human

CD28 as YMN^M (amino acid residues 191-194 of SEQ ID NO:19), in human CTLA-4 as YVK^M (amino acid residues 201-204 of SEQ ID NO:21), in m1228 as YMF^M (amino acid residues 181-184 of SEQ ID NOs:8 and 10), and in h1228 as YMF^M (amino acid residues 178-181 of SEQ ID NO:12). Taken together, these data suggest that h1228 and the corresponding m1228 function as novel Th2-specific costimulatory molecules.

The methods employed to identify the murine orthologues and the corresponding human genes and to characterize their expression patterns are described in the following examples.

10

Example 1: Th1 and Th2 mRNA Generation

Mice expressing the transgene for the DO11.10 $\alpha\beta$ -TCR, which recognizes residues 323-339 of chicken ovalbumin (OVA) in association with I-A^d, were maintained on the BALB/c background. The mice were housed in an animal facility in microisolator cages under pathogen-free conditions in accordance with institutional and state guidelines.

DO11.10 TCR-transgenic CD4⁺ T cells were cultured in complete RPMI 1640 with OVA 323-339 (1 mM) and mitomycin C-treated BALB/c spleen cells. For Th1 phenotype development, 10 ng/ml of recombinant murine IL-12 (R & D Systems) and neutralizing anti-IL-4 mAb (11B11) (10 μ g/ml) were added, and for Th2 development, recombinant murine IL-4 (R & D Systems) and neutralizing polyclonal anti-murine IL-12 (10 μ g/ml) (TOSH-2, Endogen, Cambridge, MA) were added and stimulated with the antigenic peptide OVA 323-339. Cells were cultured for three rounds of antigenic stimulations under polarizing conditions. Cells were then washed and cultured in mIL-2 (10 ng/ml) for 48 hours. Dead cells were then removed by gradient centrifugation and cells (5×10^6 /well) plated on immobilized CD3 (2C11, 10 μ g/ml) on 6 well plates in the presence of hIL-2 for 6, 24, or 48 hours. Resting cells were cultured in IL-2 for 48 hours, but not stimulated, and were used as nonactivated control cells.

Example 2: Subtractive Hybridization Protocol

Poly-A+ RNA was isolated using the FastTrack mRNA isolation kit (Invitrogen, San Diego CA). A Th2-specific library was generated using the Clontech PCR-Select cDNA Subtraction Kit (Clontech, Palo Alto, CA) according to the attached protocol. 2.0 µg of poly-A+ RNA derived from activated Th2 cells was used as "tester", and 2.0 µg of poly-A+ RNA derived from activated Th1 cells was used as "driver". PCR products from the resulting library were cloned into the PCRII cloning vector (Invitrogen, San Diego, CA). Plasmid DNA from individual clones was spotted onto nylon filters, and DNA was denatured by soaking the filters sequentially in 1.5M NaCl, 0.5M NaOH followed by 1.5M NaCl, 0.5M Tris pH 8.0. Single stranded probes were prepared from Poly-A+ RNA from the two cell populations, by reverse transcription using ³²P-labeled dCTP. Clones showing a differential hybridization to Th2 vs. Th1 cDNA were selected and sequenced. Upon further analysis, the cDNA clones termed m1419, m1022, and m1228 were identified.

Example 3: mRNA Expression of cDNA Clones m1419, m1022, and m1228

Differential expression of each of the three murine cDNA clones obtained from this library was confirmed by Northern Blot analysis using standard techniques (Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY)), with 0.1-1.0 µg of poly-A+ RNA, or 5.0 µg of total RNA, purified from two independent preparations of Th1 and Th2 cells polarized as described above. For each clone, cDNA probes were labeled with ³²P-dCTP using standard techniques (Maniatis *et al.*, *supra*). The probe for clone m1419 (SEQ ID NO:1) was of a 713 bp cDNA consisting of the region from nt 2,310 to nt 3,000 of the full-length m1419 cDNA. The probe for clone m1022 (SEQ ID NOs:3 and 5) was a 482 bp cDNA consisting of the region from nt 470 to nt 970 of the full-length m1022 cDNA. The probe for clone m1228 (SEQ ID NOs:7 and 9) was a 965 bp cDNA consisting of the region from nt 87 to nt 1051 of the full-length m1228 cDNA.

Expression of mRNA for each of these three clones was determined in (a) Th1 and Th2 mRNA 48 hours after CD3/TCR crosslinking, or (b) resting cells and

6 hours post CD3 activation in Th1 and Th2 populations. Although resting Th1 and Th2 cells both expressed the m1419 mRNA, this transcript was clearly up-regulated in the Th2 population, and down-regulated in the Th1 population.

Expression of mRNA for each of these three clones mRNA was also
5 analyzed in normal mouse tissues obtained from untreated or LPS-treated animals. Northern Blot analysis was performed using 0.5 µg of poly-A+ RNA derived from the following tissues: liver, lung, brain, kidney, heart, skeletal muscle, skin, bone, lymph node, spleen and thymus. The m1419 mRNA was detected in only the
10 activated lymph node, and to a lesser extent, in brain. Expression of clone m1022 was not detected in either normal mouse tissues or in tissue obtained from LPS treated animals.

Example 4: Full-Length cDNA Cloning

A cDNA library was prepared from murine Th2 cells derived from the
15 same poly-A+ RNA used for the subtracted Th2 library described above. cDNAs were cloned into a lambda phage expression vector, γZIPLOX (Gibco BRL, Gaithersburg, MD) using the SalI and NotI cloning sites. The cDNAs corresponding to the transcripts identified with the respective m1419, m1022, and
20 m1228 probes were isolated from this library.

Example 5: Isolation of h1228, 1022, and 1419

The human 1228 (cDNA set forth in SEQ ID NO:11), human 1022 (cDNA set forth in SEQ ID NO:13), and human 1419 (cDNA set forth in SEQ ID NO:15) clones were obtained by screening a human mixed lymphocyte library with the
25 corresponding murine probes. The materials and methods for making the library were identical to the methods used for obtaining the mouse clone, except for the source of the RNA. The library was screened with a probe that comprised the entire coding region of the murine gene for either 1228 (SEQ ID NO:9, nt 40-642), 1022 (SEQ ID NO:5, nt 36-1430), or 1419 (SEQ ID NO:1, nt 126-1304).
30 Hybridization was performed at 40°C (instead of 65°C), and the filters were washed under lower stringency (0.5X SSC, 0.1% SDS at room temperature).

Example 6: Further Characterization of the m1228 Clone

The murine clone identified as m1228, referred to below as mICOS, was selected for further characterization of its role in Th2 immune responses.

5

Materials and Methods

Expression of mICOS

The restricted pattern of mICOS expression was extended using real time quantitative PCR analysis (Taqman™). In brief, an oligonucleotide probe was designed to anneal to the mICOS gene between two PCR primers. The probe was then fluorescently labeled with FAM (reporter dye) on the 5' end and TAMRA (quencher dye) on the 3' end. A similar probe and PCR primers were designed for mGAPDH. The probe for this gene incorporated VIC as the reporter dye. PCR reactions were run that included the primers and probes for these two genes, as well as cDNA made from various cells and tissues. As the polymerase moves across the gene during the reaction, it cleaves the dye from one end of each probe, which causes a fluorescent emission that is measured by the Sequence Detector 7700. The emissions recorded for each cDNA can then be converted into the level of expression for mICOS normalized to the expression of mGAPDH. Splenic CD4, CD8, and CD3 cells were purified by negative selection (R & D Systems). B cells were isolated by positive selection by labeling cells with rat anti-CD19 and separating the cell using rat Ig coupled beads (MACS Microbeads Miltenyi Biotec, CA). Neutrophils were obtained from the peritoneum after thioglycollate treatment, and macrophages were obtained as the adherent fraction of peritoneal cells. Finally, eosinophils (92% purity) were isolated as the nonadherent population of peritoneal cells obtained from IL-5 transgenic mice.

25

Mapping mICOS to Chromosome 1

mICOS-specific primers (Forward- AACCTTCTAGTCCTTTGGTCTGC, SEQ ID NO:23; Reverse-GGCCCAGGCTACAGGCTG, SEQ ID NO:24) were used to amplify a 159 bp PCR product from both C57BL/6J and the wild-derived *Mus spretus* strain SPRET/EiJ. Single stranded conformation polymorphism (SSCP) analysis identified a polymorphism between C57BL/6J and *M. spretus*.

30

The genetic segregation of the *M. spretus* allele was followed in 181 progeny of a (C57BL/6J x *M. spretus*) x C57BL/6 mapping panel by SSCP. The segregation pattern of the *M. spretus* allele was compared with the segregation pattern of 359 other genetic loci that have been mapped in this backcross panel. mICOS mapped to murine chromosome 1, approximately 16.2±2.75 cM distal to the microsatellite marker D1MIT4 and 15.91±2.76 cM proximal of the marker D1MIT8. Further, using SSCP markers designed from the published sequence of the CD28 and CTLA-4 genes, mICOS was found to completely cosegregate with these genes on this mapping panel (no recombinations detectable among all three genes).

10

Generation of mICOS-Ig Fusion Proteins

A DNA sequence containing the extracellular domain of mICOS was PCR-amplified and cloned into a vector containing the CD5 signal sequence and the human IgG1 constant region (mICOS-Ig). COS cells were transiently transfected using lipofectamine™ (GIBCO) and the recombinant protein purified over a protein A column. The purity of ICOS-Ig was subsequently assessed by coomassie-stained SDS-PAGE and was determined to be greater than 90%. The identity of the ICOS-Ig was further confirmed by mass spectrometry by comparing the trypsin peptides generated from the extracted gel band to a theoretical trypsin digest (peptide mass fingerprinting by MALDI-TOF analysis).

20

Binding of ICOS-Ig to Transfectants and Antigen Presenting Cells (APCs)

EL-4 cell lines expressing murine B7-1 or B7-2 were incubated with 100 µg/ml of ICOS-Ig, 10 µg/ml CD28-Ig or 1 µg/ml of CTLA-4-Ig (R & D Systems) for 30 minutes at 4°C after preincubation with FcBlock™ (Pharmingen). Human Ig was used as a negative control for binding. Cells were then incubated with rat anti-human Ig-FITC and fluorescence determined by flow cytometry (FACstar Vantage, Becton Dickinson,) by gating on viable cells. In addition, we investigated binding of ICOS-Ig to bone marrow-derived dendritic cells, prepared as described in detail elsewhere (Inaba *et al.* (1992) *J. Exp. Med.* 6:1693-1702) or on purified splenic B cells. Binding was determined on resting cells or 24 hours after activation with soluble anti-CD40 mAb (10 µg/ml).

30

Generation of Stable Jurkat Cells Expressing mICOS

Jurkat cells were transfected by electroporation with 2 µg mICOS-Flag DNA subcloned in pcDNA3 (Invitrogen). After a 2-week drug selection, high
5 Flag-positive expressing cells were sorted by flow cytometry (FACStar Vantage, Beckon Dickinson), subcloned, and stable lines generated. mICOS and empty vector cells were then selected on the basis of comparable surface expression of hCD3 and hCD28.

10 Immunoprecipitation and Immunoblotting

For immunoprecipitations, Jurkat mICOS-Flag and empty vector transfected cells were either left unstimulated or stimulated with anti-CD28 (10 µg/ml, 4B10) or anti-Flag mAb (10 µg/ml) and rabbit anti-mouse antibody (5 µg/ml) for 2 and 7.5 minutes. Cells were then lysed in ice cold lysis buffer
15 containing 1% TritonX-100 (v/v) in 20 mM Tris-HCl pH 8.3, 150 mM NaCl. The lysis buffer contained 1 mM PMSF, 1 mM Na₄VO₃, 10 mM NaF and 1 mM Na₄P₂O₇. Lysates were incubated for 20 minutes on ice before centrifugation at 1500xg for 15 minutes at 4°C. Postnuclear lysates were incubated for 1 hour with agitation at 4°C with the indicated monoclonal antibody. ProteinA-Sepharose
20 beads (30 µl, Pharmacia), swollen and washed in lysis buffer were added and incubated for 1 hour at 4°C. The beads were washed three times in cold lysis buffer, and proteins were eluted by boiling for 5 minutes in SDS sample buffer, separated by SDS-PAGE, and transferred to nitrocellulose for immunoblotting. The membranes were blocked with 5% milk in TBS (10 mM Tris-HCl, pH 7.6,
25 150 mM NaCl) and incubated with p85 antiserum. Bound antibody was revealed with horseradish peroxidase (HRP)-conjugated anti-rabbit antibody using enhanced chemilluminescence (ECL, Amersham). Results are summarized below.

Lipid Kinase Assay

30 Jurkat mICOS-Flag and empty vector transfected cells were either left unstimulated or stimulated with anti-CD28 (10 µg/ml, 4B10) or anti-Flag mAb (10 µg/ml) and rabbit anti-mouse antibody (5 µg/ml) for 2 and 7.5 minutes. Cells were

solubilized in 1% Triton X-100 (v/v)-based lysis buffer with protease and phosphatase inhibitors and subjected to precipitation as described above. Immune complexes were washed three times with the lysis buffer, three times with 100 mM Tris-HCl, pH 7.5 with 0.5 M LiCl, and twice with TNE (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1 mM EGTA). The lipid kinase reaction was carried out on the beads using soybean PI liposomes and γ [32] ATP [20 μ Ci] as previously described (Prasad *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:2834-2838).

Inhibition of T Effector Function by mICOS-IG

To determine the effect of mICOS in activation of effector cells, CD4 cells were differentiated to Th1 and Th2 cells and then reactivated in 96 well plates (5×10^4 /well) together with mitomycin C-treated 1×10^5 splenocytes/well and stimulated with 10 μ g/ml OVA peptide in the presence of either hIg or mICOS-IG (1-100 μ g/ml). IL-4, IL-5 and IFN- γ were measured by specific ELISA.

Secondary T Cell Dependent B Cell Immune Responses

Male Balb/c mice (15-20g) were immunized in the footpad on day 0 with 10 μ g OVA in 4 mg alum. On day 8, mice were boosted with 100 μ g OVA/alum administered subcutaneously. ICOS-Ig or human IgG (100 μ g/mouse) was i.p. administered on day 7, 8, and 9. On day 18, mice were bled, and antigen specific IgE and IgG1 were measured by specific ELISA (Pharmingen).

Active Immunization Protocol for Aeroallergen Challenge

Male Balb/c mice (15-20 g) were immunized intraperitoneally with 10 μ g of OVA in 4 mg alum (Serva, Heidelberg, Germany) on day 0 and day 14. On day 21, mice were challenged with aerosolized OVA (50 mg/ml) for 20 minutes. Control mice were challenged with PBS instead of OVA. One hour prior to antigen sensitization and challenge, mice were injected intranasally with 100 μ g of CTLA-4-Ig, ICOS-Ig, or human Ig. Forty-eight hours later, the tracheas were cannulated and a bronchoalveolar lavage (BAL) performed. Cytospin preparations were prepared, stained with Giemsa reagent, and a total of 200 cells counted differentially using standard morphological criteria.

Adoptive Transfer of Antigen Specific T Cells *In Vivo*

Recipient normal Balb/C mice were injected i.v. with 2×10^6 Th1 or Th2 effector cells. Twenty-four hours later, mice were exposed to an aerosol of ovalbumin (50 mg/ml) for 20 minutes on two consecutive days. One hour prior to allergen exposure, recipient mice were injected i.v. with either 100 μ g of mICOS-Ig, CTLA-4-Ig, or hlg (Sigma, St. Louis, MO). Twenty four hours later, a BAL was performed and cytokine levels in the lavage fluid measured by ELISA. Lungs were removed 24 hours after antigen challenge, inflated with 10% neutral buffered formalin, and paraffin embedded. Four-micron sections were prehybridized for 2-4 hours, after which 35 S-labeled mICOS sense and antisense riboprobes (1.2×10^6 cpm/slide) were added and hybridized overnight. Slides were dipped in emulsion, exposed for 2 weeks, developed, and counterstained with haematoxylin.

Measurement of Airway Hyperresponsiveness

Airway responsiveness was measured in both Th1 and Th2 recipient mice 24 hours after the last aerosol challenge by recording respiratory pressure curves by whole body plethysmography (Buxco, EMKA Technologies, France) in response to 20 mg/ml of methacholine inhaled for 1 minute. Airway responsiveness was expressed in enhanced pause (Penh), a calculated value, which correlates with measurement of airway resistance, impedance, and intrapleural pressure in the same mouse. $Penh = (Te/TRI) \times Pef/Pif$ (Te = expiration time, Tr = relaxation time, Pef = peak expiratory flow, Pif = peak inspiratory flow), as described in detail elsewhere (Tsuyuki *et al.* (1977) *J. Exp. Med.* 9:1671-1679; Hamelmann *et al.* (1977) *Am. J. Respir. Crit. Care Med.* 156:766-775).

Results and Discussion

Expression of mICOS

Murine ICOS (mICOS) exhibits 69% homology to the human gene (Figure 2). Unlike CD28, which is expressed in comparable levels on T helper subsets, northern blot analysis confirmed the nylon microarray specific hybridization data and demonstrated that mICOS was constitutively expressed in Th2, but not Th1

clones. Similarly, mICOS was overexpressed upon CD3/TCR crosslinking in Th2 cells derived from common T helper precursor (Thp) cells as compared to activated Th1 cells. mICOS was not expressed by B cells, resting CD4, CD8, macrophages, neutrophils, or eosinophils as determined using real time quantitative PCR analysis (Taqman™, Perkin Elmer) (Figure 4). Using single stranded conformation polymorphism analysis (SSCP), mICOS mapped to chromosome 1, cosegregating with CD28 and CTLA-4, further supporting the claim that ICOS represents the third member of the CD28 family.

10 ICOS Binds a Non-B7 Counterreceptor on Activated B Cells and Dendritic Cells

mICOS, like its human counterpart, has an FDPPPF motif at positions 114-119, replacing the putative B7 MYPPPY binding domain found in both CD28 and CTLA-4. However despite the homology between CD28 and mICOS, a soluble protein consisting of the extracellular portion of mICOS and human IgG1 failed to exhibit any binding to either mB7-1 or mB7-2 stable transfectants (Figure 5). These observations support previous reports that mutation of the tyrosine residues of the putative B7 MYPPPY binding domain of CD28 to phenylalanine at corresponding positions 115 and 119 of mICOS results in a complete loss of B7 binding (Kariv *et al.* (1996) *J. Immunol.* 1:29-38). However, a putative binding site for mICOS-Ig was identified on CD40-stimulated, but not resting B cells (Figure 6A), and on bone marrow-derived dendritic cells (Figure 6B), but not resting or activated CD3+ T cells.

25 ICOS and CD28 Share Some Common Signaling Mechanisms

In a further comparison of mICOS and CD28, the receptors were compared for their ability to interact with intracellular signaling proteins. CD28 has previously been shown to bind the lipid kinase phosphatidylinositol 3-kinase (PI-3K) by means of a phosphotyrosine based motif, pYMNM, which serves as a binding domain for the Src homology domain (SH2 domain) of PI-3K (Truitt *et al.* (1994) *J. Exp. Med.* 3:1071-1076; Prasad *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:2834-2838). Upon binding to CD28, PI-3K is then sequestered to the inner face of the plasma membrane, where it can act on its target substrates. mICOS

possesses a similar YMFM motif (residues 181-184) and is therefore also potentially suitable for binding to the p85 subunit of PI-3K. Immunoprecipitation of mICOS, like CD28, co-precipitated a 85 kDa band that corresponds to the p85 subunit of PI-3K as detected by anti-p85 immunoblotting, and like CD28, increased lipid kinase activity upon crosslinking the mICOS-Flag epitope. Deletion of the cytoplasmic tail (mICOS d180C) in mICOS transfectants ablated both PI-3K association and lipid kinase activity. These data demonstrate that CD28 and mICOS share some common downstream signaling elements. However, while CD28 pYMN site also binds the SH2 domain of Grb-2, albeit at 10-fold lower activity than PI-3K, mICOS failed to recruit Grb-2, supporting previous data that the arginine residue at position 191 is required for Grb-2 association (Schneider *et al.* (1995) *Eur. J. Immunol.* 4:1044-1050). Nevertheless, despite some common signaling mechanisms, mICOS-Ig, unlike CTLA-4-Ig, failed to inhibit either antigen-specific proliferation and had only a minor effect on IL-2 secretion from antigen-stimulated naïve CD4⁺ T cells, suggesting that mICOS plays a role distinct from CD28 in T cell activation (Table 1).

Table 1. Signaling through CD28, but not ICOS, is required for antigen specific proliferation and IL-2 production. CD4⁺ antigen specific cells were stimulated with OVA peptide (10 µg/ml) in the presence of either hIgG, CLTA-4-Ig, or mICOS-Ig (100 µg/ml). Proliferation was measured on d1, d2, d3, and d4 after stimulation using ³H-thymidine incorporation. IL-2 levels were measured in the supernatants on d3 by specific ELISA. Significance was determined by a Student's T-test; a value of p<0.05 is considered significant and is indicated by *.

	Proliferation (cpm)				IL-2 (ng/ml)
	d1	d2	d3	d4	d3
hIgG	228	13497	20367	2066	45 ± 2
mICOS-Ig	274	15913	21766	3432	32 ± 1.4*
CLTA-4-Ig	183	8635*	5637*	1619	4.0 ± 0.1*

Inhibition of ICOS Attenuates Th2 Cytokine Production *In Vitro*

In vitro studies using CTLA-4-Ig have suggested that CD28/B7 costimulation is required not only for IL-2 production, but also for priming naïve CD4⁺ T cells for IFN- γ and IL-4 production (Seder *et al.* (1994) *J. Exp. Med.* 1:299-304; McKnight *et al.* (1994) *J. Immunol.* 11:5220-5225). However, signals delivered by CD28 are not required for optimal secretion of either IFN- γ or IL-4 secretion from recently activated T helper effector subsets (Schweitzer and Sharpe (1998) *J. Immunol.* 6:2762-2771). Given the overexpression of mICOS in Th2 effector cells, it was hypothesized that mICOS may provide a CD28 independent costimulatory signal specific for Th2, but not Th1 effector cells.

To address this issue, Th1 and Th2 effector cells were generated from common antigen-specific Thp cells under the influence of IL-12 + anti-IL-4 mAbs and IL-4 + anti-IL-12 mAb, respectively. To determine whether mICOS plays a critical role as a signaling molecule, experiments were performed using mICOS-Ig fusion protein that directly competes with membrane bound mICOS for binding with its putative ligand and hence blocks mICOS signaling. mICOS-Ig inhibited the production of IL-4 and IL-5 from Th2 cells (Figure 7A) in a dose dependent manner, but failed to modify IFN- γ secretion from Th1 effector cells (Figure 7B), when compared to hlg-treated cells (closed bars). These data suggest that mICOS effectively replaces the CD28 signal and can provide a costimulatory signal specific for cytokine production from Th2 effector cells. Taken together, the data support previous observations generated in CD28 gene-targeted mice that fail to support the existence of alternative ligands for CD28 (Green *et al.* (1994) *Immunity* 6:501-508) and at the same time reconcile the limited role of CD28/B7 axis in Th2 immune deviation (Brown *et al.* (1996) *J. Exp. Med.* 3:803-810).

Regulation of T Cell Dependent B Cell Antibody Production by ICOS

While CTLA-4-Ig has been reported to be effective in inhibiting a number of immune responses *in vivo* when administered at the time of initial T cell activation, delaying CTLA-4-Ig treatment has in some situations, been reported to be ineffective (Corry *et al.* (1997) *J. Immunol.* 9:4142-4148; Sayegh *et al.* (1995)

J. Exp. Med. 5:1869-1874). Likewise, although CTLA-4-Ig is effective in inhibiting a primary immune responses (Lu *et al.* (1995) *J. Immunol.* 154:1078-1087; Harris *et al.* (1999) *Eur. J. Immunol.* 29(1):311-316), some studies have shown that secondary immune responses cannot be fully suppressed by administration of CTLA-4-Ig (Tang *et al.* (1996) *J. Immunol.* 1:117-125; Gause *et al.* (1996) *J. Immunol.* 158:4082-7; Harris *et al.* (1999) *Eur. J. Immunol.* 29(1):311-316), consistent with B7 independent activation of effector cells.

To address whether ICOS can regulate effector responses, a series of *in vivo* experiments using ICOS-Ig fusion protein were performed. Initially the contribution of ICOS to T cell-dependent B cell antibody production in a secondary immune response was studied by measuring antigen-specific antibodies after soluble antigen/adjuvant immunization. Administration of ICOS-Ig resulted in a marked attenuation of antigen-specific IgE and modestly reduced IgG1 levels by approximately 10-fold (Figure 8). As the production of IgE/IgG1 is regulated by IL-4 (Snapper *et al.* (1988) *J. Exp. Med.* 167:183-196; Finkelman *et al.* (1990) *Annu. Rev. Immunol.* 8:303-333; Kopf *et al.* (1993) *Nature* 18:362, 245-248), these data provide the first *in vivo* evidence that ICOS can regulate T cell-dependent humoral immune responses.

20 Attenuation of Lung Mucosal Inflammation by ICOS-Ig

Allergen provocation of sensitized mice results in an Th2-dependent lung inflammation response. It has previously been reported that CTLA-4Ig can inhibit lung mucosal immune responses that are characterized by eosinophilic inflammation of the airways following aeroallergen provocation (Tsuyuki *et al.* (1997) *J. Exp. Med.* 9:1671-1679) and others (Padrid *et al.* (1998) *Am. J. Respir. Cell. Mol. Biol.* 4:453-462; Keane-Myers *et al.* (1997) *J. Immunol.* 158:2042-2049). To directly compare the roles of ICOS and CD28, either ICOS-Ig or CTLA-4-Ig was administered directly into the lungs, 1 hour prior to allergen challenge. The degree of lung inflammation was then measured by analysis of the cellular composition of the bronchoalveolar lavage fluid. Under these circumstances, ICOS-Ig was at least as effective as CTLA-4-Ig in suppressing airway inflammation, reducing the number of eosinophils by greater than 70%

(Figure 9). Due to the complexity of this active model of mucosal inflammation and the number of different pathways that have been implicated (for reviews, see Anderson and Coyle (1994) *Trends Pharmacol. Sci.* 15:324-332; Wills-Karp (1999) *Annu. Rev. Immunol.* 17:255-281), the contribution of mICOS to an *in vivo* lung mucosal immune response mediated exclusively by activation of antigen-specific cells generated *in vitro* was addressed in a Th1 and Th2 cell adoptive transfer model of lung mucosal immunity (Chon *et al.* (1997) *J. Exp. Med.* 10:1737-1747). Aeroallergen provocation of mice transfused with antigen-specific Th1 or Th2 cells leads to the secretion of either IFN- γ or IL-5 and IL-4 and is associated with either a neutrophilic or eosinophilic lung mucosal inflammatory response, respectively (Chon *et al.* (1997) *J. Exp. Med.* 10:1737-1747). *In situ* hybridization with an mICOS antisense riboprobe revealed a marked induction of mICOS and mRNA in the lungs after antigen challenge of Th2, but not Th1 recipient mice. Systemic administration of mICOS-Ig in OVA-exposed Th2 recipient mice inhibited the production of IL-5 and markedly suppressed eosinophilic inflammation of the airways by greater than 80% (Figure 10B). In marked contrast, inhibition of mICOS-Ig did not modify Th1 effector responses as revealed either by IFN- γ secretion or Th1-mediated neutrophilic lung inflammation (Figure 10A). These data suggest that inhibiting ICOS selectively abrogates the pathological consequences of activation of antigen-specific Th2, but not Th1 effector cells during an allergic lung mucosal inflammatory response. In contrast, administration of CTLA-4-Ig inhibited both Th1- and Th2-mediated inflammation and cytokine production, the latter being more sensitive to suppression than Th1-mediated inflammation.

25

ICOS is Critical for Th2-, but Not Th1-Mediated Altered Airway Responsiveness

Airway hyperresponsiveness to non-specific stimuli such as methacholine is a characteristic feature of bronchial asthma. While prolonged (7-10 days) aeroallergen results in airway hyperresponsiveness only in Th2-recipient mice (Cohn *et al.* (1997) *J. Exp. Med.* 10:1737-1747), acute aerochallenge (2 days) results in a dramatic Th1 cell-mediated and to a lesser extent, Th2 cell-mediated airway hyperresponsiveness (Figure 11A and 11B, respectively). While evidence

30

is emerging that IL-13 mediates Th2-dependent airway hyperresponsiveness (Cohn *et al.* (1997) *supra*; Wills-Karps *et al.* (1998) *Science* 282:2258-2261), the mechanisms underlying this Th1-mediated lung inflammation is unknown, although previous studies have demonstrated that airway exposure to LPS, which
5 results in neutrophil accumulation in the lungs also results in airway hyperresponsiveness (Lefort *et al.* (1998) *J. Immunol.* 161:474-480) in the absence of either IL-4, IL-5, or IL-13 and eosinophilic inflammation. Whatever the precise mechanisms involved, this system has been used to dissect the relative contribution of CD28/ICOS to Th1- and Th2-mediated alterations in airway responsiveness to
10 inhaled methacholine. CTLA-4-Ig treatment suppressed both Th1- and Th2-mediated heightened airway sensitivity consistent with the effects of blockade of CD28 on Th1- and Th2-mediated inflammation. In contrast, ICOS-Ig suppressed only Th2 cell-mediated airway hyperresponsiveness, in the absence of any suppressive effect of Th1-mediated airway hyperresponsiveness (Figure 11).
15 These studies provide direct evidence for the existence of Th2 subset specific costimulation mediated via the inducible ICOS gene. Although clonal expansion of naive T cells may be limited in the absence of CD28, effector responses can still develop as suggested by recent observations, demonstrating that despite limited clonal expansion in anergic cells, T helper effector function is not
20 prevented (Malvey *et al.* (1998) *J. Immunol.* 5:2168-2177). It is proposed that in the absence of CD28, ICOS engagement on Th2 effector cells would be used as an alternative signaling pathway to CD28. Finally, these data highlight the therapeutic benefit of selectively dampening down inappropriate Th2 responses via suppression of mICOS in diseases, e.g. asthma and allergy, while protective Th1
25 immunity against bacteria and intracellular parasites remains intact.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by
30 the following claims.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains.

All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


5 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Applicant's or agent's file reference	5800-10B-1	International application No.	PCT/US99/
------------------------------------------	------------	-------------------------------	-----------

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page 4, line 27; page 14, line 7-9; page 17, line 29&30; page 20, line 19; page 24, line 11; page 29, line 1; page 91, line 6; page 93, line 28; page 94, line 26; page 95, line 25; page 96, line 23	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution <p align="center">American Type Culture Collection</p>	
Address of depository institution (including postal code and country) <p align="center">10801 University Blvd. Manassas, VA 20110-2209 US</p>	
Date of deposit <p align="center">02 October 1998</p>	Accession Number <p align="center">203302</p>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
Accession Number: 203569; deposited: 08 January 1999 at ATCC, Manassas, VA; page 4, line 27; page 13, line 9-11; page 17, line 29&30; page 20, line 19; page 24, line 11; page 29, line 2; page 91, line 7 & 26; page 92, line 1&4; page 93, line 30; page 94, line 28; page 95, line 27; page 96, line 25.	
Accession Number 203797; deposited 25 February 1999 at ATCC, Manassas, VA; page 4, line 28; page 11, line 31; page 12, line 1; page 17, line 29-31; page 20, line 20; page 24, line 12; page 29, line 2; page 91, line 8; page 93, line 31; page 94, line 29; page 95, line 28; page 96, line 26.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indicators are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer 

For International Bureau use only
<input type="checkbox"/> This sheet was received with the International Bureau on:
Authorized officer

WHAT IS CLAIMED IS:

- 1 An isolated nucleic acid molecule comprising the nucleotide
sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID
5 NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, the cDNA insert of the
plasmid deposited with ATCC as Accession Number 203302, the cDNA insert of
the plasmid deposited with ATCC as Accession Number 203569, the cDNA insert
of the plasmid deposited with ATCC as Accession Number 203797, or a
complement thereof.
10
- 2 The nucleic acid molecule of claim 1 further comprising vector
nucleic acid sequences.
- 3 The nucleic acid molecule of claim 1 further comprising nucleic
15 acid sequences encoding a heterologous polypeptide.
- 4 A host cell which contains the nucleic acid molecule of claim 1.
- 5 The host cell of claim 4 which is a mammalian host cell.
20
- 6 A nonhuman mammalian host cell containing the nucleic acid
molecule of claim 1.
- 7 An isolated polypeptide comprising the amino acid sequence of
25 SEQ ID NO:14 or an amino acid sequence encoded by the cDNA insert of the
plasmid deposited with ATCC as Accession Number 203569.
- 8 The polypeptide of claim 7 further comprising heterologous amino
acid sequences.
30
- 9 A method for producing a polypeptide comprising the amino acid
sequence of SEQ ID NO:14 or an amino acid sequence encoded by the cDNA

insert of the plasmid deposited with ATCC as Accession Number 203569, said method comprising culturing a host cell which contains a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:13 or the cDNA insert of the plasmid deposited with ATCC as Accession Number 203569 under conditions in which the nucleic acid molecule is expressed.

10. A method for detecting the presence of a polypeptide of claim 7 in a sample, comprising:

- a) contacting the sample with a compound which selectively binds to a polypeptide of claim 7; and
- b) determining whether the compound binds to the polypeptide in the sample.

11. The method of claim 10, wherein the compound which binds to the polypeptide is an antibody.

12. A method for identifying a compound which binds to a polypeptide of claim 7 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 7 with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

13. The method of claim 12, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for Th2-specific-mediated signal transduction.

14. A method for modulating the activity of a polypeptide of claim 7 comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

5

15. A method for identifying a compound which modulates the activity of a polypeptide of claim 7, comprising:

a) contacting a polypeptide of claim 7 with a test compound;

and

10 b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

16. A method for modulating a Th2 response in a mammal, said method comprising administering to said mammal a therapeutically effective amount of a polypeptide or its corresponding antibody, wherein said polypeptide is selected from the group consisting of:

a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16;

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203302, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203569, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203797, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic

acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof under stringent conditions; and

- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof.

10 17. A method for modulating an immune response in a mammal, said method comprising altering activity of a polypeptide in said mammal by administering to said mammal a therapeutically effective amount of said polypeptide or an antibody corresponding to said polypeptide or by regulating in said mammal expression of a nucleotide sequence encoding said polypeptide, 15 wherein said polypeptide is selected from the group consisting of:

- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, 20 SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16;

- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID 25 NO:16, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203302, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203569, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203797, wherein the 30 polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID

NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof under stringent conditions; and

- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof.

18. A method for suppressing airway inflammation in a mammal, said method comprising altering activity of a polypeptide in said mammal by administering to said mammal a therapeutically effective amount of an antibody corresponding to said polypeptide or by regulating in said mammal expression of a nucleotide sequence encoding said polypeptide, wherein said polypeptide is selected from the group consisting of:

- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16;

- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203302, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203569, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203797, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof under stringent conditions; and

- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof.

19. A method for suppressing airway hyperresponsiveness in a mammal, said method comprising altering activity of a polypeptide in said mammal by administering to said mammal a therapeutically effective amount of an antibody corresponding to said polypeptide or by regulating in said mammal expression of a nucleotide sequence encoding said polypeptide, wherein said polypeptide is selected from the group consisting of:

- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16;

- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203302, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203569, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 203797, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof under stringent conditions; and

- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 45% identical to a nucleic acid

comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, or a complement thereof.

1 MBRAWGLV -- LGVWV -- ERUGHGER -- RPETAORCEGV -- SGVDDCICDVEITDKENN -- m1022
 1 MGRNCFLE -- LGAVM -- EESSLHGER -- BEAARCEGV -- SGVDDCICDVEITDKENN -- h1022
 1 MKML E VWPV ELG L VVQI ELRJAELDGVSF GMYTSANSGAGSYVRIKUNA LKEG CSL - JIMDEVSO X60951

59 YR - EPREKLESYERYKYNLKKPPFV -- NIJILGRRUCAVKPEHDEVPDGLKSASYKSEEA -- m1022
 59 YR - EPREKLESYERYKYNLKKPPFV -- NIJILGRRUCAVKPEHDEVPDGLKSASYKSEEA -- h1022
 70 NTEGITGL UNNITSH YERYFKYNL DREGRYVAEASCT CDSNG Q QICT E DUSGT E EIL K --- YPYJD --- X60951

125 NR - ECEGAERL GAVDES L SEETOKAVLQVTKHDDSSDSFCEIDD -- NECE ADD WICWSSKKKVF -- QSPDAEYVDL -- m1022
 125 NR - ECEGAERL GAVDES L SEETOKAVLQVTKHDDSSDSFCEIDD -- NECE ADD WICWSSKKKVF -- QSPDAEYVDL -- h1022
 134 --MSDVSAV -- ERRTAPDKHAAGFEDEI -- KPTDPR -- QSPDAEYVDL -- X60951

181 LAMPERYIGYKGRDAVRIMSVIYEENCEKPDITQRP -- SGGRKSKENFYNNWEGLCYKRAFYRL -- m1022
 195 LAMPERYIGYKGRDAV -- KLVNVIYENCFKQITL -- KRPL NPLA -- SGQITISE ENLEY SVLEGEYEKRAFYRL -- h1022
 173 LONPEJ AN TOYS LUPKJARSVMQAVYID-NG -- NTDGLP -- SNTAGV ENR --- EK ALLRQ L X60951

248 SGLHASINVELSARYLEOT -- E -- MEKKVGHVATPEOD -- RQMLDGEGRRLRNLVYFYTL -- m1022
 265 SGLHASINVELSARYLEO -- E -- MEKKVGHVATPEOD -- RQMLDGEGRRLRNLVYFYTL -- h1022
 224 SGLH TSLIMTHVAATFTYN DE KGDSPLS L GVLNPN NTSFYPCGM ERRHVKND E --- FT -- RNLFWVY QV L X60951

309 RALSKVL -- PFERPDE -- QLETGNKYODAKENKAL ELCIHEKSPFNH -- FDENSFAGDKNEAKKKEDE -- m1022
 326 RALSKVL -- PFERPDE -- QLETGNKYODAKENKAL ELCIHEKSPFNH -- FDENSFAGDKNEAKKKEDE -- h1022
 290 RAJVAKJ TKRA E LANSSLYNSG FNGAATGDVRLYSNIGE LIFSS KILIRVAT EDE GKLEJ --ESP -- JAHLLVRQM X60951

375 REHNRNLSRIMDVGCKRLEHKGKLOGLGJAKALESEKLANPESRPSYFQETRQENYSEFNATG -- m1022
 392 REHNRNLSRIMDVGCKRLEHKGKLOGLGJAKALESEKLANPESRPSYFQETRQENYSEFNATG -- h1022
 358 KRVVH NVITL MDQVTECKRANWKELEJAAJAEAKLJVEIG -- SAENWVE -- UNRGERMALITN JFA X60951

445 R - LSTSVRETFENERHLEONVH -- m1022
 462 R - LSTSV RELENER NLLQNTIH -- h1022
 417 R QLAT ESKNVRSLAAVCEKFNYSAMS -- X60951



SUBSTITUTE SHEET (RULE 26)

FIG. 1.



1	M	---	KPYF	---	CHVFECFL	IRLLTGE	ING	SADHRMFS	mICCS
1	M	---	KSG	---	WYFF	CLRLKMLTGE	ING	SANYEMFI	hICCS
1	M	---	---	---	FANF	SVVVTENK	IVKQSP	LWV	mCD28
1	M	---	---	---	CALN	RSQVGNK	IVKQSP	LWV	hCD28
1	M	MACLGLRRYKAQ	QDIP	SRTWP	FVAIL	TLLFIPV	SEALQ	MTQPSVVLIA	mCTLA4
1	M	MACLGFQRHKAQ	NAAART	WPCTL	FFLLFIPV	CKAMHMAQ	PAVVLIA	hCTLA4	
33	FHN	GGVQIISCKY	---	PEIVQ	QKMR	FREREV	---	LCEL	TKIKGSGNA
32	FHN	GGVQIISCKY	---	PDIVQ	QKMR	LKGGQI	---	LCDL	TKIKGSGNT
33	DS	NEV	SESSCRY	SYN	LAKE	FRASLYK	GVNSDW	EVGV	GVNGENFTYQPO
32	YD	NAV	NLSCY	SYN	LSRE	FRASLYK	GVNSDW	EVGV	GVNGENFTYQPO
49	SSH	GMA	SP	CEYS	PSHNTD	EVN	VIVLRQ	INDQMI	VCAI
49	SSR	GI	ASFV	CEY	ASPGKATE	EVN	VIVLRQ	INDQMI	VCAI
75	VS	IKNP	ML	CLYH	SSNSVSI	FFNN	PDSSQ	SGSY	YFCG
74	VS	IKSL	KECH	HSQ	SSNSVSI	FFNN	PDSSQ	SGSY	YFCG
79	FR	SN	AE	NCDD	DF	DN	EVN	IRL	MLN
78	VS	SK	GENC	BEKE	GNESV	TY	ONL	VNQ	DIYF
95	VG	LDY	PF	SG	ITF	NE	SRVNL	TIQ	RAVD
95	LT	FL	DD	SI	CH	TSSGN	QVNL	TIQ	RAMD
123	NL	SG	---	YL	---	IIYESQ	CCQL	---	---
1121	TL	GG	---	YL	---	IIYESQ	CCQL	---	---
1127	ERS	NG	IT	HL	REK	HL	CHIQ	---	SSPK
1126	KS	NG	IT	HL	REK	HL	CHIQ	---	SSPK
1142	GM	NG	IT	HL	REK	HL	CHIQ	---	SSPK
1142	GIG	NG	IT	HL	REK	HL	CHIQ	---	SSPK
163	IWF	SK	KY	SS	VH	DP	NS	SEY	MA
1161	CWL	TK	---	YSS	VH	DP	NS	SEY	MA
1172	LCV	WT	NS	RR	NR	LIQ	---	SDY	NM
1174	FTF	W	R	SK	SR	HL	---	SKY	NM
1184	VS	IS	KML	K	R	SP	---	IT	---
1184	VS	IS	KML	K	R	SP	---	IT	---



FIG. 2.

4/9




**FIG. 4.****FIG. 5.**

5/9

**FIG. 6A.****FIG. 6B.**



7/9

FIG. 8A.FIG. 8B.FIG. 9.

8/9




FIG. 10B.

FIG. 10A.

9/9




FIG. 11A.




FIG. 11B.

SEQUENCE LISTING

<110> Lehar, Sophie
 Manning, Stephen
 Coyle, Anthony J.
 Gutierrez-Ramos, Jose-Carlos

<120> Novel Th2-Specific Molecules and Uses Thereof

<130> 5800-10B

<140>

<141>

<150> 09/168,229

<151> 1998-10-07

<150> 09/258,670

<151> 1999-02-26

<160> 24

<170> PatentIn Ver. 2.0

<210> 1

<211> 3631

<212> DNA

<213> Mus sp.

<220>

<221> CDS.

<222> (126)..(1304)

<400> 1

ccacgcgtcc gcggacgcgt gggcgggaaa ggaatcctgg ggttttctag tatcccttc 60

tttttttctt ttttcttttc ttttctttt tggcctgcg ggcttcagac tcagggaact 120

tgctc atg gct ttt ttg atg aag aag aag aaa ttt aaa ttt caa acc act 170

Met Ala Phe Leu Met Lys Lys Lys Lys Phe Lys Phe Gln Thr Thr

1

5

10

15

ttc acc ttg gag gag ctg act gcg gtc ccc ttc gtg aac ggg gtc ctc 218

Phe Thr Leu Glu Glu Leu Thr Ala Val Pro Phe Val Asn Gly Val Leu

20

25

30

ttt tgc aag gtc cgg ctg ctg gat ggc ggg gat ttt gtc agc ttg tcg 266

Phe Cys Lys Val Arg Leu Leu Asp Gly Gly Asp Phe Val Ser Leu Ser

35	40	45	
tcc agg gag gag gtg cag gag aac tgt gta cga tgg cgg aag agg ttc			314
Ser Arg Glu Glu Val Gln Glu Asn Cys Val Arg Trp Arg Lys Arg Phe			
50	55	60	
acc ttt gtg tgt aaa atg agt gcc aac ccg gcc aca ggc ctg ctg gac			362
Thr Phe Val Cys Lys Met Ser Ala Asn Pro Ala Thr Gly Leu Leu Asp			
65	70	75	
ccc tgc atc ttt cga gtg tct gtg cgc aag gag ctg aaa ggt ggg aag			410
Pro Cys Ile Phe Arg Val Ser Val Arg Lys Glu Leu Lys Gly Gly Lys			
80	85	90	95
gcg tat tcc aag ctg ggc ttc act gac ttg aac cta gcc gag ttt gca			458
Ala Tyr Ser Lys Leu Gly Phe Thr Asp Leu Asn Leu Ala Glu Phe Ala			
100	105	110	
ggc tca ggc tcc acc gtc cgc tgc tgc cta ttg gaa gga tac gac acc			506
Gly Ser Gly Ser Thr Val Arg Cys Cys Leu Leu Glu Gly Tyr Asp Thr			
115	120	125	
aag aat acc cgc cag gac aac tcc atc ctc aag gtc acc att ggc atg			554
Lys Asn Thr Arg Gln Asp Asn Ser Ile Leu Lys Val Thr Ile Gly Met			
130	135	140	
ttc ctg ctc tct ggg gac ccc tgt ttc aag acg cca ccg tct acc gcc			602
Phe Leu Leu Ser Gly Asp Pro Cys Phe Lys Thr Pro Pro Ser Thr Ala			
145	150	155	
aaa tcc atc tcc atc ccg ggc cag gac tcc tcc ctg cag ctg acg tgt			650
Lys Ser Ile Ser Ile Pro Gly Gln Asp Ser Ser Leu Gln Leu Thr Cys			
160	165	170	175
aaa ggt ggt ggg acc agc agc ggt ggc agc agc agc acc aat tcc cta			698
Lys Gly Gly Gly Thr Ser Ser Gly Gly Ser Ser Ser Thr Asn Ser Leu			
180	185	190	
act gga tcc cgg ccc ccc aag acc cgg ccc acc atc ctg ggc tca gga			746
Thr Gly Ser Arg Pro Pro Lys Thr Arg Pro Thr Ile Leu Gly Ser Gly			
195	200	205	
cta cca gag gag cca gac cag agc ctg tcc agt cct gag gag gtg ttc			794
Leu Pro Glu Glu Pro Asp Gln Ser Leu Ser Ser Pro Glu Glu Val Phe			
210	215	220	
cac tct ggc cac tcc cgc aac tcc agc tat gcc agc cag cag tcc aag			842
His Ser Gly His Ser Arg Asn Ser Ser Tyr Ala Ser Gln Gln Ser Lys			

225	230	235	
cta tct ggc tac agt aca gag cac tct cgc tcc tcc agc ctg tct gac			890
Leu Ser Gly Tyr Ser Thr Glu His Ser Arg Ser Ser Ser Leu Ser Asp			
240	245	250	255
ttg aca cac cgc aga aat aca tcc acc agc agc agc gcc tct ggt ggc			938
Leu Thr His Arg Arg Asn Thr Ser Thr Ser Ser Ser Ala Ser Gly Gly			
	260	265	270
ctc agt atg gct gta gag ggt cct gag ggc atg gag agg gag cat cgg			986
Leu Ser Met Ala Val Glu Gly Pro Glu Gly Met Glu Arg Glu His Arg			
	275	280	285
ccc tct gag aag cca cct cgg cct cct gag aag ccc cca cgc ccc cca			1034
Pro Ser Glu Lys Pro Pro Arg Pro Pro Glu Lys Pro Pro Arg Pro Pro			
	290	295	300
cgc ccc ttg cat cta tca gat cgc tct ttt cgg cga aag aaa gac tct			1082
Arg Pro Leu His Leu Ser Asp Arg Ser Phe Arg Arg Lys Lys Asp Ser			
	305	310	315
gtg gag agc cac cca acc tgg gta gat gac act cga att gat gca gac			1130
Val Glu Ser His Pro Thr Trp Val Asp Asp Thr Arg Ile Asp Ala Asp			
	320	325	330
			335
gac att gtg gag aag ata atg cag agc cag gac ttc act gat ggc agc			1178
Asp Ile Val Glu Lys Ile Met Gln Ser Gln Asp Phe Thr Asp Gly Ser			
	340	345	350
aac act gag gac agt aac ctt cgg ctg ttc gtg agc cgt gat ggc tcc			1226
Asn Thr Glu Asp Ser Asn Leu Arg Leu Phe Val Ser Arg Asp Gly Ser			
	355	360	365
acc aca ctg agc ggc att cag ctg ggc aac aga gtc tcc tcg gga gtc			1274
Thr Thr Leu Ser Gly Ile Gln Leu Gly Asn Arg Val Ser Ser Gly Val			
	370	375	380
tac gag cca gtc gta att gag agc cac tga gggacccagg agtccggctg			1324
Tyr Glu Pro Val Val Ile Glu Ser His			
	385	390	
aagaagggtc ctgccatctc tggcaccag gcccggtgga ttctggagg atctgctctg			1384
cattgcatct gtgcctcctc ttactctagc cacactggcc cccaaagcgt cattccattt			1444
tcctcccatc caccctggaa ccactgggtcc tgggtgccac tgtgaatatt gtcctccgaa			1504

ccactagaaa atggggcaag atggagctgg ccaggactgc cctgactgga gaggacctgg 1564
gcccagcaaa ggacacagcc attccatgtt ggggtgcttgt ggcctgcccc atccctccat 1624
ccccacgac ccacttcagg agcagcagct tcagccaggc tgacggggca cttgctccat 1684
tgtccctgcc cttcacgagc tgggccaccc cagaaccctg ccacctgtga ccctctgctt 1744
actgcttcac tgtcttttct ctatcctgag gagacctgca ggcagctctc tcctgggagc 1804
taagacctca aacccacac tctggattga gacccacct ccttaactgt cctcctgctg 1864
ccctgcagcc tgcactttgc acatgcttgt cccagcaca gccaccggcc cttgcccttc 1924
tccagacctc ctgggtgctg tctgctgtgc aaccagacct aggttacagt cgcccggtg 1984
gaacgtggca ctacccttc cctctaatta accccaaact cagacccaag atcggagcct 2044
agaagggcct gagcatcatg gttccatctg ccagggctg ggtcctgagc agctggcctt 2104
cctgcaggaa aggaaggacg aggccagcc gtgctgggta agcaaaggcc ttttccccct 2164
gctctcatgt cagccggcct gggctgggtt ccaggctaga gagtcagcca ggtggcctgt 2224
gactgggtga actggagctg gcttcctgcc agacgagcct cagccctcct gggcaagggg 2284
tgtgctttcc ctggggagtc ttccccctac tactcacct cttggtacct ccccaacccc 2344
agcactttct gtcctataat ttgcttaagg agagtatagg ctgccagctc agccctggat 2404
aaattccac ccccttaagt ttactcact tcgtatcaac ccagcaggct ggtgtttcct 2464
tggccctta aggtgtttt cctcctgagt tcacagttct tgtattcctt ccaccccaac 2524
aaggggagat aggtgcctct gttccccatt ccacctgcac ccagcaggg ctggggatag 2584
gcgagtatgg gacattgttt ctgtgggtgg ggatggctgg actccccagg ttgggaaggt 2644
ccttgccctag tttgtgtctt cctcagctag caaaagttgg ggctgtggtc ttggagctgc 2704
ctggtgtcag gaccagatca tttctatagg ttctgtagcc gttgttttaa tcagcagatg 2764
aatgttagaa gatgctgcca aggcaaggca gaacatggct agagaagggt ccggcagctc 2824
agattccatc ctgcccagca ggtgcctggc actttaaggg actctggcag ctctgttcct 2884
aggtgaggtg accaccagaa gatggacaga gccctagtgt gcttgtctac taccttcccc 2944

agtcagcatt gttttggtct agttctaaat tccagggctc caaaccaagc agttggtact 3004
 gtcaggaaga ctgccccaaa ccaagagccc ctgcctaact caagccaagg tctgggactg 3064
 gatggccact ccagtagacg agagctgcca catcctctgc ttccaggcac tgggcccagga 3124
 taacttagct gaaaacatga ccacaaccaa atgaacactg gtggcagcca gaggctaaga 3184
 gcctttcctc ctgcgctcag tgatccccac gggtgcccag agcacctgga cttcaaattc 3244
 tatatacaaa gatagaggat atattagagg tatttttgaa aaggaattgg tctatgcaat 3304
 gccagtttgg gacctgtaag acagttaaat gtttctatta gagagatata aaagatctgc 3364
 aatattttta gggttctttt ctggttacc tacagctgac cacgtggtct ggcaggatga 3424
 gcaggcccat cttcttctgt ggggagaatt tgcttttgtg ttattccttt ctaaccaggt 3484
 taccactgca cccattccg tgggctgttc atatctgtct cagcttataa tagaaaatta 3544
 tgtcatatgg ggaaatcagc ctagtgtcaa tgtttggttt gggggtggaa ttaaatgccg 3604
 atgtttttgt taaaaaaaaa aaaaaaa 3631

<210> 2

<211> 392

<212> PRT

<213> Mus sp.

<400> 2

Met	Ala	Phe	Leu	Met	Lys	Lys	Lys	Lys	Phe	Lys	Phe	Gln	Thr	Thr	Phe
1				5					10					15	
Thr	Leu	Glu	Glu	Leu	Thr	Ala	Val	Pro	Phe	Val	Asn	Gly	Val	Leu	Phe
				20				25						30	
Cys	Lys	Val	Arg	Leu	Leu	Asp	Gly	Gly	Asp	Phe	Val	Ser	Leu	Ser	Ser
				35				40						45	
Arg	Glu	Glu	Val	Gln	Glu	Asn	Cys	Val	Arg	Trp	Arg	Lys	Arg	Phe	Thr
				50				55						60	
Phe	Val	Cys	Lys	Met	Ser	Ala	Asn	Pro	Ala	Thr	Gly	Leu	Leu	Asp	Pro
				65				70						75	
Cys	Ile	Phe	Arg	Val	Ser	Val	Arg	Lys	Glu	Leu	Lys	Gly	Gly	Lys	Ala
				85										90	
															95

Tyr Ser Lys Leu Gly Phe Thr Asp Leu Asn Leu Ala Glu Phe Ala Gly
 100 105 110
 Ser Gly Ser Thr Val Arg Cys Cys Leu Leu Glu Gly Tyr Asp Thr Lys
 115 120 125
 Asn Thr Arg Gln Asp Asn Ser Ile Leu Lys Val Thr Ile Gly Met Phe
 130 135 140
 Leu Leu Ser Gly Asp Pro Cys Phe Lys Thr Pro Pro Ser Thr Ala Lys
 145 150 155 160
 Ser Ile Ser Ile Pro Gly Gln Asp Ser Ser Leu Gln Leu Thr Cys Lys
 165 170 175
 Gly Gly Gly Thr Ser Ser Gly Gly Ser Ser Ser Thr Asn Ser Leu Thr
 180 185 190
 Gly Ser Arg Pro Pro Lys Thr Arg Pro Thr Ile Leu Gly Ser Gly Leu
 195 200 205
 Pro Glu Glu Pro Asp Gln Ser Leu Ser Ser Pro Glu Glu Val Phe His
 210 215 220
 Ser Gly His Ser Arg Asn Ser Ser Tyr Ala Ser Gln Gln Ser Lys Leu
 225 230 235 240
 Ser Gly Tyr Ser Thr Glu His Ser Arg Ser Ser Ser Leu Ser Asp Leu
 245 250 255
 Thr His Arg Arg Asn Thr Ser Thr Ser Ser Ser Ala Ser Gly Gly Leu
 260 265 270
 Ser Met Ala Val Glu Gly Pro Glu Gly Met Glu Arg Glu His Arg Pro
 275 280 285
 Ser Glu Lys Pro Pro Arg Pro Pro Glu Lys Pro Pro Arg Pro Pro Arg
 290 295 300
 Pro Leu His Leu Ser Asp Arg Ser Phe Arg Arg Lys Lys Asp Ser Val
 305 310 315 320
 Glu Ser His Pro Thr Trp Val Asp Asp Thr Arg Ile Asp Ala Asp Asp
 325 330 335
 Ile Val Glu Lys Ile Met Gln Ser Gln Asp Phe Thr Asp Gly Ser Asn
 340 345 350

Thr Glu Asp Ser Asn Leu Arg Leu Phe Val Ser Arg Asp Gly Ser Thr
 355 360 365

Thr Leu Ser Gly Ile Gln Leu Gly Asn Arg Val Ser Ser Gly Val Tyr
 370 375 380

Glu Pro Val Val Ile Glu Ser His
 385 390

<210> 3

<211> 1587

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (36)..(1430)

<400> 3

cggcgcgggt agagggcggt gggcggcgag cggcg atg ggc cgc gcc tgg ggc 53
 Met Gly Arg Ala Trp Gly
 1 5

ttg ctc gtt gga ctc ctg ggc gtc gtg tgg ctg ctg cgc ttg ggc cac 101
 Leu Leu Val Gly Leu Leu Gly Val Val Trp Leu Leu Arg Leu Gly His
 10 15 20

ggc gag gag cgg cgg ccg gag aca gcg gca cag cgc tgc ttc tgc cag 149
 Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala Gln Arg Cys Phe Cys Gln
 25 30 35

gtt agt ggt tac ctg gac gac tgt acc tgt gat gtc gag acc atc gat 197
 Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys Asp Val Glu Thr Ile Asp
 40 45 50

aag ttt aat aac tac aga ctt ttc cca aga cta caa aag ctt ctt gaa 245
 Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg Leu Gln Lys Leu Leu Glu
 55 60 65 70

agt gac tac ttt aga tat tac aag gtg aac ttg aag aag cct tgt cct 293
 Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn Leu Lys Lys Pro Cys Pro
 75 80 85

ttc tgg aat gac atc aac cag tgt gga aga aga gac tgt gcc gtc aaa 341
 Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg Arg Asp Cys Ala Val Lys
 90 95 100

ccc tgc cat tct gat gaa gtt cct gat gga att aag tct gcg agc tac 389
 Pro Cys His Ser Asp Glu Val Pro Asp Gly Ile Lys Ser Ala Ser Tyr
 105 110 115

aag tat tct gag gaa gcc aac cgc att gaa gaa tgt gag caa gct gag 437
 Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu Glu Cys Glu Gln Ala Glu
 120 125 130

cga ctt gga gcc gtg gat gag tct ctg agt gag gag acc cag aaa gct 485
 Arg Leu Gly Ala Val Asp Glu Ser Leu Ser Glu Glu Thr Gln Lys Ala
 135 140 145 150

gta ctt cag tgg acc aag cat gat gat tgc tca gac agc ttc tgc gaa 533
 Val Leu Gln Trp Thr Lys His Asp Asp Ser Ser Asp Ser Phe Cys Glu
 155 160 165

att gac gat ata cag tcc ccc gat gct gag tat gtg gac tta ctc ctt 581
 Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu Tyr Val Asp Leu Leu Leu
 170 175 180

aac cct gag cgc tac aca ggc tac aag ggg cca gac gct tgg agg ata 629
 Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly Pro Asp Ala Trp Arg Ile
 185 190 195

tgg agt gtc atc tat gaa gaa aac tgt ttt aag cca cag aca att caa 677
 Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe Lys Pro Gln Thr Ile Gln
 200 205 210

agg cct ttg gct tct ggg cga gga aaa agt aaa gag aac aca ttt tac 725
 Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser Lys Glu Asn Thr Phe Tyr
 215 220 225 230

aac tgg cta gaa ggc ctc tgt gta gaa aag aga gca ttc tac aga ctt 773
 Asn Trp Leu Glu Gly Leu Cys Val Glu Lys Arg Ala Phe Tyr Arg Leu
 235 240 245

ata tct ggc ctg cac gca agc att aat gtg cat ttg agt gca agg tat 821
 Ile Ser Gly Leu His Ala Ser Ile Asn Val His Leu Ser Ala Arg Tyr
 250 255 260

ctt tta caa gat act tgg ctg gaa aag aaa tgg ggt cac aat gtc aca 869
 Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys Trp Gly His Asn Val Thr
 265 270 275

gag ttc cag cag cgc ttt gat ggg att ctg act gaa gga gaa ggc cca 917
 Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu Thr Glu Gly Glu Gly Pro
 280 285 290

cga agg ctg agg aac ttg tac ttc ctg tac ctg ata gag tta agg gct 965
 Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr Leu Ile Glu Leu Arg Ala
 295 300 305 310

ctc tcc aaa gtg ctt cca ttt ttt gag cgt cca gat ttt cag ctc ttc 1013
 Leu Ser Lys Val Leu Pro Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe
 315 320 325

act ggg aat aaa gtt cag gat gca gaa aac aaa gcg tta ctt ctg gag 1061
 Thr Gly Asn Lys Val Gln Asp Ala Glu Asn Lys Ala Leu Leu Leu Glu
 330 335 340

ata ctt cat gaa atc aag tca ttt cct ttg cac ttc gat gag aat tct 1109
 Ile Leu His Glu Ile Lys Ser Phe Pro Leu His Phe Asp Glu Asn Ser
 345 350 355

ttt ttt gct ggg gat aaa aac gaa gca cat aaa cta aag gag gac ttc 1157
 Phe Phe Ala Gly Asp Lys Asn Glu Ala His Lys Leu Lys Glu Asp Phe
 360 365 370

cgg cta cac ttt agg aac att tca aga atc atg gac tgt gtt ggc tgc 1205
 Arg Leu His Phe Arg Asn Ile Ser Arg Ile Met Asp Cys Val Gly Cys
 375 380 385 390

ttc aag tgc cgc ctg tgg ggc aag ctt cag acg cag ggg ctg ggc act 1253
 Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln Thr Gln Gly Leu Gly Thr
 395 400 405

gct ctg aag atc ttg ttt tcc gaa aaa ctg atc gca aat atg ccg gaa 1301
 Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu Ile Ala Asn Met Pro Glu
 410 415 420

agc gga cca agt tat gag ttc cag cta acc aga caa gaa ata gta tca 1349
 Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr Arg Gln Glu Ile Val Ser
 425 430 435

ctg ttt aat gca ttt gga agg att tcc aca agt gtg aga gaa cta gag 1397
 Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr Ser Val Arg Glu Leu Glu
 440 445 450

aac ttc agg cac ttg tta cag aat gtt cac tga ggaggacggt tggaatgtgc 1450
 Asn Phe Arg His Leu Leu Gln Asn Val His
 455 460 465

ctgtttctgc acaggggaat ctgaaggga gaatctctct gagcaccatg gttgcaatga 1510

ctgtcctaag ccaaacgttt atataaagct gcttttgtaa aagaagagat acattgtctt 1570

aagtaaatga cattttt

1587

<210> 4

<211> 464

<212> PRT

<213> Mus sp.

<400> 4

Met Gly Arg Ala Trp Gly Leu Leu Val Gly Leu Leu Gly Val Val Trp
 1 5 10 15

Leu Leu Arg Leu Gly His Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala
 20 25 30

Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
 35 40 45

Asp Val Glu Thr Ile Asp Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg
 50 55 60

Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
 65 70 75 80

Leu Lys Lys Pro Cys Pro Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg
 85 90 95

Arg Asp Cys Ala Val Lys Pro Cys His Ser Asp Glu Val Pro Asp Gly
 100 105 110

Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu
 115 120 125

Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser
 130 135 140

Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser
 145 150 155 160

Ser Asp Ser Phe Cys Glu Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu
 165 170 175

Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly
 180 185 190

Pro Asp Ala Trp Arg Ile Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe
 195 200 205

Lys Pro Gln Thr Ile Gln Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser
 210 215 220
 Lys Glu Asn Thr Phe Tyr Asn Trp Leu Glu Gly Leu Cys Val Glu Lys
 225 230 235 240
 Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val
 245 250 255
 His Leu Ser Ala Arg Tyr Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys
 260 265 270
 Trp Gly His Asn Val Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu
 275 280 285
 Thr Glu Gly Glu Gly Pro Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr
 290 295 300
 Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg
 305 310 315 320
 Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Val Gln Asp Ala Glu Asn
 325 330 335
 Lys Ala Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu
 340 345 350
 His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Asn Glu Ala His
 355 360 365
 Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile
 370 375 380
 Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln
 385 390 395 400
 Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
 405 410 415
 Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr
 420 425 430
 Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr
 435 440 445
 Ser Val Arg Glu Leu Glu Asn Phe Arg His Leu Leu Gln Asn Val His
 450 455 460

```
<210> 5
<211> 4382
<212> DNA
<213> Mus sp.
```

```
<220>  
<221> CDS  
<222> (36)..(1430)
```

[illegible]

13

act ggg aat aaa gtt cag gat gca gaa aac aaa gcg tta ctt ctg gag 1061
 Thr Gly Asn Lys Val Gln Asp Ala Glu Asn Lys Ala Leu Leu Leu Glu
 330 335 340

ata ctt cat gaa atc aag tca ttt cct ttg cac ttc gat gag aat tct 1109
 Ile Leu His Glu Ile Lys Ser Phe Pro Leu His Phe Asp Glu Asn Ser
 345 350 355

ttt ttt gct ggg gat aaa aac gaa gca cat aaa cta aag gag gac ttc 1157
 Phe Phe Ala Gly Asp Lys Asn Glu Ala His Lys Leu Lys Glu Asp Phe
 360 365 370

cgg cta cac ttt agg aac att tca aga atc atg gac tgt gtt ggc tgc 1205
 Arg Leu His Phe Arg Asn Ile Ser Arg Ile Met Asp Cys Val Gly Cys
 375 380 385 390

ttc aag tgc cgc ctg tgg ggc aag ctt cag acg cag ggg ctg ggc act 1253
 Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln Thr Gln Gly Leu Gly Thr
 395 400 405

gct ctg aag atc ttg ttt tcc gaa aaa ctg atc gca aat atg ccg gaa 1301
 Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu Ile Ala Asn Met Pro Glu
 410 415 420

agc gga cca agt tat gag ttc cag cta acc aga caa gaa ata gta tca 1349
 Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr Arg Gln Glu Ile Val Ser
 425 430 435

ctg ttt aat gca ttt gga agg att tcc aca agt gtg aga gaa cta gag 1397
 Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr Ser Val Arg Glu Leu Glu
 440 445 450

aac ttc agg cac ttg tta cag aat gtt cac tga ggaggacggg tggaatgtgc 1450
 Asn Phe Arg His Leu Leu Gln Asn Val His
 455 460 465

ctgtttctgc acaggggaat ctgaagggca gaatctctct gagcaccatg gttgcaatga 1510

ctgtcctaag ccaaacgttt atataaagct gcttttgtaa aagaagagat acattgtctt 1570

aagtaaataa cattttttaa aattgtgttc atgtttaata ttattgtgaa tagaagtagt 1630

atattgataa tatacaaatt ttaatactaa gcaaaagtaa ggatcattaaa ctcccttatg 1690

ataaagctag gtaaatattg ccttaggctc tcaaactaga gttgaattta agaaggtaat 1750

gaaagctaag ctaaggtagc tgtgacaagt gtttggtaat aaaatactaa gaggctcagc 1810

agtaaaccat gggtatcagc ctcagatacc aatgcttttt catttgccctc atatacaaag 1870
aaaatacaga ctgcccagtt agatttaagt tttagaaaag caaccagttt tcctttcaat 1930
gttaagtgtg ttgaagttta ttagggccta ttatactac aagtattttg ctcgaagttc 1990
aagtttaact gggagccctg tgttttcctg gcaaccttaa aatacaactgg tatgaaacat 2050
tccttttaga gttaaatagc tattttgatt gtgctgtttt ggtatgttgg gaagtagaac 2110
aattcaaagg cacaggagat ttctaaacat cgtagaaaaga taaatagatt atatatatat 2170
tctcataata gtttccttaa tggaattttg gggaaaattt tatttttata taatttcata 2230
tttacagaaa agtttcaaaa acagttaaaa aaaaaaccaa actgggtttta ctcagattca 2290
tggaattgtc acatgtgttt taaccctca cccagctca gagtggcgat tgagcccagg 2350
acctcagtca tgctgggcta gccctgcatt catgagctgt gtcctcaggc cttgcttaag 2410
ctcctacata gacatagaca ccctgttttt atttaagggt ttgagtcagtg ggcctcatga 2470
tttaacccaa aatacttcag tgtggtggtc aataatttcc taaaaactat ttttgtttt 2530
ctttttaaag gaatatccaa acctacaaa tctgagctga actacttact ataagcctta 2590
aaataaggga gacatccac atcccagcca cctgacgttt gaatttggtt gcccttttcg 2650
acctgtgtag tcacaggcta tacaactcat gtttttacgc atgaaactct gtttttctcc 2710
acaggatgga gctgtaacgt agataggatg ggttggttagt agaagctcta cactgagagc 2770
agtatttgat gtggcttaag aatttacatc acatggcaat tataaatggc atatacctca 2830
aaattatgcc cccttgaggt cacatctaata gtcttgagca gttaggactg gttgagatgt 2890
cacataagaa aaagcaggac ttacgtatgt aatggctagg aatgtcactt tacactgttg 2950
tgtattttct ctgtccctaa gacttggctc agtgccaggc atacagttgg tgtctaatat 3010
ttattgatgg aaagtatatg tatttagtat acgttaagtg atggtgatgt agcttgttta 3070
gtaatgtatc ctatttcccc ctccctctca ctttttcttt tggatctcat aataaaagac 3130
atcaaccac taattaggtc agttttcttg gggacttaaa agaactaaag tgatcaccac 3190
acacaagcca gcccttttga aacctcact gctttcacgt gcttttccca cttgattggc 3250

tatgtcctct gtccctccaa gtgaagtcta atacctaatt ctaagtttat agttaacaag 3310
 cagtttaatt ttttaagaaat cttaactttt cctgtacatg acacaattga caatccctat 3370
 tcctttgtgt ccttgtgttt ggattactcc tgggtatctt tcttctggtc tcttcattta 3430
 acctaagtat cattcctcag acttttttgc cttaagtcac tggaccgtac ttttgagtaa 3490
 tttcaatgca gtaatctcat tttagcttct cagtctgtct ctctgctgtg ctccacttggc 3550
 tgccctgtgt cgcttctgca tcttcaagga ctccagtcacc acaaacctac tctatgtttg 3610
 tgttccttac ttggttaatt tcagagccgt tgcaccgttc aaggctttac agttcattcc 3670
 tgtatcgtcc acctgactat tgggtgtctta agctctgccc attttctctc aacatttcta 3730
 tcagtgtttt tcagttttta ttacgatcac caaaggatta cctgtctttt cccatctctc 3790
 tgttggtccc taccaccaga ttgggctttc tagaaacctt cagcctaatt cctgctggca 3850
 agtttcatga gcttttttgt gagagtctct gcttgatata caagacctc ctcttgtgtt 3910
 tgccactgtt ctgataagag tgttaaaacg ttttccaaaa gtccagagtt gttggccttc 3970
 caaacctttg caaacacagt atttgcattg agagccctag gcttctttct catctgggaa 4030
 attccatgca tttttgaaat ctgtgaaatt acccctgtcc ccttcctatg gtcaccactg 4090
 taactgcaac ctacctctac tgaatcactt attgtactgt atattttatt ttatgaagtg 4150
 tcctttatta gaatgtgagc tccttagggg caggaaaaga aactattcat tttggcacct 4210
 ctatagcata atgaatagtt tcttttcctg cccctaagga gctcacattc taataaagga 4270
 cacttcataa aataaaatat acagtacaat aagtgattca gtagaggtag gttgcagtta 4330
 cagtgggtgac cataggaagg ggacaggggt aatttcacag atttcaaaaa tg 4382

<210> 6

<211> 464

<212> PRT

<213> Mus sp.

<400> 6

Met Gly Arg Ala Trp Gly Leu Leu Val Gly Leu Leu Gly Val Val Trp
 1 5 10 15

Leu Leu Arg Leu Gly His Gly Glu Glu Arg Arg Pro Glu Thr Ala Ala
 20 25 30
 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
 35 40 45
 Asp Val Glu Thr Ile Asp Lys Phe Asn Asn Tyr Arg Leu Phe Pro Arg
 50 55 60
 Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
 65 70 75 80
 Leu Lys Lys Pro Cys Pro Phe Trp Asn Asp Ile Asn Gln Cys Gly Arg
 85 90 95
 Arg Asp Cys Ala Val Lys Pro Cys His Ser Asp Glu Val Pro Asp Gly
 100 105 110
 Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Arg Ile Glu
 115 120 125
 Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser
 130 135 140
 Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser
 145 150 155 160
 Ser Asp Ser Phe Cys Glu Ile Asp Asp Ile Gln Ser Pro Asp Ala Glu
 165 170 175
 Tyr Val Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly
 180 185 190
 Pro Asp Ala Trp Arg Ile Trp Ser Val Ile Tyr Glu Glu Asn Cys Phe
 195 200 205
 Lys Pro Gln Thr Ile Gln Arg Pro Leu Ala Ser Gly Arg Gly Lys Ser
 210 215 220
 Lys Glu Asn Thr Phe Tyr Asn Trp Leu Glu Gly Leu Cys Val Glu Lys
 225 230 235 240
 Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val
 245 250 255
 His Leu Ser Ala Arg Tyr Leu Leu Gln Asp Thr Trp Leu Glu Lys Lys
 260 265 270

Trp Gly His Asn Val Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu
 275 280 285
 Thr Glu Gly Glu Gly Pro Arg Arg Leu Arg Asn Leu Tyr Phe Leu Tyr
 290 295 300
 Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg
 305 310 315 320
 Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Val Gln Asp Ala Glu Asn
 325 330 335
 Lys Ala Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu
 340 345 350
 His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Asn Glu Ala His
 355 360 365
 Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile
 370 375 380
 Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln
 385 390 395 400
 Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
 405 410 415
 Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe Gln Leu Thr
 420 425 430
 Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr
 435 440 445
 Ser Val Arg Glu Leu Glu Asn Phe Arg His Leu Leu Gln Asn Val His
 450 455 460

<210> 7

<211> 2080

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (46)..(648)

<400> 7

gtcgacccac gcgtccggag aagactgcaa ctgctcctgg cagac atg aag ccg tac 57

Met Lys Pro Tyr

1

ttc tgc cat gtc ttt gtc ttc tgc ttc cta atc aga ctt tta aca gga 105
 Phe Cys His Val Phe Val Phe Cys Phe Leu Ile Arg Leu Leu Thr Gly
 5 10 15 20

gaa atc aat ggc tcg gcc gat cat agg atg ttt tca ttt cac aat gga 153
 Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser Phe His Asn Gly
 25 30 35

ggt gta cag att tct tgt aaa tac cct gag act gtc cag cag tta aaa 201
 Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val Gln Gln Leu Lys
 40 45 50

atg cga ttg ttc aga gag aga gaa gtc ctc tgc gaa ctc acc aag acc 249
 Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu Leu Thr Lys Thr
 55 60 65

aag gga agc gga aat gcg gtg tcc atc aag aat cca atg ctc tgt cta 297
 Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro Met Leu Cys Leu
 70 75 80

tat cat ctg tca aac aac agc gtc tct ttt ttc cta aac aac cca gac 345
 Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu Asn Asn Pro Asp
 85 90 95 100

agc tcc cag gga agc tat tac ttc tgc agc ctg tcc att ttt gac cca 393
 Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser Ile Phe Asp Pro
 105 110 115

cct cct ttt caa gaa agg aac ctt agt gga gga tat ttg cat att tat 441
 Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr Leu His Ile Tyr
 120 125 130

gaa tcc cag ctc tgc tgc cag ctg aag ctc tgg cta ccc gta ggg tgt 489
 Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu Pro Val Gly Cys
 135 140 145

gca gct ttc gtt gtg gta ctc ctt ttt gga tgc ata ctt atc atc tgg 537
 Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile Leu Ile Ile Trp
 150 155 160

ttt tca aaa aag aaa tac gga tcc agt gtg cat gac cct aat agt gaa 585
 Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp Pro Asn Ser Glu
 165 170 175 180

tac atg ttc atg gcg gca gtc aac aca aac aaa aag tct aga ctt gca 633

Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys Ser Arg Leu Ala
 185 190 195

ggt gtg acc tca taa gctggaacac ccggaccac agaggaaacg catggactag 688
 Gly Val Thr Ser
 200

ttccctgaa acttgaatgg agaaattctt ctatcttctg gaccacaggg cacctgactt 748
 gatttaacta cagacaacat tctgctggtg ttttgtttgt ctggatcagt gactatcagt 808
 cattcagaat ttcagcagac tgccctgggt ttgctgagtc cttttaagat gaaccccttc 868
 ttaaggaaga cccagttcat atatattcaa caaacagacc tcaactgggat agaatgcccc 928
 tctctccgtg cctgattcta gctatgcact ggccaggaaa acaaacatat ctccagcatt 988
 tttttacaaa aaatgccaaag ggtatgaatc tgtaaagcac acaggcagcc aatggccacc 1048
 atctgtcctc atttttcaga ttccattttc ttccatgga gatcagcatt ctttctagaa 1108
 tcagacagta gagggagatg cttcacaaca gaagcgcttg tgtttctgcy attttgatgt 1168
 atatacttta tcgaactcat gcattagaac caacatgctc tcttccaatt cctagactct 1228
 agctgatcac tgcttcaggg cttagatgcc tgcctctgcc ttcaaatttc cccttaaaga 1288
 tatgtccaca tgtctacttg gcagcctgct gccactccaa ataggaagct cagcctacat 1348
 tccctccac cctgttgct caaaaaaaaa aattagtaga tatgatgttc ccatattctc 1408
 cctgccaaag taattttttc cagaaaagac atctaaattc agttaatatg gtttactatg 1468
 ttgatattag tggtagtaaa catttctcag aaacaaaagc aaattaattt tgctgtggtg 1528
 ttttctacta ttatctgtgt ttccatgggtg ctattaatca caagcttagc tatttttgta 1588
 gatcatatta aagttgcaag caaggaaagc aaccctctgt taatgggcaa acattctcct 1648
 ggggtagaat gaattatcta tttagcctga aagctgcggt ttctgggtgg tggtgccag 1708
 actacagcca cactttgctc tctctgagtt tgacagggtg aagtagtccc cctggagcag 1768
 cactccaggc tacgctggag tcccagagtt gggagatgcc tgggacaagc tgctgctttg 1828
 gtctctggga tctgggaagt acagtagggc caagacagaa ttccctctcc tagaaactat 1888
 gcagcctgga agtcagccct agcactttaa gatagccttc tttagaatat gagttagttg 1948

gaaggattct gaagtgtaaa gagcatatga ctgctctgag ctggaccatt ttctctactt 2008

tcctgtctgt atgcctaaga cttctggagc agccaatgtg tatgcaacat aaaaaaaaaa 2068

aaaaaaaaaa aa

2080

<210> 8

<211> 200

<212> PRT

<213> Mus sp.

<400> 8

Met Lys Pro Tyr Phe Cys His Val Phe Val Phe Cys Phe Leu Ile Arg
1 5 10 15

Leu Leu Thr Gly Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser
20 25 30

Phe His Asn Gly Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val
35 40 45

Gln Gln Leu Lys Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu
50 55 60

Leu Thr Lys Thr Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro
65 70 75 80

Met Leu Cys Leu Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
85 90 95

Asn Asn Pro Asp Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser
100 105 110

Ile Phe Asp Pro Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr
115 120 125

Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu
130 135 140

Pro Val Gly Cys Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile
145 150 155 160

Leu Ile Ile Trp Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp
165 170 175

Pro Asn Ser Glu Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys

180

185

190

Ser Arg Leu Ala Gly Val Thr Ser

195

200

<210> 9

<211> 3266

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (40)..(642)

<220>

<221> unsure

<222> (1)..(3266)

<223> n= a, g, c, or t

<400> 9

ccacgcgtcc ggagaagact gcaactgctc ctggcagac atg aag ccg tac ttc 54
 Met Lys Pro Tyr Phe
 1 5

tgc cat gtc ttt gtc ttc tgc ttc cta atc aga ctt tta aca gga gaa 102
 Cys His Val Phe Val Phe Cys Phe Leu Ile Arg Leu Leu Thr Gly Glu
 10 15 20

atc aat ggc tcg gcc gat cat agg atg ttt tca ttt cac aat gga ggt 150
 Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser Phe His Asn Gly Gly
 25 30 35

gta cag att tct tgt aaa tac cct gag act gtc cag cag tta aaa atg 198
 Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val Gln Gln Leu Lys Met
 40 45 50

cga ttg ttc aga gag aga gaa gtc ctc tgc gaa ctc acc aag acc aag 246
 Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu Leu Thr Lys Thr Lys
 55 60 65

gga agc gga aat gcg gtg tcc atc aag aat cca atg ctc tgt cta tat 294
 Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro Met Leu Cys Leu Tyr
 70 75 80 85

cat ctg tca aac aac agc gtc tct ttt ttc cta aac aac cca gac agc 342
 His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu Asn Asn Pro Asp Ser
 90 95 100

tcc cag gga agc tat tac ttc tgc agc ctg tcc att ttt gac cca cct 390
 Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser Ile Phe Asp Pro Pro
 105 110 115

cct ttt caa gaa agg aac ctt agt gga gga tat ttg cat att tat gaa 438
 Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr Leu His Ile Tyr Glu
 120 125 130

tcc cag ctc tgc tgc cag ctg aag ctc tgg cta ccc gta ggg tgt gca 486
 Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu Pro Val Gly Cys Ala
 135 140 145

gct ttc gtt gtg gta ctc ctt ttt gga tgc ata ctt atc atc tgg ttt 534
 Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile Leu Ile Ile Trp Phe
 150 155 160 165

tca aaa aag aaa tac gga tcc agt gtg cat gac cct aat agt gaa tac 582
 Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp Pro Asn Ser Glu Tyr
 170 175 180

atg ttc atg gcg gca gtc aac aca aac aaa aag tct aga ctt gca ggt 630
 Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys Ser Arg Leu Ala Gly
 185 190 195

gtg acc tca taa gctggaacac ccggaccac agaggaaacg catggactag 682
 Val Thr Ser
 200

ttcccctgaa acttgaatgg agaaattctt ctattttctg gaccacaggg cacctgactt 742

gatttaacta cagacaacat tctgctggtg ttttgtttgt ctggatcagt gactatcagt 802

cattcagaat ttcagcagac tgccctgggt ttgctgagtc cttttaagat gaacccttc 862

ttaaggaaga cccagctcat atatattcaa caaacagacc tcaactgggat agaatgcccc 922

tctctccgtg cctgattcta gctatgcact ggccaggaaa acaaacatat ctccagcatt 982

tttttacaaa aaatgccaag ggtatgaatc tgtaaagcac acaggcagcc aatggccacc 1042

atctgtcctc atttttcaga ttccattttc ttcccatgga gatcagcatt ctttctagaa 1102

tcagacagta gagggagatg cttcacaaca gaagcgcttg tgtttctgcg attttgatgt 1162

atatacttta tcgaactcat gcattagaac caacatgctc tcttccaatt cctagactct 1222

agctgatcac tgcttcaggg cttagatgcc tgctcttgcc ttcaaaattt ccccttaaag 1282

atattgtccac atgtctactt ggcagcctgc tgccactcca aataggaagc tcagcctaca 1342
ttccctccca cccctgttgc tcaaaaaaaaa aaattagtag atatgatgtt cccatattct 1402
ccctgccaaa gtaatttttt ccagaaaaga catctaaatt cagttaatat ggtttactat 1462
gttgatatta gtggtagtaa acatttctca gaaacaaaag caaattaatt ttgctgtggt 1522
gttttctact attatctgtg tttccatggt gctattaatc acaagcttag ctatttttgt 1582
agatcatatt aaagttgcaa gcaaggaaag caaccctctg ttaatgggca aacattctcc 1642
tggggtagaa tgaattatct atttagcctg aaagctgagg tttctgggtg gtggctgcc 1702
gactacagcc acactttgct ctctctgagt ttgacagggt gaagtagtcc ccctggagca 1762
gcactccagg ctacgctgga gtcccagagt tgggagatgc ctgggacaag ctgctgcttt 1822
ggtctctggg atctgggaag tacagtaggg ccaagacaga attccctctc ctagaaacta 1882
tgcagcctgg aagtcagccc tagcacttta agatagcctt ctttagaata tgagttagtt 1942
ggaaggattc tgaagtgtaa agagcatatg actgctctga gctggaccat tttctctact 2002
ttcctgtctg tatgcctaag acttctggag cagccaatgt gtatgcaaca taaaaaaca 2062
aaaaacaaaa aaactcacia actttaagta aaatatggct gcatcatagt tttaagttat 2122
agttgcttac ttacagtta ctttaaaagt gagctgtgca tcagtatata gttattacgt 2182
taagcatgtg taatgctggc tatgtacagt acagtactga acgtgtaatt tgaatcaagt 2242
atggtgttct ctctcttcag atgaccggg cagtctgact ggctttgtta gggcattccc 2302
caagttggac ggtcctttct gtgtgagggg gaaggtgctt tactctgttc cttgaaggat 2362
ccccattccc aacacgaaca cctaacaatg acttcttgaa gaacaaaatt tctgtgaaat 2422
aaaatctggc ttaaagagga gccacttgct aaaagatggt agcaataata caaagtaaag 2482
gctaagcact tgtgtgcagc aatgggctat aaccttgctg tgttttctgg ggggtgaagaa 2542
gtgatgacct tagctacat atgcaaatta gcccttgctc tccaatgacc tttcgtgcta 2602
cataagatag ttgctccctt tgtctcggtt tcccccttt agactctgaa atattcacia 2662
gcttataaaa gagtcagaag cacaggaaac agcacgctct gtgcctgagt tagtttctgc 2722

gttgacctcc tggccccaca gaatggtgcc tatttcctat ggaaatgaag actgcactct 2782
 tgataacttg acagtcacca atatcagaaa attaacactg atatgtcact accctctagt 2842
 ctttggtctg cattcaagat cttcccctgg cttctaggat gtatgtagga gctgaaagtt 2902
 ctgctgggga tgtccctttg tggtcgattg acctgtctcg ggagtgttct tcagtctaga 2962
 cagttctctt cagcctgtag cctgggccct ttgcagatc acacaccatt attttgtaga 3022
 atgttccttt tgtggggggg cagctgatg tttcttcatt aatgaaatga gggtactcgt 3082
 ctttagcaga aataacacag aagtgggtgt gtgccctata gggcggtca ctttttggtt 3142
 tgccaagtaa ctgccagtgt ttgttttcat ctctgtcaa gcttctccat tgtaaaggga 3202
 ttctgctcct gaacagccaa taaatatgct ttgtgagaga aaaaaaaaaa ananaaaaaa 3262
 aaaa 3266

<210> 10

<211> 200

<212> PRT

<213> Mus sp.

<400> 10

Met Lys Pro Tyr Phe Cys His Val Phe Val Phe Cys Phe Leu Ile Arg
 1 5 10 15

Leu Leu Thr Gly Glu Ile Asn Gly Ser Ala Asp His Arg Met Phe Ser
 20 25 30

Phe His Asn Gly Gly Val Gln Ile Ser Cys Lys Tyr Pro Glu Thr Val
 35 40 45

Gln Gln Leu Lys Met Arg Leu Phe Arg Glu Arg Glu Val Leu Cys Glu
 50 55 60

Leu Thr Lys Thr Lys Gly Ser Gly Asn Ala Val Ser Ile Lys Asn Pro
 65 70 75 80

Met Leu Cys Leu Tyr His Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
 85 90 95

Asn Asn Pro Asp Ser Ser Gln Gly Ser Tyr Tyr Phe Cys Ser Leu Ser
 100 105 110

Ile Phe Asp Pro Pro Pro Phe Gln Glu Arg Asn Leu Ser Gly Gly Tyr
 115 120 125
 Leu His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Leu Trp Leu
 130 135 140
 Pro Val Gly Cys Ala Ala Phe Val Val Val Leu Leu Phe Gly Cys Ile
 145 150 155 160
 Leu Ile Ile Trp Phe Ser Lys Lys Lys Tyr Gly Ser Ser Val His Asp
 165 170 175
 Pro Asn Ser Glu Tyr Met Phe Met Ala Ala Val Asn Thr Asn Lys Lys
 180 185 190
 Ser Arg Leu Ala Gly Val Thr Ser
 195 200

<210> 11
 <211> 2703
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (115)..(711)

<400> 11
 tccggaattc ccgggtcgac ccacgcgtcc gcggacgcgt gggcggacgc gtgggcggac 60
 gcgtgggcgg acgcgtgggc tgaacgcgag gactgttaac tgtttctggc aaac atg 117
 Met
 1
 aag tca ggc ctc tgg tat ttc ttt ctc ttc tgc ttg cgc att aaa gtt 165
 Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys Val
 5 10 15
 tta aca gga gaa atc aat ggt tct gcc aat tat gag atg ttt ata ttt 213
 Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile Phe
 20 25 30
 cac aac gga ggt gta caa att tta tgc aaa tat cct gac att gtc cag 261
 His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val Gln
 35 40 45

caa ttt aaa atg cag ttg ctg aaa ggg ggg caa ata ctc tgc gat ctc 309
 Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp Leu
 50 55 60 65

act aag aca aaa gga agt gga aac aca gtg tcc att aag agt ctg aaa 357
 Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu Lys
 70 75 80

ttc tgc cat tct cag tta tcc aac aac agt gtc tct ttt ttt cta tac 405
 Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu Tyr
 85 90 95

aac ttg gac cat tct cat gcc aac tat tac ttc tgc aac cta tca att 453
 Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser Ile
 100 105 110

ttt gat cct cct cct ttt aaa gta act ctt aca gga gga tat ttg cat 501
 Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu His
 115 120 125

att tat gaa tca caa ctt tgt tgc cag ctg aag ttc tgg tta ccc ata 549
 Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro Ile
 130 135 140 145

gga tgt gca gcc ttt gtt gta gtc tgc att ttg gga tgc ata ctt att 597
 Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu Ile
 150 155 160

tgt tgg ctt aca aaa aag tat tca tcc agt gtg cac gac cct aac ggt 645
 Cys Trp Leu Thr Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn Gly
 165 170 175

gaa tac atg ttc atg aga gca gtg aac aca gcc aaa aaa tct aga ctc 693
 Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg Leu
 180 185 190

aca gat gtg acc cta taa tatggaactc tggcaccag gcatgaagca 741
 Thr Asp Val Thr Leu
 195

cgttggccag ttttctcaa cttgaagtgc aagattctct tatttccggg accacggaga 801

gtctgactta actacatata ttttctgctg gtgttttggt caatctggaa gaatgactgt 861

atcagtcaat ggggatttta acagactgcc ttggtactgc cgagtcctct caaaacaaac 921

accctcttgc aaccagcttt ggagaaagcc cagctcctgt gtgctcactg ggagtggaaat 981

cctgtctcc acatctgtct ctagcagtgc atcagccagt aaaacaaaca catttacaag 1041
aaaaatgttt taaagatgcc aggggtactg aatctgcaaa gcaaatgagc agccaaggac 1101
cagcatctgt ccgcatttca ctatcatact acctcttctt tctgtaggga tgagaattcc 1161
tcttttaatc agtgaaggga gatgcttcaa agctggagct attttatttc tgagatgttg 1221
atgtgaactg tacattagta catactcagt actctccttc aattgctgaa cccagttga 1281
ccattttacc aagactttag atgctttctt gtgccctcaa ttttcttttt aaaaatactt 1341
ctacatgact gcttgacagc ccaacagcca ctctcaatag agagctatgt cttacattct 1401
ttcctctgct gctcaatagt tttatatatc tatgcataca tatatacaca catatgtata 1461
taaaattcat aatgaatata ttgcctata ttctccctac aagaatattt ttgctccaga 1521
aagacatgtt cttttctcaa attcagttaa aatgggttac ttgtttcaag ttagtggttag 1581
gaaacattgc ccggaattga aagcaaattt attttattat cctattttct accattatct 1641
atgttttcat ggtgctatta attacaagtt tagttctttt tgtacgatca tattaataatt 1701
gcaaacaaaa tcatctttaa tgggccagca ttctcatggg gtagagcaga atattcattt 1761
agcctgaaag ctgcagttac tataggttgc tgcagacta taccatggg gcctctgggc 1821
ttgacaggtc aaaatgggtc ccatcagcct ggagcagccc tccagacctg ggtggaattc 1881
cagggttgag agactcccct gagccagagg ccactaggta ttcttgctcc cagaggctga 1941
agtcaccctg ggaatcacag tgggtctacct gcattcataa ttccaggatc tgtgaagagc 2001
acatatgtgt cagggcaciaa ttccctctca taaaaccac acagcctgga aattggccct 2061
ggcccttcaa gatagccttc tttagaatat gatttggtta gaaagattct taaatatgtg 2121
gaatatgatt attcttagct ggaatatatt ctctacttcc tgtctgcatg cccaaggctt 2181
ctgaagcagc caatgtcgat gcaacaacat ttgtaacttt aggtaaactg ggattatgtt 2241
gtagtttaac attttgtaac tgtgtgctta tagtttaciaa gtgagacccg atatgtcatt 2301
atgcatactt atattatctt aagcatgtgt aatgctggat gtgtacagta cagtactgaa 2361
cttgtaattt gaatctagta tgggtgtctg ttttcagctg acttgacaaa cctgactggc 2421

ttgcacagg tgttcctga gttgtttgca ggtttctgtg tgtgggggtgg ggtatgggga 2481
 ggagaacctt catggtggcc cacctggcct ggttgtccaa gctgtgcctc gacacatcct 2541
 catccccagc atgggacacc tcaagatgaa taataattca caaaatttct gtgaaatcaa 2601
 atccagtttt aagaggagcc acttatcaaa gagattttta cagtagtaag aaggcaaaga 2661
 ataaacattt gatattcagc aactgaaaaa aaaaaaaaaa aa 2703

<210> 12
 <211> 198
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Lys Ser Gly Leu Trp Tyr Phe Phe Leu Phe Cys Leu Arg Ile Lys
 1 5 10 15
 Val Leu Thr Gly Glu Ile Asn Gly Ser Ala Asn Tyr Glu Met Phe Ile
 20 25 30
 Phe His Asn Gly Gly Val Gln Ile Leu Cys Lys Tyr Pro Asp Ile Val
 35 40 45
 Gln Gln Phe Lys Met Gln Leu Leu Lys Gly Gly Gln Ile Leu Cys Asp
 50 55 60
 Leu Thr Lys Thr Lys Gly Ser Gly Asn Thr Val Ser Ile Lys Ser Leu
 65 70 75 80
 Lys Phe Cys His Ser Gln Leu Ser Asn Asn Ser Val Ser Phe Phe Leu
 85 90 95
 Tyr Asn Leu Asp His Ser His Ala Asn Tyr Tyr Phe Cys Asn Leu Ser
 100 105 110
 Ile Phe Asp Pro Pro Pro Phe Lys Val Thr Leu Thr Gly Gly Tyr Leu
 115 120 125
 His Ile Tyr Glu Ser Gln Leu Cys Cys Gln Leu Lys Phe Trp Leu Pro
 130 135 140
 Ile Gly Cys Ala Ala Phe Val Val Val Cys Ile Leu Gly Cys Ile Leu
 145 150 155 160
 Ile Cys Trp Leu Thr Lys Lys Tyr Ser Ser Ser Val His Asp Pro Asn

165

170

175

Gly Glu Tyr Met Phe Met Arg Ala Val Asn Thr Ala Lys Lys Ser Arg
 180 185 190

Leu Thr Asp Val Thr Leu
 195

<210> 13

<211> 1795

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (57)..(1502)

<400> 13

gtcgacccac gcgtccgggc ctcccaagcg tggggcgaca agctgccgga gctgca atg 59

Met

1

ggc cgc ggc tgg gga ttc ttg ttt ggc ctc ctg ggc gcc gtg tgg ctg 107
 Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val Trp Leu
 5 10 15

ctc agc tcg ggc cac gga gag gag cag ccc ccg gag aca gcg gca cag 155
 Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr Ala Ala Gln
 20 25 30

agg tgc ttc tgc cag gtt agt ggt tac ttg gat gat tgt acc tgt gat 203
 Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys Asp
 35 40 45

gtt gaa acc att gat aga ttt aat aac tac agg ctt ttc cca aga cta 251
 Val Glu Thr Ile Asp Arg Phe Asn Asn Tyr Arg Leu Phe Pro Arg Leu
 50 55 60 65

caa aaa ctt ctt gaa agt gac tac ttt agg tat tac aag gta aac ctg 299
 Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn Leu
 70 75 80

aag agg ccg tgt cct ttc tgg aat gac atc agc cag tgt gga aga agg 347
 Lys Arg Pro Cys Pro Phe Trp Asn Asp Ile Ser Gln Cys Gly Arg Arg
 85 90 95

gac tgt gct gtc aaa cca tgt caa tct gat gaa gtt cct gat gga att 395

Asp Cys Ala Val Lys Pro Cys Gln Ser Asp Glu Val Pro Asp Gly Ile
 100 105 110

aaa tct gcg agc tac aag tat tct gaa gaa gcc aat aat ctc att gaa 443
 Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Asn Leu Ile Glu
 115 120 125

gaa tgt gaa caa gct gaa cga ctt gga gca gtg gat gaa tct ctg agt 491
 Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu Ser
 130 135 140 145

gag gaa aca cag aag gct gtt ctt cag tgg acc aag cat gat gat tct 539
 Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp Ser
 150 155 160

tca gat aac ttc tgt gaa gct gat gat tgg atc tgc tgg tgg tca tct 587
 Ser Asp Asn Phe Cys Glu Ala Asp Asp Trp Ile Cys Trp Trp Ser Ser
 165 170 175

aag aag aaa gta ttt gac att cag tcc cct gaa gct gaa tat gta gat 635
 Lys Lys Lys Val Phe Asp Ile Gln Ser Pro Glu Ala Glu Tyr Val Asp
 180 185 190

ttg ctt ctt aat cct gag cgc tac act ggt tac aag gga cca gat gct 683
 Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly Pro Asp Ala
 195 200 205

tgg aaa ata tgg aat gtc atc tac gaa gaa aac tgt ttt aag cca cag 731
 Trp Lys Ile Trp Asn Val Ile Tyr Glu Glu Asn Cys Phe Lys Pro Gln
 210 215 220 225

aca att aaa aga cct tta aat cct ttg gct tct ggt caa ggg aca agt 779
 Thr Ile Lys Arg Pro Leu Asn Pro Leu Ala Ser Gly Gln Gly Thr Ser
 230 235 240

gaa gag aac act ttt tac agt tgg cta gaa ggt ctc tgt gta gaa aaa 827
 Glu Glu Asn Thr Phe Tyr Ser Trp Leu Glu Gly Leu Cys Val Glu Lys
 245 250 255

aga gca ttc tac aga ctt ata tct ggc cta cat gca agc att aat gtg 875
 Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn Val
 260 265 270

cat ttg agt gca aga tat ctt tta caa gag acc tgg tta gaa aag aaa 923
 His Leu Ser Ala Arg Tyr Leu Leu Gln Glu Thr Trp Leu Glu Lys Lys
 275 280 285

tgg gga cac aac att aca gaa ttt caa cag cga ttt gat gga att ttg 971

Trp Gly His Asn Ile Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile Leu
 290 295 300 305
 act gaa gga gaa ggt cca aga agg ctt aag aac ttg tat ttt ctc tac 1019
 Thr Glu Gly Glu Gly Pro Arg Arg Leu Lys Asn Leu Tyr Phe Leu Tyr
 310 315 320
 tta ata gaa cta agg gcc tta tcc aaa gtg tta cca ttc ttc gag cgc 1067
 Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu Arg
 325 330 335
 cca gat ttt caa ctc ttt act gga aat aaa att cag gat gag gaa aac 1115
 Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Ile Gln Asp Glu Glu Asn
 340 345 350
 aaa atg tta ctt ctg gaa ata ctt cat gaa atc aag tca ttt cct ttg 1163
 Lys Met Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro Leu
 355 360 365
 cat ttt gat gag aat tca ttt ttt gct ggg gat aaa aaa gaa gca cac 1211
 His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Lys Glu Ala His
 370 375 380 385
 aaa cta aag gag gac ttt cga ctg cat ttt aga aat att tca aga att 1259
 Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg Ile
 390 395 400
 atg gat tgt gtt ggt tgt ttt aaa tgt cgt ctg tgg gga aag ctt cag 1307
 Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu Gln
 405 410 415
 act cag ggt ttg ggc act gct ctg aag atc tta ttt tct gag aaa ttg 1355
 Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys Leu
 420 425 430
 ata gca aat atg cca gaa agt gga cct agt tat gaa ttc cat cta acc 1403
 Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe His Leu Thr
 435 440 445
 aga caa gaa ata gta tca tta ttc aac gca ttt gga aga att tct aca 1451
 Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser Thr
 450 455 460 465
 agt gtg aaa gaa tta gaa aac ttc agg aac ttg tta cag aat att cat 1499
 Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu Gln Asn Ile His
 470 475 480
 taa agaaaacaag ctgatatgtg cctgtttctg gacaatggag gcgaaagagt 1552

ggaatttcat tcaaaggcat aatagcaatg acagtcttaa gccaaacatt ttatataaag 1612
 ttgcttttgt aaaggagaat tatattgttt taagtaaaca cattttttaa aattgtgtta 1672
 agtctatgta taatactact gtgagtaaaa gtaatacttt aataatgtgg tacaaatttt 1732
 aaagtttaat attgaataaa aggaggatta tcaaattcaa aaaaaaaaaa aaagggcggc 1792
 cgc 1795

<210> 14
 <211> 481
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Gly Arg Gly Trp Gly Phe Leu Phe Gly Leu Leu Gly Ala Val Trp
 1 5 10 15
 Leu Leu Ser Ser Gly His Gly Glu Glu Gln Pro Pro Glu Thr Ala Ala
 20 25 30
 Gln Arg Cys Phe Cys Gln Val Ser Gly Tyr Leu Asp Asp Cys Thr Cys
 35 40 45
 Asp Val Glu Thr Ile Asp Arg Phe Asn Asn Tyr Arg Leu Phe Pro Arg
 50 55 60
 Leu Gln Lys Leu Leu Glu Ser Asp Tyr Phe Arg Tyr Tyr Lys Val Asn
 65 70 75 80
 Leu Lys Arg Pro Cys Pro Phe Trp Asn Asp Ile Ser Gln Cys Gly Arg
 85 90 95
 Arg Asp Cys Ala Val Lys Pro Cys Gln Ser Asp Glu Val Pro Asp Gly
 100 105 110
 Ile Lys Ser Ala Ser Tyr Lys Tyr Ser Glu Glu Ala Asn Asn Leu Ile
 115 120 125
 Glu Glu Cys Glu Gln Ala Glu Arg Leu Gly Ala Val Asp Glu Ser Leu
 130 135 140
 Ser Glu Glu Thr Gln Lys Ala Val Leu Gln Trp Thr Lys His Asp Asp
 145 150 155 160

Ser Ser Asp Asn Phe Cys Glu Ala Asp Asp Trp Ile Cys Trp Trp Ser
 165 170 175
 Ser Lys Lys Lys Val Phe Asp Ile Gln Ser Pro Glu Ala Glu Tyr Val
 180 185 190
 Asp Leu Leu Leu Asn Pro Glu Arg Tyr Thr Gly Tyr Lys Gly Pro Asp
 195 200 205
 Ala Trp Lys Ile Trp Asn Val Ile Tyr Glu Glu Asn Cys Phe Lys Pro
 210 215 220
 Gln Thr Ile Lys Arg Pro Leu Asn Pro Leu Ala Ser Gly Gln Gly Thr
 225 230 235 240
 Ser Glu Glu Asn Thr Phe Tyr Ser Trp Leu Glu Gly Leu Cys Val Glu
 245 250 255
 Lys Arg Ala Phe Tyr Arg Leu Ile Ser Gly Leu His Ala Ser Ile Asn
 260 265 270
 Val His Leu Ser Ala Arg Tyr Leu Leu Gln Glu Thr Trp Leu Glu Lys
 275 280 285
 Lys Trp Gly His Asn Ile Thr Glu Phe Gln Gln Arg Phe Asp Gly Ile
 290 295 300
 Leu Thr Glu Gly Glu Gly Pro Arg Arg Leu Lys Asn Leu Tyr Phe Leu
 305 310 315 320
 Tyr Leu Ile Glu Leu Arg Ala Leu Ser Lys Val Leu Pro Phe Phe Glu
 325 330 335
 Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn Lys Ile Gln Asp Glu Glu
 340 345 350
 Asn Lys Met Leu Leu Leu Glu Ile Leu His Glu Ile Lys Ser Phe Pro
 355 360 365
 Leu His Phe Asp Glu Asn Ser Phe Phe Ala Gly Asp Lys Lys Glu Ala
 370 375 380
 His Lys Leu Lys Glu Asp Phe Arg Leu His Phe Arg Asn Ile Ser Arg
 385 390 395 400
 Ile Met Asp Cys Val Gly Cys Phe Lys Cys Arg Leu Trp Gly Lys Leu
 405 410 415

Gln Thr Gln Gly Leu Gly Thr Ala Leu Lys Ile Leu Phe Ser Glu Lys
 420 425 430

Leu Ile Ala Asn Met Pro Glu Ser Gly Pro Ser Tyr Glu Phe His Leu
 435 440 445

Thr Arg Gln Glu Ile Val Ser Leu Phe Asn Ala Phe Gly Arg Ile Ser
 450 455 460

Thr Ser Val Lys Glu Leu Glu Asn Phe Arg Asn Leu Leu Gln Asn Ile
 465 470 475 480

His

<210> 15

<211> 3868

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (325)..(1479)

<400> 15

gcggcgctc gcgcgcagcc ccgcacctcc gccctgcct ctgcctcctg ggccatgccc 60
 tgctgtttac atgccggtga ggtecccgcc cgctccgaac cctccgagc cccggctccc 120
 cgagggtgaa gcccgccggc ccgcgaactg gactggtgga tctctcagac ctggggcccc 180
 ggactccgat ctccgcgctc tccgccacca tcagggcggg atccggctct ggtgttttga 240
 ggaggggggtg tgggtgtaggg aaaggaatcc cgtccctctc cacctttttt cgccttcggg 300
 gcttcagact cagggaaactc gctc atg gct ttc ttg atg aag aag aag aaa 351
 Met Ala Phe Leu Met Lys Lys Lys Lys
 1 5

ttc aaa ttc caa act act ttc acc ctg gag gag ctg act gcg gtt ccc 399
 Phe Lys Phe Gln Thr Thr Phe Thr Leu Glu Glu Leu Thr Ala Val Pro
 10 15 20 25

ttc gtg aac ggg gtc etc ttc tgc aag gtc cgg ctg ctg gat gga ggg 447
 Phe Val Asn Gly Val Leu Phe Cys Lys Val Arg Leu Leu Asp Gly Gly
 30 35 40

gat ttt gtc agc ttg tct tca agg gag gag gta cag gag aac tgt gtg 495
Asp Phe Val Ser Leu Ser Ser Arg Glu Glu Val Gln Glu Asn Cys Val
45 50 55

cgg tgg cga aag agg ttc acc ttc gtg tgt aag atg agt gct aac ccg 543
Arg Trp Arg Lys Arg Phe Thr Phe Val Cys Lys Met Ser Ala Asn Pro
60 65 70

gcc acc ggc ctg ctg gac ccc tgt gtc ttc cgt gtg tct gtg cgc aag 591
Ala Thr Gly Leu Leu Asp Pro Cys Val Phe Arg Val Ser Val Arg Lys
75 80 85

gag ctg aaa ggc ggg aag gct tat tcc aag ctg ggc ttc gct gac ttg 639
Glu Leu Lys Gly Gly Lys Ala Tyr Ser Lys Leu Gly Phe Ala Asp Leu
90 95 100 105

aac ctg gcc gag ttt gcg ggc tct ggc tcc acg gtg cgc tgc tgc ctg 687
Asn Leu Ala Glu Phe Ala Gly Ser Gly Ser Thr Val Arg Cys Cys Leu
110 115 120

ctc gag gga tat gac acg aag aac act cgc cag gac aac tcc atc ctt 735
Leu Glu Gly Tyr Asp Thr Lys Asn Thr Arg Gln Asp Asn Ser Ile Leu
125 130 135

aag gtc acc att ggt atg ttc ctg ctc tct gga gat ccc tgc ttc aag 783
Lys Val Thr Ile Gly Met Phe Leu Leu Ser Gly Asp Pro Cys Phe Lys
140 145 150

acg cca cca tct act gcc aag tcc atc tcc atc cca ggc cag gat tcc 831
Thr Pro Pro Ser Thr Ala Lys Ser Ile Ser Ile Pro Gly Gln Asp Ser
155 160 165

tcc ctg cag ctg acg tgt aag ggt ggt ggg acc agc agt ggg ggc agc 879
Ser Leu Gln Leu Thr Cys Lys Gly Gly Gly Thr Ser Ser Gly Gly Ser
170 175 180 185

agc acc aac tcc ctg act ggg tcc cgg ccc ccc aag gct cgg ccc act 927
Ser Thr Asn Ser Leu Thr Gly Ser Arg Pro Pro Lys Ala Arg Pro Thr
190 195 200

att ctc agc tca ggg ctg cca gag gaa ccc gac cag aac ctg tcc agc 975
Ile Leu Ser Ser Gly Leu Pro Glu Glu Pro Asp Gln Asn Leu Ser Ser
205 210 215

cct gag gag gtg ttc cac tct ggc cac tcc cgc aac tcc agc tat gcc 1023
Pro Glu Glu Val Phe His Ser Gly His Ser Arg Asn Ser Ser Tyr Ala
220 225 230

agc cag cag tcc aag atc tcc ggc tac agc aca gag cac tcg cgc tcc 1071
 Ser Gln Gln Ser Lys Ile Ser Gly Tyr Ser Thr Glu His Ser Arg Ser
 235 240 245

tcc agc ctc tca gac ctg acg cac cgc cgc aac acg tcc acc agc agc 1119
 Ser Ser Leu Ser Asp Leu Thr His Arg Arg Asn Thr Ser Thr Ser Ser
 250 255 260 265

agc gcc tct ggg ggc ctt ggc atg acc gtg gag ggc cct gag ggc agt 1167
 Ser Ala Ser Gly Gly Leu Gly Met Thr Val Glu Gly Pro Glu Gly Ser
 270 275 280

gag cgg gag cac cgg ccc ccg gag aag ccg ccg cgg cca ccc cgg ccc 1215
 Glu Arg Glu His Arg Pro Pro Glu Lys Pro Pro Arg Pro Pro Arg Pro
 285 290 295

ctg cat ctg tcc gat cgc tct ttc agg cgg aag aag gac tcg gtg gag 1263
 Leu His Leu Ser Asp Arg Ser Phe Arg Arg Lys Lys Asp Ser Val Glu
 300 305 310

agc cac ccg acc tgg gtg gac gac acg cgg atc gat gcg gat gcc atc 1311
 Ser His Pro Thr Trp Val Asp Asp Thr Arg Ile Asp Ala Asp Ala Ile
 315 320 325

gtg gag aag atc gtg cag agc cag gac ttc aca gat ggc agc aac acc 1359
 Val Glu Lys Ile Val Gln Ser Gln Asp Phe Thr Asp Gly Ser Asn Thr
 330 335 340 345

gag gac agc aac ctc cgg ctg ttc gtg agc cgc gat ggc tct gcc acg 1407
 Glu Asp Ser Asn Leu Arg Leu Phe Val Ser Arg Asp Gly Ser Ala Thr
 350 355 360

ctg agc ggc atc cag ctt gcc acc agg gtc tct tct ggg gtc tac gag 1455
 Leu Ser Gly Ile Gln Leu Ala Thr Arg Val Ser Ser Gly Val Tyr Glu
 365 370 375

cca gtt gtg att gaa agc cat tga ggagcaggtg tccgggctgg agaagagtcc 1509
 Pro Val Val Ile Glu Ser His
 380 385

tgctttctct ggagtccaga cctgtatcat tccatgagga actttccctc tcagatcacc 1569

tctgcgccac atctcatcca tgcctcctcc atgcactcca gtccacactc cccgtagcat 1629

cattccattg cccctcccat ccattgctggg accctcctgg ccaccaagg cccaggcacc 1689

actgtgaata ttctcctctg aaccactaga gggcaggcca ggcaggccag gcggggcccg 1749

gcagcttggtg ggcaagaagg agctggcaag gaccggcgct gctggagact gaccagccc 1809
tctggctgag gacatgcagc agctcctaaa tgtagagatg cctgtggctg agggggcctc 1869
tctacctgtg tccccactca ctccaggagc actggctttg gtcacgtctt agcagcaggg 1929
ccttgctccg ttgttccctt gccctgggtg tgggggggccc agaccgcctc cggaatcctg 1989
ccacctgtga ctgtctgact gcttagtgct tcagctgtcc ctcccttggtg tcctggggga 2049
cctgctggcg gcctcttctt gggagccatg acctcagacc ccaccacac tccagatcga 2109
gaccctgccc tccccccggc aaatgtcctc ccgtgcctt gcagcctgca ctttgacat 2169
gctcaccccc agcacagtcc cactggcccc tcacctcccc ttcctgagc tccttcccaa 2229
ggactcctgg tcactgcctg ctgtgcagtc agaggcccag ggtccagcag cccggcggga 2289
acgggtgctg cctcttctc cagttagctc cagctcaggt ctgagacccg tgctgagaaa 2349
ggtctgagca ccgaccgtgc cctctgcccc gggtgggtc ctgagcagct ggttttctg 2409
caggaagggt ggagcaagca aagtccttct ctgccctcag ggtcagctgc ccagactggg 2469
gcggatgcca gagaggcagg tgggctgtgg ctggactggg ccggagctgg ctccctacc 2529
agaaaagcct cagccttctt ctggaagcat cccccgttct gggcaagggg gaagggtcc 2589
tttaaggggt gtgcttctcc agtggggagc agtctggccc tgccccctac taaagcctct 2649
gctctcagca ctttccccca agtccttgta acttgcttga aggtgggttc tggtgccag 2709
ccagtcctg gacaaactct cctgccccct ttaaatttca ctcatcttgt ataaaccag 2769
caggctgggt tttacttagc cctgtagctt ttttcatttt ttctttccgt ctttcttctt 2829
gagttcacgg ttcaatattg cctcctcgcc ctggtagagg gaggtgctgc ttttctgccc 2889
cacctgccgg ctggttccag cagcgtggg gccagctgg ggggccggga tgggggttc 2949
tctctctggg aggggtgcag gtgccctccc caggctggga gggttcctc cctagctccc 3009
catctgcccc cgtggtgag agttgggtt ctgggtcttg gaactccctg gcattgggaa 3069
cagagcattt ccagcattt ttgtgttgt ttactcacc taacccttag aaaatgaatg 3129
ttagaagggt cctgccgagg cgggacagag tgtttgctcg cgctggagaa ggctctgctc 3189

agccctgaga gtcccttcct gccccaccga tactggcact ttaaaaagga agctgaccgc 3249
 acagtgtcca gacgaattgg cccccagaag atggggagtt ctgtcctgcc cttctgtgtc 3309
 tgcgtgacct caccagcct aggagggagg tgcattcagg gtagatttgc ctctcattca 3369
 aagttctggg gctttgggcg gaaaacagcc agctttggcg ctgttgggga gactcctcca 3429
 gaccaggaac cccagaagga gacagagcct gccacatcct cccacgccag gccctgggcc 3489
 aggggtgattg gactgagaat ttggccacaa ccaaattgat gctggctgga accagaggcc 3549
 agaaagcctg gccttgctcc catgtgggag ccctgtcctc agccctcttg tccccttgag 3609
 ctcagtgaat tcccaccagg tgcccacagc tcttggaact caaattctat atattgagag 3669
 agttggagag tatatcagag atatttttgg aaaggagttg gtctatgcaa tgtcagtttg 3729
 gaatcttctt gaaagttaa tgtttttatt aggagattta aagaaaataa aggtctacaa 3789
 tatcaaaaaa aaaaccacg cgctccgccca cgcgctccgc cacgcgtccg cccacgcgtc 3849
 cgcggaacgc tgggtcgac 3868

<210> 16

<211> 384

<212> PRT

<213> Homo sapiens

<400> 16

Met	Ala	Phe	Leu	Met	Lys	Lys	Lys	Lys	Phe	Lys	Phe	Gln	Thr	Thr	Phe
1				5					10					15	
Thr	Leu	Glu	Glu	Leu	Thr	Ala	Val	Pro	Phe	Val	Asn	Gly	Val	Leu	Phe
			20					25					30		
Cys	Lys	Val	Arg	Leu	Leu	Asp	Gly	Gly	Asp	Phe	Val	Ser	Leu	Ser	Ser
		35					40					45			
Arg	Glu	Glu	Val	Gln	Glu	Asn	Cys	Val	Arg	Trp	Arg	Lys	Arg	Phe	Thr
	50					55				60					
Phe	Val	Cys	Lys	Met	Ser	Ala	Asn	Pro	Ala	Thr	Gly	Leu	Leu	Asp	Pro
65					70					75				80	
Cys	Val	Phe	Arg	Val	Ser	Val	Arg	Lys	Glu	Leu	Lys	Gly	Gly	Lys	Ala
				85					90					95	

Tyr Ser Lys Leu Gly Phe Ala Asp Leu Asn Leu Ala Glu Phe Ala Gly
 100 105 110
 Ser Gly Ser Thr Val Arg Cys Cys Leu Leu Glu Gly Tyr Asp Thr Lys
 115 120 125
 Asn Thr Arg Gln Asp Asn Ser Ile Leu Lys Val Thr Ile Gly Met Phe
 130 135 140
 Leu Leu Ser Gly Asp Pro Cys Phe Lys Thr Pro Pro Ser Thr Ala Lys
 145 150 155 160
 Ser Ile Ser Ile Pro Gly Gln Asp Ser Ser Leu Gln Leu Thr Cys Lys
 165 170 175
 Gly Gly Gly Thr Ser Ser Gly Gly Ser Ser Thr Asn Ser Leu Thr Gly
 180 185 190
 Ser Arg Pro Pro Lys Ala Arg Pro Thr Ile Leu Ser Ser Gly Leu Pro
 195 200 205
 Glu Glu Pro Asp Gln Asn Leu Ser Ser Pro Glu Glu Val Phe His Ser
 210 215 220
 Gly His Ser Arg Asn Ser Ser Tyr Ala Ser Gln Gln Ser Lys Ile Ser
 225 230 235 240
 Gly Tyr Ser Thr Glu His Ser Arg Ser Ser Ser Leu Ser Asp Leu Thr
 245 250 255
 His Arg Arg Asn Thr Ser Thr Ser Ser Ser Ala Ser Gly Gly Leu Gly
 260 265 270
 Met Thr Val Glu Gly Pro Glu Gly Ser Glu Arg Glu His Arg Pro Pro
 275 280 285
 Glu Lys Pro Pro Arg Pro Pro Arg Pro Leu His Leu Ser Asp Arg Ser
 290 295 300
 Phe Arg Arg Lys Lys Asp Ser Val Glu Ser His Pro Thr Trp Val Asp
 305 310 315 320
 Asp Thr Arg Ile Asp Ala Asp Ala Ile Val Glu Lys Ile Val Gln Ser
 325 330 335
 Gln Asp Phe Thr Asp Gly Ser Asn Thr Glu Asp Ser Asn Leu Arg Leu
 340 345 350

Phe Val Ser Arg Asp Gly Ser Ala Thr Leu Ser Gly Ile Gln Leu Ala
 355 360 365

Thr Arg Val Ser Ser Gly Val Tyr Glu Pro Val Val Ile Glu Ser His
 370 375 380

<210> 17

<211> 442

<212> PRT

<213> Trypanosoma brucei

<400> 17

Met Leu Lys Met Arg Leu Leu Ile Val Val Pro Val Leu Leu Gly Leu
 1 5 10 15

Val Trp Gln Ile Leu Leu Arg Ala Glu Leu Asp Gly Val Ser Phe Phe
 20 25 30

Gly Met Tyr Ile Ser Ala Asn Asn Ser Gly Ala Gly Ser Tyr Val Arg
 35 40 45

Thr Lys Lys Gly Asn Ala Leu Lys Glu Gly Phe Cys Ser Leu Thr Met
 50 55 60

Asp Glu Val Ser Gln Asn Thr Glu Gly Ile Thr Gly Leu Leu Asn Asn
 65 70 75 80

Ile Thr Ser His Pro Tyr Phe Arg Tyr Phe Lys Val Asn Leu Asp Arg
 85 90 95

Glu Cys Arg Tyr Trp Val Ala Glu Ala Ser Cys Thr Cys Asp Ser Asn
 100 105 110

Gly Cys Gln Ile Cys Thr Cys Asp Asp Ser Gly Ile Pro Glu Thr Leu
 115 120 125

Lys Tyr Pro Tyr Asp Met Ser Asp Val Ser Ala Val Glu Arg Arg Thr
 130 135 140

Ala Pro Asp Lys His Ala Ala Lys Gly Phe Glu Asp Glu Ile Lys Pro
 145 150 155 160

Ile Asp Pro Asp Arg Asp Ala Thr Tyr Val Asp Leu Leu Gln Asn Pro
 165 170 175

Glu Ala Asn Thr Gly Tyr Ser Gly Pro Lys Ala Ala Arg Val Trp Gln

180	185	190
Ala Val Tyr Asp Asn Cys Asn Ile Asp Gly Leu Pro Ser Asn Asp Thr		
195	200	205
Ala Gly Val Glu Asn Arg Glu Lys Ala Leu Leu Arg Gln Leu Leu Ser		
210	215	220
Gly Leu His Thr Ser Ile Thr Met His Val Ala Ala Phe Phe Tyr Asn		
225	230	235
Asp Thr Lys Gly Asp Ser Pro Leu Arg Ser Leu Gly Val Leu Asn Asn		
245	250	255
Pro Asn Ile Ser Phe Tyr Pro Asn Cys Gly Met Phe Arg Arg Ile Val		
260	265	270
Lys Asn Asp Glu Phe Ile Arg Asn Leu Phe Val Val Tyr Gln Phe Val		
275	280	285
Leu Arg Ala Val Ala Lys Thr Lys Arg Ala Phe Leu Ala Asn Ser Ser		
290	295	300
Leu Tyr Asn Ser Gly Phe Asn Gly Ala Ala Thr Asp Gly Asp Val Arg		
305	310	315
Leu Tyr Ser Asn Ile Gly Glu Leu Phe Ser Ser Lys Leu Phe Arg Val		
325	330	335
Ala Thr Phe Asp Glu Gln Lys Phe Phe Glu Ser Pro Gly Ala His Leu		
340	345	350
Leu Val Arg Gln Met Lys Arg Val Val His Asn Val Thr Thr Leu Met		
355	360	365
Asp Cys Val Thr Cys Glu Lys Cys Arg Ala Trp Gly Lys Leu Glu Thr		
370	375	380
Ala Ala Leu Ala Thr Ala Leu Lys Ile Val Phe Gly Ser Ala Glu Asn		
385	390	395
Val Val Glu Leu Asn Arg Gly Glu Arg Val Ala Leu Ile Asn Phe Ala		
405	410	415
Arg Gln Leu Ala Ile Ser Val Lys Asn Val Arg Ser Leu Ala Ala Val		
420	425	430
Cys Glu Lys Phe Asn Tyr Thr Ala Met Ser		

435

440

<210> 18

<211> 218

<212> PRT

<213> Mus sp.

<400> 18

Met Thr Leu Arg Leu Leu Phe Leu Ala Leu Asn Phe Phe Ser Val Gln
 1 5 10 15

Val Thr Glu Asn Lys Ile Leu Val Lys Gln Ser Pro Leu Leu Val Val
 20 25 30

Asp Ser Asn Glu Val Ser Leu Ser Cys Arg Tyr Ser Tyr Asn Leu Leu
 35 40 45

Ala Lys Glu Phe Arg Ala Ser Leu Tyr Lys Gly Val Asn Ser Asp Val
 50 55 60

Glu Val Cys Val Gly Asn Gly Asn Phe Thr Tyr Gln Pro Gln Phe Arg
 65 70 75 80

Ser Asn Ala Glu Phe Asn Cys Asp Gly Asp Phe Asp Asn Glu Thr Val
 85 90 95

Thr Phe Arg Leu Trp Asn Leu His Val Asn His Thr Asp Ile Tyr Phe
 100 105 110

Cys Lys Ile Glu Phe Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Arg
 115 120 125

Ser Asn Gly Thr Ile Ile His Ile Lys Glu Lys His Leu Cys His Thr
 130 135 140

Gln Ser Ser Pro Lys Leu Phe Trp Ala Leu Val Val Val Ala Gly Val
 145 150 155 160

Leu Phe Cys Tyr Gly Leu Leu Val Thr Val Ala Leu Cys Val Ile Trp
 165 170 175

Thr Asn Ser Arg Arg Asn Arg Leu Leu Gln Val Thr Thr Met Asn Met
 180 185 190

Thr Pro Arg Arg Pro Gly Leu Thr Arg Lys Pro Tyr Gln Pro Tyr Ala
 195 200 205

Pro Ala Arg Asp Phe Ala Ala Tyr Arg Pro
210 215

<210> 19
<211> 220
<212> PRT
<213> Homo sapiens

<400> 19

Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val
1 5 10 15

Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr
20 25 30

Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser
35 40 45

Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu
50 55 60

Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser
65 70 75 80

Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr
85 90 95

Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys
100 105 110

Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser
115 120 125

Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro
130 135 140

Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly
145 150 155 160

Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile
165 170 175

Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met
180 185 190

Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro
195 200 205

Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser
 210 215 220

<210> 20
 <211> 223
 <212> PRT
 <213> Mus sp.

<400> 20
 Met Ala Cys Leu Gly Leu Arg Arg Tyr Lys Ala Gln Leu Gln Leu Pro
 1 5 10 15

Ser Arg Thr Trp Pro Phe Val Ala Leu Leu Thr Leu Leu Phe Ile Pro
 20 25 30

Val Phe Ser Glu Ala Ile Gln Val Thr Gln Pro Ser Val Val Leu Ala
 35 40 45

Ser Ser His Gly Val Ala Ser Phe Pro Cys Glu Tyr Ser Pro Ser His
 50 55 60

Asn Thr Asp Glu Val Arg Val Thr Val Leu Arg Gln Thr Asn Asp Gln
 65 70 75 80

Met Thr Glu Val Cys Ala Thr Thr Phe Thr Glu Lys Asn Thr Val Gly
 85 90 95

Phe Leu Asp Tyr Pro Phe Cys Ser Gly Thr Phe Asn Glu Ser Arg Val
 100 105 110

Asn Leu Thr Ile Gln Gly Leu Arg Ala Val Asp Thr Gly Leu Tyr Leu
 115 120 125

Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Phe Val Gly Met Gly
 130 135 140

Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
 145 150 155 160

Asp Phe Leu Leu Trp Ile Leu Val Ala Val Ser Leu Gly Leu Phe Phe
 165 170 175

Tyr Ser Phe Leu Val Ser Ala Val Ser Leu Ser Lys Met Leu Lys Lys
 180 185 190

Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu

195

200

205

Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn
 210 215 220

<210> 21

<211> 223

<212> PRT

<213> Homo sapiens

<400> 21

Met Ala Cys Leu Gly Phe Gln Arg His Lys Ala Gln Leu Asn Leu Ala
 1 5 10 15

Ala Arg Thr Trp Pro Cys Thr Leu Leu Phe Phe Leu Leu Phe Ile Pro
 20 25 30

Val Phe Cys Lys Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala
 35 40 45

Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly
 50 55 60

Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln
 65 70 75 80

Val Thr Glu Val Cys Ala Ala Thr Tyr Met Thr Gly Asn Glu Leu Thr
 85 90 95

Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val
 100 105 110

Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile
 115 120 125

Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly
 130 135 140

Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser
 145 150 155 160

Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe
 165 170 175

Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met Leu Lys Lys
 180 185 190

Arg Ser Pro Leu Thr Thr Gly Val Tyr Val Lys Met Pro Pro Thr Glu
 195 200 205

Pro Glu Cys Glu Lys Gln Phe Gln Pro Tyr Phe Ile Pro Ile Asn
 210 215 220

<210> 22

<211> 284

<212> PRT

<213> Caenorhabditis elegans

<400> 22

Met Asn Phe Ile Ser Ala Lys Leu Val Phe Val Pro Trp Leu Trp Asn
 1 5 10 15

Lys Met Ala Phe Ile Lys Arg Lys Thr Val Lys Phe Ser Val Asp Leu
 20 25 30

Gln Val Cys Gln Leu Ser Asp Val Pro Leu Val Asn Ala Thr Val Phe
 35 40 45

Gly Lys Met Arg Leu Leu Asp Gly Gly Ser Phe Glu Glu Ala Thr Glu
 50 55 60

Arg Val Glu Glu Gln Lys Gly Gly Lys Ser Tyr Tyr Lys Leu Gly Phe
 65 70 75 80

Val Asp Ile Asn Leu Ser Glu Tyr Ala Ala Ser Gly Val Glu Gly Ile
 85 90 95

Ser Arg Thr Tyr Leu Leu Asn Gly Tyr Thr Ser Asn Gln Arg Leu Asp
 100 105 110

Asn Ser Lys Val Cys Ile Lys Val Ala Met Thr His Gln Ser Ala Asp
 115 120 125

Pro Phe Phe Arg Val Pro Arg Leu Ser Thr Phe Gly Pro Arg Gln Asp
 130 135 140

Gly Ala Ile Asp Gln Asp Gly Phe Arg Ala Asp Asp Glu Thr Asp Ser
 145 150 155 160

Glu Glu Gly Thr Ser Ser His Pro Lys Leu Ser Asn Val Asp Val Leu
 165 170 175

Glu Ser Ser Ser Ala Ala Ser Asn Ser Gln Val Asp Glu Pro Val Val
 180 185 190

Glu Arg Arg Val Ile His Pro Pro Gln His Pro Thr Cys Gln Leu Arg
 195 200 205

Arg Phe Ser Gln Asp Arg Ser Ala Gln Lys Ile Gln His Ser Arg Phe
 210 215 220

Asp Ala Asp Asn Val Ile Asp Lys Ile Ile Ala Glu Cys Arg Ile Ser
 225 230 235 240

Glu Asp Glu Val Glu Ser Asn Ser Gly Gly Leu Val Leu Glu Lys Phe
 245 250 255

Leu Asp Lys His Gly Lys Pro Leu Val Asn Pro Arg Gln Pro Val Lys
 260 265 270

Arg Thr Ser Tyr Val Ala Glu His Phe Asn Asp Ala
 275 280

<210> 23

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide
 primer

<400> 23

aaccttctag tcctttgggc tgc

23

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
 oligonucleotide primer

<400> 24

ggcccaggct acaggctg

18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/23156**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet

US CL :Please See Extra Sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. 424/185.1; 435/7.1, 69.1, 91.1, 352, 320.1; 514/44, 530/350, 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE CANCERLIT EMBASE BIOSIS SCISEARCH WEST: ALL DATABASES

Th2, allergy, nucleic acid DNA, polynucleotide

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98/38216 A1 (JAPAN TOBACCO INC.) 03 September 1998, see abstract and sequences	1-19
Y	US 5,783,182 A (THOMPSON) 21 July 1998, see entire document.	1-19
Y,P	HUANG, SK, Molecular modulation of allergic responses. J. Allergy Clin Immunol, Vol. 102, 1998, December pages 887-892, see entire document.	1-19
Y	DATABASE GenBank on STN Accession No. AA21744, MARRA et.al. T wash U-HHMI Mouse EST Project, 21 January 1997.	1-19

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 29 DECEMBER 1999	Date of mailing of the international search report 14 JAN 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer MARY BE HUNG Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/23156

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

A61K 29/00; A01N 43/04; C07H 21/04; C07K 14/00; C12N 5/10, 15/00; C12P 19/34; G01N 33/53

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/185.1; 435/7.1, 69.1, 91.1, 352, 320.1; 514/44; 530/350; 536/23.5